Vault Complexes for Cytokine Delivery

ABSTRACT

The invention relates to compositions of vault complexes containing recombinant cytokine fusion proteins that include a cytokine and a vault targeting domain, and methods of using the vault complexes to deliver the cytokines to a cell or subject, and methods for using the compositions to treat cancer, such as lung cancer.

CROSS REFERENCE TO RELATED APPLICATIONS

This application is a continuation of U.S. application Ser. No. 15/424,654, which is a continuation of U.S. application Ser. No. 14/553,146, which is a continuation of U.S. application Ser. No. 13/505,420, which is a 371 National Phase entry of PCT/US10/55146, filed Nov. 2, 2010, and claims the benefit of U.S. Provisional Application No. 61/257,358, filed Nov. 2, 2009, which are hereby incorporated by reference in their entirety for all purposes.

STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT

This invention was made with Government support under Grant No. CA126944, awarded by the National Institutes of Health. This work was supported by the U.S. Department of Veterans Affairs, and the Federal Government has certain rights in the invention.

REFERENCE TO A SEQUENCE LISTING SUBMITTED VIA EFS-WEB

The content of the ASCII text file of the sequence listing named “20200812 034044 137CON3 ST25” which is 203 kb in size was created on Aug. 12, 2020 and electronically submitted via EFS-Web herewith the application is incorporated herein by reference in its entirety.

BACKGROUND OF THE INVENTION Field of the Invention

The invention relates to compositions of vault complexes containing cytokines, such as the chemokine CCL-21, and use of vault complexes for delivering the cytokines to a cell. The vault complexes include a fusion protein of the cytokine of interest fused to major vault interaction domain. Also included in the invention is the use of the compositions as cancer immunotherapy agents for activating an immune response against a tumor and for treating cancers, including lung cancer.

Description of the Related Art

Vaults are cytoplasmic ubiquitous ribonucleoprotein particles first described in 1986 that are found in all eukaryotic cells [1]. Native vaults are 12.9±1 MDa ovoid spheres with overall dimensions of approximately 40 nm in width and 70 nm in length [2,3], present in nearly all-eukaryotic organisms with between 10⁴ and 10⁷ particles per cell [4]. Despite their cellular abundance, vault function remains elusive although they have been linked to many cellular processes, including the innate immune response, multidrug resistance in cancer cells, multifaceted signaling pathways, and intracellular transport [5].

Vaults are highly stable structures in vitro, and a number of studies indicate that the particles are non-immunogenic [6]. Vaults can be engineered and expressed using a baculovirus expression system and heterologous proteins can be encapsulated inside of these recombinant particles using a protein-targeting domain termed INT for vault INTeraction. Several heterologous proteins have been fused to the INT domain (e.g. fluorescent and enzymatic proteins) and these fusion proteins are expressed in the recombinant vaults and retain their native characteristics, thus conferring new properties onto these vaults [7,8].

CCL-21 has been identified as a lymphoid chemokine that is predominantly and constitutively expressed by high endothelial venules in lymph nodes and Peyer's patches and by lymphatic vessels, stromal cells in the spleen and appendix [9]. CCL-21 binds to the chemokine receptor CCR7 and is a chemoattractant for mature DCs, naive and memory T cells [10,11]. This chemokine, along with CCL-19, is required for normal lymphoid tissue organization that is ultimately essential for effective T cell-DC interactions. Natural killer (NK) and natural killer T (NKT) antitumor effectors express the CCR7 receptor and are chemo attracted by CCL-21. The use of chemokines that attract DC, lymphocyte, and NK and NKT effectors into tumors can serve as an effective antitumor strategy. Based on this concept, it has been previously shown that intratumoral administration of recombinant CCL-21 reduces tumor burden in murine lung cancer models [12]. The antitumor responses induced by recombinant CCL-21 however required high and frequent dosing because proteins administered intratumorally are not retained locally for prolonged periods. Although these studies delineated the role of CCL-21 as an effective antitumor agent, frequent high dose intratumoral administration is clinically limiting with the potential of unnecessary systemic toxicity. Based on the limitations of this approach, the use of autologous dendritic cells for intratumoral CCL-21 delivery was examined [13.14]. In preclinical studies, it was demonstrated that intratumoral administration of CCL-21 gene modified dendritic cells led to tumor eradication in murine lung cancer models. Following this initial description of the antitumor properties of CCL-21, several other research groups have reported that CCL-21 has potent antitumor properties in a variety of model systems [15-19]. In all models, CCL-21 demonstrated potent regression of tumors, which was shown to be dependent on host T cell immunity. Based on extensive pre-clinical evaluation, the intratumoral injection of DC transduced with an adenoviral vector expressing the secondary lymphoid chemokine gene (Ad-CCL-21-DC) was assessed in a phase I trial in advanced non-small cell lung cancer (NSCLC).

While clinical studies utilizing intratumoral administration of chemokine gene modified DC show promise as an effective therapy, the preparation of CCL-21 expressing autologous dendritic cells is cumbersome, expensive and time consuming. A reagent that is efficacious and works through a similar therapeutic mechanism is highly desired. Compositions and methods are needed to circumvent autologous DC preparation, minimize batch to batch variability and allow for comparability and standardization. There is a need for cytokine delivery, e.g., a non-DC based approach for intratumoral CCL-21 delivery for the purpose of initiating antitumor immune responses

Vaults are generally described in U.S. Pat. No. 7,482,319, filed on Mar. 10, 2004; U.S. application Ser. No. 12/252,200, filed on Oct. 15, 2008; International Application No. PCT/US2004/007434, filed on Mar. 10, 2004; U.S. Provisional Application No. 60/453,800, filed on Mar. 20, 2003; U.S. Pat. No. 6,156,879, filed on Jun. 3, 1998; U.S. Pat. No. 6,555,347, filed on Jun. 28, 2000; U.S. Pat. No. 6,110,740, filed on Mar. 26, 1999; International Application No. PCT/US1999/06683, filed on Mar. 26, 1999; U.S. Provisional App. No. 60/079,634, filed on Mar. 27, 1998; and International Application No. PCT/US1998/011348, filed on Jun. 3, 1998. Vault compositions for immunization against chlamydia genital infection are described in U.S. application Ser. No. 12/467,255, filed on May 15, 2009. The entire contents of these applications are incorporated by reference in their entirety for all purposes.

SUMMARY OF THE INVENTION

Disclosed herein are compositions including a vault complex having a fusion protein of a cytokine and a vault targeting domain, e.g., mINT. In one embodiment, the vault complex includes a chemokine fusion protein having a chemokine (C—C motif) ligand 21 (CCL-21) consisting of SEQ ID NO:1 (mouse CCL21 amino acid sequence) and a major vault protein interaction domain (mINT) consisting of SEQ ID NO:9 (mouse mINT amino acid sequence). In another embodiment, the vault complex includes a chemokine fusion protein having a chemokine (C—C motif) ligand 21 (CCL-21) consisting of SEQ ID NO:2 (human CCL21 amino acid sequence) and a major vault protein interaction domain (mINT) consisting of SEQ ID NO:8 (human mINT amino acid sequence).

Accordingly, in one aspect of the invention, the cytokine is a chemokine. In one aspect, the cytokine is a cysteine-cysteine (CC) chemokine. In another aspect, the cytokine is a CCL-21 chemokine. The chemokine can include all or part of human or mouse CCL-21, e.g, SEQ ID NO:1 or SEQ ID NO:2. In some embodiments, the cytokine fusion protein includes a fluorescent protein, e.g., mCherry fluorescent protein.

In one embodiment, the vault targeting domain is a vault interaction domain from a vault poly ADP-ribose polymerase (VPARP). In one embodiment, the vault targeting domain is a major vault protein interaction (mINT) domain. In another embodiment, the vault targeting domain comprises or consists of SEQ ID NO:8 (a human amino acid sequence). In yet another embodiment, the vault targeting domain comprises SEQ ID NO:9 (a mouse amino acid sequence).

In some embodiments, the vault complex includes a MVP. The MVP can be a human MVP, e.g., SEQ ID NO:16.

Vault complexes of the invention can include a vault poly ADP-ribose polymerase (VPARP), and/or a telomerase vault associated protein 1 (TEP1), and/or an untranslated RNA molecule (vRNA).

In addition, the invention provides an isolated nucleic acid encoding a cytokine fusion protein that includes a cytokine encoding sequence and a mINT encoding sequence. In one embodiment, the mINT encoding sequence is SEQ ID NO:7 (a human sequence) or SEQ ID NO:6 (a mouse sequence). In another embodiment, the cytokine encoding sequence is SEQ ID NO:5 (human) and the mINT encoding sequence consists of SEQ ID NO:7 (human). In one embodiment, the cytokine encoding sequence is SEQ ID NO:3 (a mouse sequence) and the mINT encoding sequence is SEQ ID NO:6 (a mouse sequence).

In some embodiments, the cytokine fusion protein is SEQ ID NO:13 (human). In other embodiments, the cytokine fusion protein is SEQ ID NO:12 (mouse). Also included in the invention are vectors including an isolated nucleic acid described herein, cells having an isolated nucleic acid described herein, and cells having a vector described herein.

The invention also includes a method of delivering a cytokine to a cell, including introducing the vault complexes of the invention to the cell. In some embodiments, the method includes introducing the vault complexes into the extracellular environment surrounding the cell. The invention includes a method for stimulating an immune response in a cell by contacting the cell with the vault complexes of the invention. In some embodiments, the cell is a human cell. In other embodiments, the immune response induces migration of T cells and dendritic cells. In another embodiment, contacting the cell with the vault complexes of the invention increases T cell migration to the cell by at least 5% compared to administration of CCL-21 cytokine alone.

In addition, the invention provides a method for stimulating an immune response in a subject by administering the vault complexes the invention to the subject. In one embodiment, the subject is a human.

In another embodiment, the invention includes a method of treating or managing cancer in a subject in need of treatment or management of cancer including administering to a subject a therapeutically effective amount of the vault complexes described herein. In some embodiments, administering includes intra-tumoral injection of the composition to a tumor in the subject. In one embodiment, the cancer is lung cancer. In another embodiment, administering reduces tumor volume and/or reduces tumor growth. In some embodiments, administering increases interleukin-2 (IL-2) expression. In one embodiment, the method includes a subject that is a mammal or a human.

The invention includes a method of preparing the vault complexes of the invention including a) mixing a fusion protein comprising a cytokine fused to a mINT generated in Sf9 cells with a rat MVP generated in Sf9 cells to generate a mixture; b) incubating the mixture for a sufficient period of time to allow packaging of the fusion protein inside of vault complexes, thereby generating the vault complexes.

In yet another embodiment, the invention also provides method of preparing the vault complexes of the invention including a) mixing a fusion protein comprising a cytokine fused to a mINT generated in insect larvae cells with a rat MVP generated in insect larvae cells to generate a mixture; b) incubating the mixture for a sufficient period of time to allow packaging of the fusion protein inside of vault complexes, thereby generating the vault complexes described herein.

In another embodiment, the invention provides a method of preparing the composition of the invention including a) mixing a fusion protein comprising a cytokine fused to a mINT generated in Sf9 cells or insect larvae cells with a human MVP generated in Sf9 cells or insect larvae cells to generate a mixture; b) incubating the mixture for a sufficient period of time to allow packaging of the fusion protein inside of vault complexes, thereby generating the vault complexes described herein.

BRIEF DESCRIPTION OF THE SEVERAL VIEWS OF THE DRAWINGS

These and other features, aspects, and advantages of the present invention will become better understood with regard to the following description, and accompanying drawings, where:

FIG. 1A shows a diagram of the CCL-21 and mCherry-INT constructs that were fused to create the CCL-21 fusion protein.

FIG. 1B shows the incorporation into a pFastBac expression vector by restriction digest and expression of CCL-21 fusion protein as analyzed by gel electrophoresis.

FIG. 1C shows the MVP recombinant vaults containing packaged CCL-21-mCherry-mINT purified on a sucrose gradient. The 40 and 45% fractions were analyzed by SDS-PAGE.

FIG. 1D shows the MVP recombinant vaults containing packaged CCL-21-mCherry-mINT purified on a sucrose gradient and analyzed by staining with Coomassie.

FIG. 1E shows purified vault complexes examined by negative stain transmission electron microscopy.

FIG. 2A is a graph that shows CCL-21 vault complexes increases the migration of T2 cells.

FIG. 2B is a graph showing T cell activation by CCL-21 vault complexes measured by IL-2 production.

FIG. 3 is a graph showing a decrease in tumor burden by intratumoral injection of CCL-21 vault complexes (200 ng) compared to empty vaults.

FIG. 4A shows the leukocytic infiltrates in cells treated with a control vault.

FIG. 4B shows the leukocytic infiltrates in cells treated with CCL-21 vault complexes.

FIG. 5A is a photo showing the effects of treatment of 3LL lung cancer cells with diluent.

FIG. 5B is a photo showing the effects of treatment of 3LL lung cancer cells with control vault.

FIG. 5C is a photo showing the effects of treatment of 3LL lung cancer cells with CCL-21 vault complex.

FIG. 6A is a set of graphs showing the percentage tumor burden in naïve 3LL cells, and 3LL cells treated with diluents, control vault (VC), or CCL-21 vault complexes as measured in a flow cytometry assay. Tumor burden was calculated on total percentage of GFP and Epcam expressing tumor cells in total lung digest.

FIG. 6B is a bar graph showing percentage tumor burden in 3LL cells after treatment with diluents, control vault, or CCL-21 vault complexes.

FIG. 7A is a graph showing percentage of intratumoral leukocytic populations (CD4, CD8, CD3 CXCR3, CD3 CCR7, DEC205, MDSC and Tregs) at the tumor site after injection with diluent, control vault, or CCL-21 vault complexes. CCL-21 vault complex augmented CD4, CD8, CXCR3⁺CD3⁻T, CCR7⁺CD3⁺T and DEC205⁺DC infiltrates and reduced MDSC and Tregs.

FIG. 7B is a graph of the percentage of CD4+ cells with IFNγ and IL-10 expression after treatment with diluent, control vault, or CCL-21 vault complexes. Tumor T lymphocytic infiltrates from CCL-21 vault complex treated mice had increased intracytoplasmic IFNγ and reduced IL-10 expression.

FIG. 7C is a graph of the percentage of CD8+ cells with IFNγ and IL-10 expression after treatment with diluent, control vault, or CCL-21 vault complexes.

FIG. 7D is a graph of percentage tumor lysis of splenic T cells after intratumoral injection with diluent, control vault, or CCL-21 vault complexes.

DETAILED DESCRIPTION OF THE INVENTION

The descriptions of various aspects of the invention are presented for purposes of illustration, and are not intended to be exhaustive or to limit the invention to the forms disclosed. Persons skilled in the relevant art can appreciate that many modifications and variations are possible in light of the embodiment teachings.

It should be noted that the language used herein has been principally selected for readability and instructional purposes, and it may not have been selected to delineate or circumscribe the inventive subject matter. Accordingly, the disclosure is intended to be illustrative, but not limiting, of the scope of invention.

It must be noted that, as used in the specification, the singular forms “a”, “an”, and “the” include plural referents unless the context clearly dictates otherwise.

Any terms not directly defined herein shall be understood to have the meanings commonly associated with them as understood within the art of the invention. Certain terms are discussed herein to provide additional guidance to the practitioner in describing the compositions, devices, methods and the like of embodiments of the invention, and how to make or use them. It will be appreciated that the same thing can be said in more than one way. Consequently, alternative language and synonyms can be used for any one or more of the terms discussed herein. No significance is to be placed upon whether or not a term is elaborated or discussed herein. Some synonyms or substitutable methods, materials and the like are provided. Recital of one or a few synonyms or equivalents does not exclude use of other synonyms or equivalents, unless it is explicitly stated. Use of examples, including examples of terms, is for illustrative purposes only and does not limit the scope and meaning of the embodiments of the invention herein.

Briefly, and as described in more detail below, described herein are compositions of vault complexes containing cytokines, such as CCL-21, and their use in delivering the cytokines to a cell. The vault particles include a fusion protein of the cytokine of interest fused to major vault interaction domain. Also included in the invention is the use of the compositions as cancer immunotherapy agents for activating an immune response against a tumor and for treating cancers, including lung cancer.

CCL-21 and other cytokines have been shown to be effective as cancer immunotherapy agents. However, conventional approaches for cancer therapy treatment with cytokines, such as CCL-21, involve use of modified dendritic cells. These preparations and treatments are cumbersome, expensive and time consuming. Difficulties with conventional methods include autologous DC preparation, batch to batch variability and lack of comparability and standardization. More convenient and efficacious options for delivery and treatment with cytokine reagents are required.

The invention supplies the deficiencies of the conventional DC-based methods. Vault complexes provide effective and efficient intratumoral cytokine, e.g., CCL-21 delivery for the purpose of initiating antitumor immune responses.

Definitions

Terms used in the claims and specification are defined as set forth below unless otherwise specified.

The term “cytokine” is a protein that is a member of a family of secreted cell-signaling proteins involved in immunoregulatory and inflammatory processes. A “chemokine” is a member of a family of cytokines defined by invariant cysteine residues that form disulfide bonds. One example of a chemokine is “CCL-21” referring to a chemokine (C—C motif) ligand 21. A C—C motif is a cysteine-cysteine motif.

As used herein, the term “vault” or “vault particle” refers to a large cytoplasmic ribonucleoprotein (RNP) particle found in eukaryotic cells. The vault or vault particle is composed of MVP, VPARP, and/or TEP1 proteins and one or more untranslated vRNA molecules.

As used herein, the term “vault complex” refers to a recombinant vault that encapsulates a small molecule or protein of interest. A vault complex of the invention includes a fusion protein, e.g., a cytokine fusion protein.

As used herein, the term “cytokine fusion protein” is a recombinant protein expressed from a nucleotide encoding a cytokine fused in frame to a vault targeting domain.

As used herein, the term “vault targeting domain” or “vault interaction domain” is a domain that is responsible for interaction or binding of a heterologous fusion protein with a vault protein, or interaction of a VPARP with a vault protein, such as a MVP. As used herein, the term “mINT domain” is a vault interaction domain from a vault poly ADP-ribose polymerase (VPARP) that is responsible for the interaction of VPARP with a major vault protein (MVP). The term “mINT domain” refers to a major vault protein (MVP) interaction domain.

As used herein, the term “MVP” is major vault protein. The term “cp-MVP” is a cysteine-rich peptide major vault protein.

The term “VPARP” refers to a vault poly ADP-ribose polymerase.

As used herein, the term “TEP-1” is a telomerase/vault associated protein 1.

As used herein, the term “vRNA” is an untranslated RNA molecule found in vaults.

As used herein, the term “fluorescent protein” is a protein that has the property of forming a visible wavelength chromophore from within its polypeptide sequence. Fluorescent proteins can be engineered to be expressed with other proteins, and include, but are not limited to, green fluorescent protein (GFP), red fluorescent protein (mCherry), blue fluorescent protein (EBFP, EBFP2, Azurite, mKalama1), cyan fluorescent protein (ECFP, Cerulean, CyPet) and yellow fluorescent protein derivatives (YFP, Citrine, Venus, YPet).

As used herein, the term “vector” is a DNA or RNA molecule used as a vehicle to transfer foreign genetic material into a cell. The four major types of vectors are plasmids, bacteriophages and other viruses, cosmids, and artificial chromosomes. Vectors can include an origin of replication, a multi-cloning site, and a selectable marker.

As used herein, a “cell” includes eukaryotic and prokaryotic cells.

As used herein, the terms “organism”, “tissue” and “cell” include naturally occurring organisms, tissues and cells, genetically modified organisms, tissues and cells, and pathological tissues and cells, such as tumor cell lines in vitro and tumors in vivo.

As used herein, the term “T cell” or T lymphocyte is a white blood cell known as a lymphocyte, and plays a central role in cell-mediated immunity.

As used herein, the term “extracellular environment” is the environment external to the cell.

As used herein, the term “in vivo” refers to processes that occur in a living organism.

A “subject” referred to herein can be any animal, including a mammal (e.g., a laboratory animal such as a rat, mouse, guinea pig, rabbit, primates, etc.), a farm or commercial animal (e.g., a cow, horse, goat, donkey, sheep, etc.), a domestic animal (e.g., cat, dog, ferret, etc.), an avian species, or a human.

The term “mammal” as used herein includes both humans and non-humans and include but is not limited to humans, non-human primates, canines, felines, murines, bovines, equines, and porcines.

As used herein, the term “human” refers to “Homo sapiens.”

As used herein, the term “sufficient amount” is an amount sufficient to produce a desired effect, e.g., an amount sufficient to modulate protein aggregation in a cell.

As used herein, the term “therapeutically effective amount” is an amount that is effective to ameliorate a symptom of a disease, such as cancer.

A “prophylactically effective amount” refers to an amount that is effective for prophylaxis.

An “immune response” is a response by a host against foreign immunogens or antigens. A “cell-mediated immune response” refers to a helper T cell response which involves the production of interferon-gamma (IFN-γ), leading to cell-mediated immunity.

As used herein, the term “stimulating” refers to activating, increasing, or triggering a molecular, cellular or enzymatic activity or response from within a cell or organism.

As used herein, the term “administering” includes any suitable route of administration, as will be appreciated by one of ordinary skill in the art with reference to this disclosure, including direct injection into a solid organ, direct injection into a cell mass such as a tumor, inhalation, intraperitoneal injection, intravenous injection, topical application on a mucous membrane, or application to or dispersion within an environmental medium, and a combination of the preceding.

As used in this disclosure, the term “modified” and variations of the term, such as “modification,” means one or more than one change to the naturally occurring sequence of MVP, VPARP or TEP1 selected from the group consisting of addition of a polypeptide sequence to the C-terminal, addition of a polypeptide sequence to the N-terminal, deletion of between about 1 and 100 amino acid residues from the C-terminal, deletion of between about 1 and 100 amino acid residues from the N-terminal, substitution of one or more than one amino acid residue that does not change the function of the polypeptide, as will be appreciated by one of ordinary skill in the art with reference to this disclosure, such as for example, an alanine to glycine substitution, and a combination of the preceding.

As used herein, the term percent “identity,” in the context of two or more nucleic acid or polypeptide sequences, refers to two or more sequences or subsequences that have a specified percentage of nucleotides or amino acid residues that are the same, when compared and aligned for maximum correspondence, as measured using one of the sequence comparison algorithms described below (e.g., BLASTP and BLASTN or other algorithms available to persons of skill) or by visual inspection. Depending on the application, the percent “identity” can exist over a region of the sequence being compared, e.g., over a functional domain, or, alternatively, exist over the full length of the two sequences to be compared.

For sequence comparison, typically one sequence acts as a reference sequence to which test sequences are compared. When using a sequence comparison algorithm, test and reference sequences are input into a computer, subsequence coordinates are designated, if necessary, and sequence algorithm program parameters are designated. The sequence comparison algorithm then calculates the percent sequence identity for the test sequence(s) relative to the reference sequence, based on the designated program parameters.

Optimal alignment of sequences for comparison can be conducted, e.g., by the local homology algorithm of Smith & Waterman, Adv. Appl. Math. 2:482 (1981), by the homology alignment algorithm of Needleman & Wunsch, J. Mol. Biol. 48:443 (1970), by the search for similarity method of Pearson & Lipman, Proc. Nat'l. Acad. Sci. USA 85:2444 (1988), by computerized implementations of these algorithms (GAP, BESTFIT, FASTA, and TFASTA in the Wisconsin Genetics Software Package, Genetics Computer Group, 575 Science Dr., Madison, Wis.), or by visual inspection (see generally Ausubel et al., infra).

One example of an algorithm that is suitable for determining percent sequence identity and sequence similarity is the BLAST algorithm, which is described in Altschul et al., J. Mol. Biol. 215:403-410 (1990). Software for performing BLAST analyses is publicly available through the National Center for Biotechnology Information (www.ncbi.nlm.nih.gov/).

As used in this disclosure, the term “comprise” and variations of the term, such as “comprising” and “comprises,” are not intended to exclude other additives, components, integers or steps.

It must be noted that, as used in the specification and the appended claims, the singular forms “a,” “an” and “the” include plural referents unless the context clearly dictates otherwise.

Compositions of the Invention

As described in more detail below, the invention includes compositions and methods of using vault particles. The vault particles are recombinant particles having a MVP and a fusion protein and mINT and a protein of interest, e.g., a cytokine, e.g., CCL-21. The vault particle can be used for delivery of the protein of interest, e.g., the cytokine, to a cell or tumor or subject.

Vaults and Vault Complexes

The compositions of the invention comprise a vault complex. A vault complex is a recombinant particle that encapsulates a small molecule (drug, sensor, toxin, etc.), or a protein of interest, e.g., a peptide, or a protein, including an endogenous protein, a heterologous protein, a recombinant protein, or recombinant fusion protein. Vault complexes are of the invention include a cytokine recombinant fusion protein. Vault complexes are derived from vault particles.

Vaults, e.g., vault particles are ubiquitous, highly conserved ribonucleoprotein particles found in nearly all eukaryotic tissues and cells, including dendritic cells (DCs), endometrium, and lung, and in phylogeny as diverse as mammals, avians, amphibians, the slime mold Dictyostelium discoideum, and the protozoan Trypanosoma brucei (Izquierdo et al., Am. J. Pathol., 148(3):877-87 (1996)). Vaults have a hollow, barrel-like structure with two protruding end caps, an invaginated waist, and regular small openings surround the vault cap. These openings are large enough to allow small molecules and ions to enter the interior of the vault. Vaults have a mass of about 12.9±1 MDa (Kedersha et al., J. Cell Biol., 112(2):225-35 (1991)) and overall dimensions of about 42×42×75 nm (Kong et al., Structure, 7(4):371-9 (1999)). The volume of the internal vault cavity is approximately 50×10³ nm³, which is large enough to enclose an entire ribosomal protein.

Vaults comprise three different proteins, designated MVP, VPARP and TEP1, and comprise one or more different untranslated RNA molecules, designated vRNAs. The number of vRNA can vary. For example, the rat Rattus norvegicus has only one form of vRNA per vault, while humans have three forms of vRNA per vault. The most abundant protein, major vault protein (MVP), is a 95.8 kDa protein in Rattus norvegicus and a 99.3 kDa protein in humans which is present in 96 copies per vault and accounts for about 75% of the total protein mass of the vault particle. The two other proteins, the vault poly-ADP ribose polymerase, VPARP, a 193.3 kDa protein in humans, and the telomerase/vault associated protein 1, TEP1, a 292 kDa protein in Rattus norvegicus and a 290 kDa protein in humans, are each present in between about 2 and 16 copies per vault.

VPARP, mINT Domain, and mINT Fusion Proteins

A vault poly ADP-ribose polymerase (VPARP) includes a region of about 350 amino acids that shares 28% identity with the catalytic domain of poly ADP-ribosyl polymerase, PARP, a nuclear protein that catalyzes the formation of ADP-ribose polymers in response to DNA damage. VPARP catalyzes an NAD-dependent poly ADP-ribosylation reaction, and purified vaults have poly ADP-ribosylation activity that targets MVP, as well as VPARP itself. VPARP includes a mINT domain (major vault protein (MVP) interaction domain). The mINT domain is responsible for the interaction of VPARP with a major vault protein (MVP).

A vault complex of the invention includes a mINT domain. The mINT domain is responsible for interaction of a protein of interest, e.g., a cytokine, with a vault protein such as a MVP. In general, the mINT domain is expressed as a fusion protein with a protein of interest, e.g., a cytokine. The mINT of the vault complexes of the invention are derived from VPARP sequences. Exemplary VPARP sequences and mINT sequences can be found in Table 1. One of skill in the art understands that the mINT can have the entire naturally occurring sequence or portions of the sequence or fragments thereof. In other embodiments, the mINT has at least 50%, 60%, 70%, 80%, 90%, 95%, 96%, 97%, 98% or 99% sequence identity to any of the VPARP and/or mINT sequences disclosed in Table 1.

In one embodiment, the mINT is derived from a human VPARP, SEQ ID NO:14, GenBank accession number AAD47250, encoded by the cDNA, SEQ ID NO:15, GenBank accession number AF158255. In some embodiments, the vault targeting domain comprises or consists of the INT domain corresponding to residues 1473-1724 (SEQ ID NO:69) of human VPARP protein sequence (full human VPARP amino acid sequence is SEQ ID NO:14). In other embodiments, the vault targeting domain comprises or consists of the mINT domain comprising residues 1563-1724 (SEQ ID NO: 8) of the human VPARP protein sequence. In certain embodiments, the vault targeting domain comprises or consists of a mINT domain (SEQ ID NO: 6) (mouse mINT). In some embodiments, the vault targeting domain comprises or consists of SEQ ID NO: 7 (human mINT). In certain embodiments, the vault targeting domain is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NOs: 6 or 7.

In alternative embodiments, the mINT domain is derived from TEP1 sequences. One of skill in the art understands that the mINT can have the entire naturally occurring sequence of the vault interaction domain in TEP1 or portions of the sequence or fragments thereof.

MVP

A vault complex of the invention generally includes an MVP. Exemplary MVP sequences can be found in Table 1. One of skill in the art understands that the MVP can have the entire naturally occurring sequence or portions of the sequence or fragments thereof. In other embodiments, the MVP has at least 50%, 60%, 70%, 80%, 90%, 95%, 96%, 97%, 98% or 99% sequence identity to any of the MVP sequences disclosed in Table 1.

In one embodiment, the MVP is human MVP, SEQ ID NO:16, GenBank accession number CAA56256, encoded by the cDNA, SEQ ID NO:17, GenBank accession number X79882. In another embodiment, the MVP is Rattus norvegicus MVP, SEQ ID NO:18, GenBank accession number AAC52161, encoded by the cDNA, SEQ ID NO:19, GenBank accession number U09870. In other embodiments, the MVP is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to the MVP sequences described herein.

In one embodiment, there is provided a vault complex comprising, consisting essentially of, or consisting of an MVP modified by adding a peptide to the N-terminal to create a one or more than one of heavy metal binding domains. In a preferred embodiment, the heavy metal binding domains bind a heavy metal selected from the group consisting of cadmium, copper, gold and mercury. In a preferred embodiment, the peptide added to the N-terminal is a cysteine-rich peptide (CP), such as for example, SEQ ID NO:20, the MVP is human MVP, SEQ ID NO:16, and the modification results in CP-MVP, SEQ ID NO:21, encoded by the cDNA, SEQ ID NO:22. In another preferred embodiment, the cysteine-rich peptide is SEQ ID NO:20, the MVP is Rattus norvegicus MVP, SEQ ID NO:18, and the modification results in CP-MVP, SEQ ID NO:23, encoded by the cDNA, SEQ ID NO:24. These embodiments are particularly useful because vault particles consisting of CP-MVP, SEQ ID NO:21 or SEQ ID NO:23, are stable without the presence of other vault proteins.

Any of the vault complexes described herein can include MVPs or modified MVPs disclosed herein.

TEP1

In some embodiments, a vault particle of the invention includes a TEP1 protein. Exemplary TEP1 sequences can be found in Table 1. One of skill in the art understands that the TEP1 can have the entire naturally occurring sequence or portions of the sequence or fragments thereof. In other embodiments, the TEP1 has at least 50%, 60%, 70%, 80%, 90%, 95%, 96%, 97%, 98% or 99% sequence identity to any of the TEP1 sequences disclosed in Table 1.

The TEP1 can be human TEP1, SEQ ID NO:25, GenBank accession number AAC51107, encoded by the cDNA, SEQ ID NO:26, GenBank accession number U86136. In another embodiment, the TEP1 is Rattus norvegicus TEP1, SEQ ID NO:27, GenBank accession number AAB51690, encoded by the cDNA, SEQ ID NO:28, GenBank accession number U89282. Any of the vault complexes described herein can include TEP1 or modifications thereof vRNA

A vault complex of the invention can include a vRNA. Exemplary vRNA sequences can be found in Table 1. One of skill in the art understands that the vRNA can have the entire naturally occurring sequence or portions of the sequence or fragments thereof. In other embodiments, the vRNA has at least 50%, 60%, 70%, 80%, 90%, 95%, 96%, 97%, 98% or 99% sequence identity to any of the vRNA sequences disclosed in Table 1.

In one embodiment, the vRNA can be a human vRNA, SEQ ID NO:29, GenBank accession number AF045143, SEQ ID NO:30, GenBank accession number AF045144, or SEQ ID NO:31, GenBank accession number AF045145, or a combination of the preceding. In another embodiment, the vRNA is Rattus norvegicus vRNA, SEQ ID NO:32, GenBank accession number Z1171.

As will be appreciated by one of ordinary skill in the art with reference to this disclosure, the actual sequence of any of MVP, VPARP, TEP1 and vRNAs can be from any species suitable for the purposes disclosed in this disclosure, even though reference or examples are made to sequences from specific species. For example, when delivering chemokines or cytokines to human organs or tissues, it is preferred to use human vaults or vault-like particles comprising human sequences for MVP, VPARP, TEP1 and vRNAs. Further, as will be appreciated by one of ordinary skill in the art with reference to this disclosure, there are some intraspecies variations in the sequences of MVP, VPARP, TEP1 and vRNAs that are not relevant to the purposes of the present invention. Therefore, references to MVP, VPARP, TEP1 and vRNAs are intended to include such intraspecies variants.

Cytokines

The compositions of the invention include a vault complex including a cytokine. In general, the vault complex includes a cytokine fusion protein.

Cytokines are a family of secreted cell-signaling proteins involved in immunoregulatory and inflammatory processes, which are secreted by the glial cells of the nervous system and by numerous cells of the immune system. Cytokines can be classified as proteins, peptides or glycoproteins, and encompass a large and diverse family of regulators. Cytokines bind to cell surface receptors to trigger intracellular signaling, which can result in upregulation or downregulation of several genes and their transcription factors, or feedback inhibition.

In certain embodiments, the cytokines of the invention include immunomodulating agents, such as interleukins (IL) and interferons (IFN). Suitable cytokines can include proteins from one or more of the following types: the four α-helix bundle family (which includes the IL-2 subfamily, the IFN subfamily, and the IL-10 subfamily); the IL-1 family (which includes IL-1 and IL-8), and the IL-17 family. Cytokines can also include those classified as type 1 cytokines, which enhance cellular immune responses (e.g., IFN-γ, TGF-β, etc.), or type 2 cytokines, which favor antibody responses (e.g., IL-4, IL-10, IL-13, etc.).

In one embodiment, the cytokine is a chemokine. Chemokines are the largest family of cytokines and are defined by four invariant cysteine residues that form disulfide bonds. Chemokines function by activating specific G protein-coupled receptors, which results in the migration of inflammatory and noninflammatory cells to the appropriate tissues or compartments within tissues. The role of chemokines is to act as a chemoattractant to guide the migration of cells and to promote accumulation of cells at the source of chemokine production.

In some embodiments, the cytokines of the invention include homeostatic chemokines, which are constitutively produced and secreted. Homeostatic chemokines direct trafficking of lymphocytes to lymphoid tissues and are involved in immune surveillance and function to localize T cells or B cells with an antigen in the lymphatic system. In other embodiments, the chemokines of the invention include inflammatory chemokines that promote recruitment and localization of dendritic cells to sites of inflammation and infection. Several chemokines are involved in migration of monocytes and immature dendritic cells, which express chemokine receptors such as CCR1, CCR2, CCR5, CCR6, CCR7 and CXCR2. Chemokine receptor expression is regulated on these dendritic cells. Upon exposure to maturation signals, dendritic cells undergo a chemokine receptor switch, with downregulation of inflammatory chemokine receptors followed by induction of CCR7. This allows immature dendritic cells to leave tissues and to localize in lymphoid organs (due to CCR7 agonists), where antigen presentation takes place.

In certain embodiments, the cytokine comprises CC or β-chemokines, which have the first two cysteines adjacent to each other. In other embodiments, the chemokine comprises CXC or a chemokines, which have an intervening amino acid between the first two cysteines. In other embodiments, the chemokine comprises a CX3C or γ-chemokine, which possess only one protein in its category and is defined by three intervening residues between the first two cysteines. One of two exceptions to the four-cysteine paradigm is the C or δ-chemokine, in which the polypeptide has only two of the four cysteines.

In some embodiments, the cytokine comprises a CC chemokine. The CC chemokine is characterized by two adjacent cysteines near the amino terminus and is also called a β-chemokine or 17q chemokine. The CC subfamily includes at least 27 distinct members of the subfamily in mammals. These include, but are not limited to the following CC chemokines: CCL-1, CCL-2, CCL-3, CCL-4, CCL-5, CCL-7, CCL-8, CCL-9/CCL-10, CCL-11, CCL-12, CCL-13, CCL-14, CCL-15, CCL-16, CCL-17, CCL-18, CCL-19, CCL-20, CCL-21, CCL-22, CCL-23, CCL-24, CCL-25, CCL-26, CCL-27 and CCL-28. Chemokines of this subfamily usually contain four cysteines (C4-CC chemokines), but a small number of CC chemokines possess six cysteines (C6-CC chemokines). C6-CC chemokines include CCL1, CCL15, CCL21, CCL23 and CCL28. CC chemokines inhibit hemopoiesis and induce the migration of monocytes and other cell types such as natural killer (NK) cells and dendritic cells. CC Chemokines are chemotactic in vitro for thymocytes and activated T cells, but not for B cells, macrophages, or neutrophils. CC Chemokines may also play a role in mediating homing of lymphocytes to secondary lymphoid organs.

In other embodiments, the cytokine comprises a CXC chemokine. CXC chemokines have two N-terminal cysteines separated by an amino acid “X”. There are 17 different CXC chemokines in mammals and are separated in two categories, those with a specific amino acid sequence (or motif) of glutamic acid-leucine-arginine (or ELR for short) immediately before the first cysteine of the CXC motif (ELR-positive), and those without an ELR motif (ELR-negative). Other CXC chemokines that lack the ELR motif, such as CXCL13, tend to be chemoattractant for lymphocytes. CXC chemokines bind to CXC chemokine receptors, of which seven have been discovered to date, designated CXCR1-7.

In another embodiment, the cytokine comprises a C chemokine (also called γ chemokine), which has only two cysteines (one N-terminal cysteine and one cysteine downstream). Two chemokines are included in this subgroup (XCL1 (lymphotactin-α) and XCL2 (lymphotactin-ß)). These chemokines attract T cell precursors to the thymus.

In yet another embodiment, the cytokine comprises a CX3C chemokine (or d-chemokines). The CX₃C chemokine has three amino acids between the two cysteines. The only CX₃C chemokine discovered to date is called fractalkine (or CX₃CL1).

In some embodiments, the cytokine comprises a CCL-21 protein. CCL-21 stands for chemokine (C—C motif) ligand 21 and is a member of the CC chemokine family. CCL-21 is encoded by the Scya21 gene and is also called secondary lymphoid-tissue chemokine (SLC), 6Ckine, Exodus-2, Ckß9, and TCA-4. The CCL-21 binds to the CCR7 receptor, a cell surface chemokine receptor. The human CCL-21 gene is found on the p-arm of chromosome 9 and has the Genbank Accession No. NP_002980.

Exemplary cytokine sequences can be found in Table 1. One of skill in the art understands that the cytokine can have the entire naturally occurring sequence or portions of the sequence or fragments thereof. In other embodiments, the cytokine has at least 50%, 60%, 70%, 80%, 90%, 95%, 96%, 97%, 98% or 99% sequence identity to any of the cytokine sequences disclosed in Table 1.

In some embodiments, the cytokine comprises or consists of SEQ ID NO: 1 (mouse CCL-21 protein sequence). In other embodiments, the cytokine comprises or consists of SEQ ID NO:2 (human CCL-21 protein sequence). In other embodiments, the cytokine has at least 50%, 60%, 70%, 80%, 90%, 95%, 96%, 97%, 98% or 99% sequence identity to SEQ ID NOs:1 or 2. In another embodiment, the cytokine of the invention is encoded by a nucleic acid comprising SEQ ID NO:3 (mouse CCL-21 DNA sequence minus 3 amino acids for stop codon) or SEQ ID NO:4 (full mouse CCL-21 DNA sequence). In yet another embodiment, the cytokine of the invention is encoded by a nucleic acid comprising SEQ ID NO:5 (human CCL-21 DNA sequence). In certain embodiments, the cytokine of the invention comprises the entire naturally occurring DNA sequence, portions of the DNA sequence or fragments thereof. In some embodiments, the cytokine of the invention is encoded by a nucleic acid comprising 50%, 60%, 70%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NOs:3, 4 or 5.

In yet another embodiment, the cytokine comprises one of any of the sequences of cytokines or chemokines in Table 1, shown below. Suitable cytokines from humans for use in compositions and methods of the invention include, but are not limited to, interleukin-2 (IL-2) (DNA sequence is SEQ ID NO:33 and protein sequence is SEQ ID NO:34), interleukin-7 (IL-7) (DNA sequence is SEQ ID NO:35 and protein sequence is SEQ ID NO:36), interleukin 15 (IL-15) (DNA sequence is SEQ ID NO:37 and protein sequence is SEQ ID NO:38), interleukin 12B (IL-12B) (DNA sequence is SEQ ID NO:39 and protein sequence is SEQ ID NO:40), interleukin 12A (IL-12A) (DNA sequence is SEQ ID NO:41 and protein sequence is SEQ ID NO:42), colony stimulating factor 2 (DNA sequence is SEQ ID NO:43 and protein sequence is SEQ ID NO:44), chemokine (C—X—C motif) ligand 9 (CXCL9) (DNA sequence is SEQ ID NO:45 and protein sequence is SEQ ID NO:46), chemokine (C—X—C motif) ligand 10 (CXCL10) (DNA sequence is SEQ ID NO:47 and protein sequence is SEQ ID NO:48), interferon alpha-d (IFN-alpha) (DNA sequence is SEQ ID NO:49 and protein sequence is SEQ ID NO:50), interferon-gamma IEF SSP 5111 (DNA sequence is SEQ ID NO:51 and protein sequence is SEQ ID NO:52), chemokine (C—C motif) ligand 19 (CCL-19) (DNA sequence is SEQ ID NO:53 and protein sequence is SEQ ID NO:54), chemokine (C—C motif) ligand 21 (CCL-21) (DNA sequence is SEQ ID NO:55 and protein sequence is SEQ ID NO:56), tumor necrosis factor (TNF) (DNA sequence is SEQ ID NO:57 and protein sequence is SEQ ID NO:58), and interleukin 27 (IL-27) (DNA sequence is SEQ ID NO:59 and protein sequence is SEQ ID NO:60).

As will be appreciated by one of ordinary skill in the art with reference to this disclosure, the actual sequence of any of cytokine can be from any species suitable for the purposes disclosed in this disclosure, even though reference or examples are made to sequences from specific species. For example, when delivering chemokines or cytokines to human organs or tissues, it is preferred to use human cytokines. Further, as will be appreciated by one of ordinary skill in the art with reference to this disclosure, there are some intraspecies variations in the sequences of cytokine that are not relevant to the purposes of the present invention. Therefore, references to cytokine are intended to include such intraspecies variants.

Fusion Proteins

In general, the vault complexes of the invention include a fusion protein, e.g., a cytokine fusion protein. The cytokine fusion protein is a recombinant protein expressed from a nucleotide encoding a chemokine or cytokine fused in frame to a vault targeting domain, e.g., mINT. In some embodiments, the cytokine fusion protein comprises a mINT domain fused to a chemokine protein sequence. In other embodiments, the cytokine fusion protein comprises a mINT domain fused to a CCL-21 protein. In another embodiment, the cytokine is fused to the N-terminus of an MVP protein. In one embodiment, the cytokine is fused to the C-terminus of the MVP protein.

Exemplary cytokine fusion sequences can be found in Table 1. One of skill in the art understands that the cytokine fusion sequences can have the entire naturally occurring sequence or portions of the sequence or fragments thereof. In other embodiments, the cytokine fusion sequence has at least 50%, 60%, 70%, 80%, 90%, 95%, 96%, 97%, 98% or 99% sequence identity to any of the cytokine fusion sequences disclosed in Table 1.

In certain embodiments, the cytokine fusion protein is encoded by the nucleic acid sequence of SEQ ID NO: 10 (mouse CCL21-mINT fusion DNA sequence). In other embodiments, the cytokine fusion protein is encoded by the nucleic acid sequence of SEQ ID NO: 11 (human CCL21-mINT fusion DNA sequence). In some embodiments, the cytokine fusion protein comprises or consists of SEQ ID NO:12 (mouse CCL-21-mINT fusion protein sequence). In some embodiments, the cytokine fusion protein comprises or consists of SEQ ID NO: 13 (human CCL-21-mINT fusion protein sequence).

In one embodiment, the cytokine fusion protein includes the entire naturally occurring cytokine protein sequence, a portion of the cytokine protein sequence, or fragments thereof. In other embodiments, the cytokine fusion protein is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NOs: 12 or 13. In another embodiment, the cytokine fusion recombinant DNA sequence includes the entire naturally occurring cytokine DNA sequence, a portion of the cytokine DNA sequence, or fragments thereof.

Any of the cytokines described herein can be expressed as a fusion protein with any of the mINT domain disclosed herein.

Fluorescent Proteins

In certain embodiments, the vault complex of the invention includes a fluorescent protein. In some embodiments, the cytokine fusion protein comprises a fluorescent protein. Fluorescent proteins can be engineered to be expressed with other proteins, and include, but are not limited to, green fluorescent protein (GFP), red fluorescent protein (mCherry), blue fluorescent protein (EBFP, EBFP2, Azurite, mKalama1), cyan fluorescent protein (ECFP, Cerulean, CyPet) and yellow fluorescent protein derivatives (YFP, Citrine, Venus, YPet). In one embodiment, the cytokine fusion protein comprises a mCherry fluorescent protein or a portion of a mCherry fluorescent protein.

Isolated Nucleic Acids and Vectors

The invention also includes isolated nucleic acid encoding a cytokine fusion protein comprising a cytokine encoding sequence and a vault targeting domain encoding sequence. In one embodiment, the isolated nucleic acid encodes a chemokine fusion protein comprising a CCL-21 encoding sequence and a mINT encoding sequence. In another embodiment, the chemokine encoding sequence comprises or consists of SEQ ID NO:5 (human) and the mINT encoding sequence consists of SEQ ID NO:7 (human). In another embodiment, the chemokine encoding sequence comprises or consists of SEQ ID NO:3 (mouse) and the mINT encoding sequence consists of SEQ ID NO:6 (mouse). In one embodiment, the isolated nucleic acid is a cDNA plasmid construct encoding the full length cytokine protein and a mINT domain comprising or consisting of SEQ ID NO: 6 or 7 (human and mouse mINT). Table 1 lists nucleic acid sequences encoding some exemplary chemokine or cytokine fusion proteins.

The nucleic acid molecules encoding a cytokine fusion protein of the invention can be expressed from a vector, such as a recombinant viral vector. The recombinant viral vectors of the invention comprise sequences encoding the cytokine fusion protein of the invention and any suitable promoter for expressing the cytokine fusion sequences. Suitable promoters include, for example, the U6 or H1 RNA pol III promoter sequences and the cytomegalovirus promoter. Selection of other suitable promoters is within the skill in the art. The recombinant viral vectors of the invention can also comprise inducible or regulatable promoters for expression of the cytokine fusion recombinant genes in a particular tissue or in a particular intracellular environment. In one embodiment, recombinant baculoviruses and promoters can be used from pFastBac plasmid and the Bac-to-Bac protocol (Invitrogen, Gaithersburg, Md., Cat. No. 13459-016 or 10608-016).

Suitable expression vectors generally include DNA plasmids or viral vectors. Expression vectors compatible with eukaryotic cells, preferably those compatible with vertebrate cells, can be used to produce recombinant constructs for the expression of an iRNA as described herein. Eukaryotic cell expression vectors are well known in the art and are available from a number of commercial sources. Typically, such vectors are provided containing convenient restriction sites for insertion of the desired nucleic acid segment. Delivery of expression vectors can be systemic, such as by intravenous or intramuscular administration, by administration to target cells ex-planted from the patient followed by reintroduction into the patient, or by any other means that allows for introduction into a desired target cell.

Plasmids expressing a nucleic acid sequence encoding a cytokine fusion protein can be transfected into target cells as a complex with cationic lipid carriers (e.g., Oligofectamine) or non-cationic lipid-based carriers (e.g., Transit-TKO′). Successful introduction of vectors into host cells can be monitored using various known methods. For example, transient transfection can be signaled with a reporter, such as a fluorescent marker, such as Green Fluorescent Protein (GFP). Stable transfection of cells ex vivo can be ensured using markers that provide the transfected cell with resistance to specific environmental factors (e.g., antibiotics and drugs), such as hygromycin B resistance.

Viral vector systems which can be utilized with the methods and compositions described herein include, but are not limited to, (a) adenovirus vectors; (b) retrovirus vectors, including but not limited to lentiviral vectors, moloney murine leukemia virus, etc.; (c) adeno-associated virus vectors; (d) herpes simplex virus vectors; (e) SV 40 vectors; (f) polyoma virus vectors; (g) papilloma virus vectors; (h) picornavirus vectors; (i) pox virus vectors such as an orthopox, e.g., vaccinia virus vectors or avipox, e.g. canary pox or fowl pox; and (j) a helper-dependent or gutless adenovirus. Replication-defective viruses can also be advantageous. Different vectors will or will not become incorporated into the cells' genome. The constructs can include viral sequences for transfection, if desired. Alternatively, the construct may be incorporated into vectors capable of episomal replication, e.g., EPV and EBV vectors. Constructs for the recombinant expression of a nucleic acid encoding a cytokine fusion protein will generally require regulatory elements, e.g., promoters, enhancers, etc., to ensure the expression of the cytokine fusion nucleic acid in target cells. Other aspects to consider for vectors and constructs are further described below.

Vectors useful for the delivery of a cytokine fusion nucleic acid can include regulatory elements (promoter, enhancer, etc.) sufficient for expression of the cytokine fusion nucleic acid in the desired target cell or tissue. The regulatory elements can be chosen to provide either constitutive or regulated/inducible expression. A person skilled in the art would be able to choose the appropriate regulatory/promoter sequence based on the intended use of the transgene.

In a specific embodiment, viral vectors that contain the recombinant gene can be used. For example, a retroviral vector can be used (see Miller et al., Meth. Enzymol. 217:581-599 (1993)). These retroviral vectors contain the components necessary for the correct packaging of the viral genome and integration into the host cell DNA. The nucleic acid sequences encoding a cytokine fusion protein are cloned into one or more vectors, which facilitates delivery of the nucleic acid into a patient. More detail about retroviral vectors can be found, for example, in Boesen et al., Biotherapy 6:291-302 (1994), which describes the use of a retroviral vector to deliver the mdr1 gene to hematopoietic stem cells in order to make the stem cells more resistant to chemotherapy. Other references illustrating the use of retroviral vectors in gene therapy are: Clowes et al., J. Clin. Invest. 93:644-651 (1994); Kiem et al., Blood 83:1467-1473 (1994); Salmons and Gunzberg, Human Gene Therapy 4:129-141 (1993); and Grossman and Wilson, Curr. Opin. in Genetics and Devel. 3:110-114 (1993). Lentiviral vectors contemplated for use include, for example, the HIV based vectors described in U.S. Pat. Nos. 6,143,520; 5,665,557; and 5,981,276, which are herein incorporated by reference.

Adenoviruses are also contemplated for use in delivery of isolated nucleic acids encoding cytokine fusion proteins into a cell. Adenoviruses are especially attractive vehicles for delivering genes to respiratory epithelia or for use in adenovirus-based delivery systems such as delivery to the liver, the central nervous system, endothelial cells, and muscle. Adenoviruses have the advantage of being capable of infecting non-dividing cells. Kozarsky and Wilson, Current Opinion in Genetics and Development 3:499-503 (1993) present a review of adenovirus-based gene therapy. Bout et al., Human Gene Therapy 5:3-10 (1994) demonstrated the use of adenovirus vectors to transfer genes to the respiratory epithelia of rhesus monkeys. Other instances of the use of adenoviruses in gene therapy can be found in Rosenfeld et al., Science 252:431-434 (1991); Rosenfeld et al., Cell 68:143-155 (1992); Mastrangeli et al., J. Clin. Invest. 91:225-234 (1993); PCT Publication WO94/12649; and Wang, et al., Gene Therapy 2:775-783 (1995). A suitable AV vector for expressing a nucleic acid molecule featured in the invention, a method for constructing the recombinant AV vector, and a method for delivering the vector into target cells, are described in Xia H et al. (2002), Nat. Biotech. 20: 1006-1010.

Use of Adeno-associated virus (AAV) vectors is also contemplated (Walsh et al., Proc. Soc. Exp. Biol. Med. 204:289-300 (1993); U.S. Pat. No. 5,436,146). Suitable AAV vectors for expressing the dsRNA featured in the invention, methods for constructing the recombinant AV vector, and methods for delivering the vectors into target cells are described in Samulski R et al. (1987), J. Virol. 61: 3096-3101; Fisher K J et al. (1996), J. Virol, 70: 520-532; Samulski R et al. (1989), J. Virol. 63: 3822-3826; U.S. Pat. Nos. 5,252,479; 5,139,941; International Patent Application No. WO 94/13788; and International Patent Application No. WO 93/24641, the entire disclosures of which are herein incorporated by reference.

Another preferred viral vector is a pox virus such as a vaccinia virus, for example an attenuated vaccinia such as Modified Virus Ankara (MVA) or NYVAC, an avipox such as fowl pox or canary pox.

The pharmaceutical preparation of a vector can include the vector in an acceptable diluent, or can include a slow release matrix in which the gene delivery vehicle is imbedded. Alternatively, where the complete gene delivery vector can be produced intact from recombinant cells, e.g., retroviral vectors, the pharmaceutical preparation can include one or more cells which produce the gene delivery system.

Examples of additional expression vectors that can be used in the invention include pFASTBAC expression vectors and E. coli pET28a expression vectors.

Generally, recombinant vectors capable of expressing genes for recombinant cytokine fusion proteins are delivered into and persist in target cells. The vectors or plasmids can be transfected into target cells by a transfection agent, such as Lipofectamine. Examples of cells useful for expressing the nucleic acids encoding the cytokine fusion proteins of the invention include Sf9 cells or insect larvae cells. Recombinant vaults based on expression of the MVP protein alone can be produced in insect cells. Stephen, A. G. et al. (2001). J. Biol. Chem. 276:23217:23220; Poderycki, M. J., et al. (2006). Biochemistry (Mosc). 45: 12184-12193.

Pharmaceutical Compositions of the Invention

In one embodiment, the invention provides methods using pharmaceutical compositions comprising the vault complexes of the invention. These compositions can comprise, in addition to one or more of the vault complexes, a pharmaceutically acceptable excipient, carrier, buffer, stabilizer or other materials well known to those skilled in the art. Such materials should be non-toxic and should not interfere with the efficacy of the active ingredient. The precise nature of the carrier or other material can depend on the route of administration, e.g. oral, intravenous, cutaneous or subcutaneous, nasal, intramuscular, intraperitoneal routes.

In certain embodiments, the pharmaceutical compositions that are injected intratumorally comprise an isotonic or other suitable carrier fluid or solution.

For intravenous, cutaneous or subcutaneous injection, or injection at the site of affliction, the active ingredient will be in the form of a parenterally acceptable aqueous solution which is pyrogen-free and has suitable pH, isotonicity and stability. Those of relevant skill in the art are well able to prepare suitable solutions using, for example, isotonic vehicles such as Sodium Chloride Injection, Ringer's Injection, Lactated Ringer's Injection. Preservatives, stabilizers, buffers, antioxidants and/or other additives can be included, as required.

In other embodiments, pharmaceutical compositions for oral administration can be in tablet, capsule, powder or liquid form. A tablet can include a solid carrier such as gelatin or an adjuvant. Liquid pharmaceutical compositions generally include a liquid carrier such as water, petroleum, animal or vegetable oils, mineral oil or synthetic oil. Physiological saline solution, dextrose or other saccharide solution or glycols such as ethylene glycol, propylene glycol or polyethylene glycol can be included.

In some embodiments, administration of the pharmaceutical compositions may be topical, pulmonary, e.g., by inhalation or insufflation of powders or aerosols, including by nebulizer; intratracheal, intranasal, epidermal and transdermal, oral or parenteral. Parenteral administration includes intravenous, intraarterial, subcutaneous, intraperitoneal or intramuscular injection or infusion; or intracranial, e.g., intraparenchymal, intrathecal or intraventricular, administration. Formulations for parenteral administration may include sterile aqueous solutions which may also contain buffers, diluents and other suitable additives. For intravenous use, the total concentration of solutes should be controlled to render the preparation isotonic.

Methods of Use

Vault complexes described herein can be used to deliver a protein of interest, e.g., cytokines, to a cell, a tissue, an environment outside a cell, a tumor, an organism or a subject. In one embodiment, the vault complex comprises a cytokine described herein, e.g., CCL-21, and the vault complex is introduced to the cell, tissue, or tumor. In some embodiments, the vault complex is introduced into the extracellular environment surrounding the cell. In other embodiments, the vault complex is introduced into an organism or subject. Delivery of the vault complex of the invention can include administering the vault complex to a specific tissue, specific cells, an environmental medium, or to the organism. In some embodiments, delivery of the vault complex can be detected by a sensor within the cell, tissue, or organism. For example, detection can be performed using standard techniques, such as fluorometry or spectrophotometry. This method can be used, for example, to determine the pH within cells, where the sensor is a pH dependent fluorescent sensor, as will be appreciated by one of ordinary skill in the art with reference to this disclosure.

The methods of the invention comprise stimulating an immune response to a cell by contacting the cell with any of the vault complexes described herein. Cells of the invention can include, but are not limited to, any eukaryotic cell, mammalian cell, or human cells, including tumor cells. In some embodiments, contacting the cell with a vault complex induces migration of T cells and/or dendritic cells to the cell.

Methods of the invention include delivery of the vault complex to a subject. The delivery of a vault complex to a subject in need thereof can be achieved in a number of different ways. In vivo delivery can be performed directly by administering a vault complex to a subject. Alternatively, delivery can be performed indirectly by administering one or more vectors that encode and direct the expression of the vault complex or components of the vault complex. In one embodiment, the vault complex is administered to a mammal, such as a mouse or rat. In another embodiment, the vault complex is administered to a human.

In one embodiment, the methods of delivery of the invention include systemic injection of vault complexes to tumors, producing the enhanced permeability and retention (EPR) effect. See Maeda et al., J. of Controlled Release 2000, 65: 271-284; Griesh, K., J. of Drug Targeting 2007, 15(7-8): 457-464; Allen et al., Science 2004, 303:1818-1822. Solid tumors possess extensive angiogenesis and hence hypervasculature, defective vascular architecture, impaired lymphatic drainage/recovery systems, and greatly increased production of a number of permeability mediators. Due to the biology of solid tumors, macromolecular anticancer drugs and agents, including vault complexes, administered intravenously can accumulate and are retained in the tumor due to the lack of efficient lymphatic drainage in the solid tumor. The invention includes methods of systemic or targeted delivery of vault complexes described herein to solid tumors, such as those found in lung cancer.

Other methods of the invention include stimulating an immune response in a subject. The method comprises administering the vault complex to a subject. Administering can include intra-tumoral injection of the vault complex in a subject, which is described in detail herein.

Methods of Treatment

The invention features a method of treating or managing disease, such as cancer, by administering the vault complex of the invention to a subject (e.g., patient). In some embodiments, the vault complexes of the invention can be used for treating or managing lung cancer. In another embodiment, the method of the invention comprises treating or managing cancer in a subject in need of such treatment or management, comprising administering to the subject a therapeutically effective amount of the vault complexes described herein. In one embodiment, the method involves treating a human by identifying a human diagnosed as having lung cancer or at risk for developing lung cancer and administering to the human a therapeutically or prophylactically effective amount of the CCL-21 vault complex to the human. In another embodiment, the method comprises administering to the human to therapeutically or prophylactically effective amount of the CCL-21 vault complex by intra-tumoral injection.

Vault complexes of the invention can be used to treat any solid cancer, e.g., lung cancer, breast cancer, head and neck cancer, prostate cancer, etc. Advances in mouse genetics have generated a number of mouse models for the study of various human diseases, such as treatment of lung cancer. Such models are used for in vivo testing of vault complexes, as well as for determining a therapeutically effective dose. A suitable mouse model is, for example, a tumor-bearing mouse that is administered an intra-tumoral injection of a CCL-21 vault complex.

The data obtained from cell culture assays and animal studies can be used in formulating a range of dosage for use in humans. For any compound used in the methods featured in the invention, the therapeutically effective dose can be estimated initially from cell culture assays. A dose may be formulated in animal models to achieve a circulating plasma concentration range of the vault complex. Such information can be used to more accurately determine useful doses in humans. Analysis of tumor cell samples of mice administered a vault complex can also indicate a therapeutically effective dose.

The pharmaceutical composition according to the present invention to be given to a subject, administration is preferably in a “therapeutically effective amount” or “prophylactically effective amount” (as the case can be, although prophylaxis can be considered therapy), this being sufficient to show benefit to the individual. The actual amount administered, and rate and time-course of administration, will depend on the nature and severity of protein aggregation disease being treated. Prescription of treatment, e.g. decisions on dosage etc, is within the responsibility of general practitioners and other medical doctors, and typically takes account of the disorder to be treated, the condition of the individual patient, the site of delivery, the method of administration and other factors known to practitioners. Examples of the techniques and protocols mentioned above can be found in Remington's Pharmaceutical Sciences, 16th edition, Osol, A. (ed), 1980. A composition can be administered alone or in combination with other treatments, either simultaneously or sequentially dependent upon the condition to be treated.

In certain embodiments, the dosage of vault complexes is between about 0.1 and 10,000 micrograms per kilogram of body weight or environmental medium. In another embodiment, the dosage of vault complexes is between about 1 and 1,000 micrograms per kilogram of body weight or environmental medium. In another embodiment, the dosage of vault complexes is between about 10 and 1,000 micrograms per kilogram of body weight or environmental medium. For intravenous injection and intraperitoneal injection, the dosage is preferably administered in a final volume of between about 0.1 and 10 ml. For inhalation the dosage is preferably administered in a final volume of between about 0.01 and 1 ml. As will be appreciated by one of ordinary skill in the art with reference to this disclosure, the dose can be repeated a one or multiple times as needed using the same parameters to effect the purposes disclosed in this disclosure.

For instance, the pharmaceutical composition may be administered once for each tumor in a subject, or the vault complex may be administered as two, three, or more sub-doses or injections at appropriate intervals. In that case, the vault complexes can be injected in sub-doses in order to achieve the total required dosage.

The vault complexes featured in the invention can be administered in combination with other known agents effective in treatment of cancers, including lung cancer. An administering physician can adjust the amount and timing of vault complex administration or injection on the basis of results observed using standard measures of efficacy known in the art or described herein. The skilled artisan will also appreciate that certain factors may influence the dosage and timing required to effectively treat a subject, including but not limited to the severity of the disease or disorder, previous treatments, the general health and/or age of the subject, and other diseases present.

Methods of Preparing Vault Complexes

The methods of the invention include preparing the vault complexes described herein.

In one embodiment, the vault complexes are derived or purified from natural sources, such as mammalian liver or spleen tissue, using methods known to those with skill in the art, such as for example tissue homogenization, differential centrifugation, discontinuous sucrose gradient fractionation and cesium chloride gradient fractionation. In another embodiment, the vault complexes are made using recombinant technology. Details about the methods for recombinant vault complexes are described below.

In some embodiments, a target of interest, i.e., protein of interest, is selected for packaging in the vault complexes. The target of interest may be selected from the group consisting of an enzyme, a pharmaceutical agent, a plasmid, a polynucleotide, a polypeptide, a sensor and a combination of the preceding. In a preferred embodiment, the target of interest is a recombinant protein, e.g., a cytokine fusion protein, e.g., a CCL-21 fusion protein.

Preferably, if the target of interest is a recombinant protein, the polynucleotide sequences encoding the recombinant protein are used to generate a bacmid DNA, which is used to generate a baculovirus comprising the sequence. The baculovirus is then used to infect insect cells for protein production using an in situ assembly system, such as the baculovirus protein expression system, according to standard techniques, as will be appreciated by one of ordinary skill in the art with reference to this disclosure. Advantageously, the baculovirus protein expression system can be used to produce milligram quantities of vault complexes, and this system can be scaled up to allow production of gram quantities of vault complexes according to the present invention.

In another embodiment, the target of interest is incorporated into the provided vaults. In a preferred embodiment, incorporation is accomplished by incubating the vaults with the target of interest at an appropriate temperature and for an appropriate time, as will be appreciated by one of ordinary skill in the art with reference to this disclosure. The vaults containing the protein of interest are then purified, such as, for example sucrose gradient fractionation, as will be appreciated by one of ordinary skill in the art with reference to this disclosure.

In other embodiments, the vaults comprising the target of interest are administered to an organism, to a specific tissue, to specific cells, or to an environmental medium. Administration is accomplished using any suitable route, as will be appreciated by one of ordinary skill in the art with reference to this disclosure.

In one embodiment, the method comprises preparing the composition of the invention by a) mixing a fusion protein comprising a chemokine fused to a mINT generated in Sf9 cells with a rat MVP generated in Sf9 cells to generate a mixture; b) incubating the mixture for a sufficient period of time to allow packaging of the fusion protein inside of vault complexes, thereby generating the composition. Sf9 cells are infected with CCL-21-mCherry-mINT or CP-MVP encoding recombinant baculoviruses. Lysates containing recombinant CCL-21-mINT and rat MVP generated in Sf-9 cells can be mixed to allow the formation of a macromolecular vault complex containing the CCL-21 fusion protein.

In another embodiment, the composition is prepared by a) mixing a fusion protein comprising a chemokine fused to a mINT generated in insect larvae cells with a rat MVP generated in insect larvae cells to generate a mixture; b) incubating the mixture for a sufficient period of time to allow packaging of the fusion protein inside of vault complexes.

Details about methods of preparing vault complexes are further described in the Examples.

EXAMPLES

Below are examples of specific embodiments for carrying out the present invention. The examples are offered for illustrative purposes only, and are not intended to limit the scope of the present invention in any way. Efforts have been made to ensure accuracy with respect to numbers used (e.g., amounts, temperatures, etc.), but some experimental error and deviation should, of course, be allowed for.

The practice of the present invention will employ, unless otherwise indicated, conventional methods of protein chemistry, biochemistry, recombinant DNA techniques and pharmacology, within the skill of the art. Such techniques are explained fully in the literature. See, e.g., T. E. Creighton, Proteins: Structures and Molecular Properties (W.H. Freeman and Company, 1993); A. L. Lehninger, Biochemistry (Worth Publishers, Inc., current addition); Sambrook, et al., Molecular Cloning: A Laboratory Manual (2nd Edition, 1989); Methods In Enzymology (S. Colowick and N. Kaplan eds., Academic Press, Inc.); Remington's Pharmaceutical Sciences, 18th Edition (Easton, Pa.: Mack Publishing Company, 1990); Carey and Sundberg Advanced Organic Chemistry 3rd Ed. (Plenum Press) Vols A and B(1992).

Methods

Cloning, Expression, and Purification of Vault Complexes

A cDNA encoding CCL-21 was fused in frame to either mINT or mCherry-mINT [21]. Murine CCL-21 was PCR amplified using the following primers: CCL21-forward GCGCGGATCCCCATGGCTCAGATGATG (SEQ ID NO:63) and CCL-21-reverse GCGCAGATCTTCCTCTTGAGGGCTGTGTCTG (SEQ ID NO:64). To form mCCL-21-mCherry-mINT in pFastBac, the CCL21 PCR product was purified on a Qiagen column, digested with BamH1 and Bgl I, gel purified, and ligated to BamH1 phosphatase treated mCherry-mINT pFastBac. Human CCL21 was PCR amplified with the following primers:

CCL-21 F-SpeI (SEQ ID NO:  65) CCCCACTAGTCCAGTTCTCAGTCACTGGCTCTG, CCL-21-NheI (SEQ ID NO:  66) CCCCGCTAGCTGGCCCTTTAGGGGTCTGTG, mINTwith NheI (SEQ ID NO:  67) CCCCGCTAGCTGCACACAACACTGGCAGGA, mINT with XhoI (SEQ ID NO:  68) GGGGCTCGAGTTAGCCTTGACTGTAATGGA to form hCCL-21-mINT.

Recombinant baculoviruses were generated using the Bac-to-Bac protocol (Invitrogen, Gaithersburg, Md.). 519 cells were infected with CCL-21-mCherry-mINT or CP-MVP encoding recombinant baculoviruses at a multiplicity of infection (MOI) of 0.01 for 65 h. The infected cells were pelleted, and lysed on ice in buffer A [50 mM Tris-HCl (pH 7.4), 75 mM NaCl, and 0.5 mM MgCl₂] with 1% Triton X-100, 1 mM dithiotreitol, 0.5 mM PMSF, and protease inhibitor cocktail (Sigma P8849). Lysates containing CP-MVP vaults were mixed with lysates containing mCCL-21-mCherry-mINT, hCCL-21-mINT and were incubated on ice for 30 min to allow the INT fusion proteins to package inside of vaults. Recombinant vault complexes were purified as previously described [7]. Purified recombinant vault complexes were resuspended in 100-200 μl of sterile phosphate buffered saline. Protein concentration was determined using the BCA assay (Bio-Rad Laboratories, Hercules, Calif.) and sample integrity was analyzed by negative stain electron microscopy and SDS-PAGE followed by Coomassie staining and Western blot analysis.

Antibodies

Primary antibodies for Western blot analyses were rabbit anti-MVP polyclonal antibody (1/1000 dilution) or rabbit anti-VPARP polyclonal antibody (1/500 dilution, overnight) and secondary goat anti-rabbit HRP-conjugated antibodies (1:2000 dilution) (Amersham). The anti-CCL-21 antibodies were purchased from R&D Systems, (Minneapolis, Minn.). Primary antibody for immunostaining for CD3 was purchased from DAKO. Fluorescein isothiocyanate-, phycoerythrin-, allophycocyanin-, PerCP- or PerCP-Cy7-conjugated anti-mouse mAbs to CD3 (145-2C11), CD4 (RM4-5), CD8a (53-6.7) and subclass control antibody, were purchased from BD Biosciences (San Diego, Calif.). Anti-mouse mAbs to detect Tregs with cell surface CD4 (GK1.5), CD25 (PC61), intranuclear Foxp3 (FJK-16s) IL-10 (JESS-16E3), and IFNγ (XMG1.2) were purchased from eBioScience (San Diego, Calif.) were purchased from eBioScience (San Diego, Calif.). Antibodies to DEC205 (205yekta), CCR7 (4B12) and EpCam (G8.8) were from eBioScience. Antibody to mouse CD11b (M1/70), Gr1 (RB6-8C5), were purchased from BioLegend (San Diego). Anti-mouse mAb to CXCR3 (220803), was purchased from R&D Systems (Minneapolis, Minn.). Ovalbumin protein and Bradford protein quantification dye was obtained from Sigma (St. Louis, Mo.). Tissue digestion buffer consisted of [0.2 mg/ml of Collagenase A (Boehringer Mannheim/Roche, Indianapolis, Ind.), DNase 25 U/ml (Sigma), and 0.3 U/ml of Dispase (Invitrogen, Carlsbad, Ca)] in RPMI.

Chemotaxis Assay

Dual-chamber chemotaxis assays were performed using 24-well plates with 3 μm pore size inserts (Costar/Corning, Corning, N.Y., United States) according to the manufacturer's instructions. Briefly, 2.0×10⁵ T2 cells were resuspended in serum-free medium and loaded in the upper chamber. 200 ng/ml of CCL-21-mcherry-vault, 600 ng/ml recombinant CCL-21 (R&D Systems), 200 ng/ml CCL-21-mcherry-vault with neutralizing anti-CCL-21 recombinant antibody (5 μg/ml), 600 ng/ml CCL-21 with neutralizing anti-CCL-21 antibody (5 μg/ml) were added to the lower chamber of the wells (in triplicate). The neutralizing concentration of anti-CCL-21 antibody (R&D) used in these studies (5 μg/ml) was based on the ND50 (50% maximum inhibition of cytokine activity when CCL-21 is present at a concentration high enough to elicit maximum response). After 2 hours incubation at 37° C., migrated cells were recovered from the lower chamber and the inserts according to the manufacturer's instructions. Migrated T2 cells were resuspended in FACS buffer and evaluated by counting the number of lymphocytes.

Antigen Processing and Presentation Assay

Cells (DC2.4 (5×10⁴c/well)) were plated in triplicates in 96-well plates with OVA protein (350 μg/ml), MHC Class I restricted CD8 T cell line B3Z (10⁵c/well), in the presence of control vaults (200 ng/ml), or CCL-21 vault complex (200 ng/ml) or rCCL-21 (200 ng/ml) for 24 hrs. To determine the impact of CCL-21 on APC activity, CCL-21 was neutralized with anti-CCL-21 Ab (5 μg/ml) (R&D). IL-2 secreted by the activated CD8 T cells in the supernatant was quantified by ELISA (eBioScience).

Cell Culture

The murine Lewis lung carcinoma cell line (3LL, H2^(b)) was obtained from American Type Culture Collection (ATCC, Manassas, Va.). The cells were routinely cultured as monolayers in 25-cm² tissue culture flasks containing RPMI 1640 medium (Irvine Scientific, Santa Ana, Calif.) supplemented with 10% FBS (Gemini Bioproducts, Calabasas, Calif.), penicillin (100 U/ml), streptomycin (0.1 mg/ml), and 2 mM glutamine (JRH Biosciences, Lenexa, Kans.), and maintained at 37° C. in humidified atmosphere containing 5% CO₂ in air. The cell line was mycoplasma free, and cells were utilized before the tenth passage.

Tumorigenesis Model

Pathogen-free C57BL/6 mice and UBC-GFP/BL6 (6-8 wk old; Jackson Laboratory) were maintained in the West Los Angeles Veterans Affairs Animal Research vivarium. For tumorigenesis experiments, 1.5×10⁵ 3 LL tumor cells were injected s.c. in the right suprascapular area of C57BL/6 mice. Mice bearing 9-day-old established tumors were treated with a single intratumoral injection of mCCL-21-mCherry-CP-MVP vaults (200 ng), CP-MVP vaults (200 ng) in 200 μl or normal saline diluents. Tumor volumes were monitored by measuring two bisecting diameters of each tumor with calipers. Tumor volumes were calculated using the formula: V=0.4ab², with “a” as the larger diameter and “b” as the smaller diameter. To determine the extent of lymphocytes infiltrating the tumors, UBC-GFP/BL6 mice bearing 9-day tumors were treated as described and 7 days post treatment, non-necrotic tumors were isolated and frozen in OCT. The frozen tissue was sectioned to 5-μm thickness, fixed onto slides, and counterstained with 4′,6-diamidino-2-phenylindole (DAPI) fixative. The slides were observed under a 1×71 Olympus fluorescence microscope attached to a charge-coupled device camera. The images were acquired under ×10 and ×40 objectives using the Image Pro software.

Orthotopic Model

Implantation of the tumors in the lung was performed as previously described in Andersson, A. et al. J Immunol 2009, 182(11):6951-6958 [24]. Briefly, 5×10³ 3 LL-GFP cells in 25 μl NS diluent were injected by the transthoracic route of C57BL/6 mice utilizing a tuberculin syringe with a 30-gauge needle in the left lung under ketamine/xylazine anesthesia. One week following tumor inoculation, mice were treated with diluent, control vault or CCL-21 vault complex via transthoracic injection. Four weeks after tumor implantation, lungs were harvested for evaluation of tumor burden and leukocytic infiltrates. Tumor burden was quantified by gating on the GFP and EpCam expressing 3LL tumor cells in single cell suspension of lung-tumor digests.

Immunostaining

Immunohistochemical staining was performed to determine and characterize the infiltrating cells. Specifically, paraffin sections of 5 μm were deparaffinized in xylene and rehydrated in decreasing concentrations of ethanol according to standard protocol [25]. Heat-induced antigen retrieval in citrate buffer (3 min in a steamer) was followed by blockade of endogenous peroxidase activity with 3% hydrogen peroxide in TBS for 10 min. All tissue was blocked (4% BSA, 10% sucrose, 1% normal swine serum in TBS) for 20 min at room temperature (RT). Primary antibody (DAKO, Cytomation, Carpinteria, Calif., USA) was diluted in the blocking solution to the following concentrations: CD3 1:200. Sections were incubated with the antibodies overnight at 4° C. On the second day, the slides were washed with Tris-buffered saline containing 0.02% Tween. This was followed by incubation with secondary biotinylated goat anti-mouse antibody at room temperature, streptavidin-conjugated alkaline phosphatase (Vectastain ABC-AP kit; Vector Laboratories, Burlingame, Calif.), and chromagen development with Vector Red substrate solution (Vector Laboratories). Slides were counterstained with hematoxylin, dehydrated, and mounted for analysis and photography.

Flow Cytometry

Flow cytometry was performed for the following leukocytic markers CD3, CD4, CD8, CCR7, CD11b, Gr1, DEC205, CD25, FOXP3 and CXCR3 on single cell suspension of tumors following treatment as described above. T cells were stained for intracytoplasmic IFNγ and IL-10. For analyses in the tumor tissue, tumors were mechanically dissociated on a wire mesh by crushing with a 10 ml syringe and incubated in tissue digestion buffer at 37° C. for 25 min. The cells were filtered through 70 μm nylon strainers (BD Biosciences, Bedford, Mass.) and stained with specific markers and analyzed by flow cytometry. Samples were acquired on a FACSCanto (BD Biosciences/FACSCalibur flow cytometer (Becton Dickinson, San Jose, Calif.) in the University of California, Los Angeles, Jonsson Cancer Center Flow Cytometry Core Facility. A total of 10,000 to 25,000 gated events were analyzed using FCS Express 3 (De Novo Software, Canada). Cells incubated with irrelevant isotype-matched antibodies and unstained cells served as controls. The cutoffs were set according to control staining.

T Cell Cytolysis

T lymphocyte lytic responses were evaluated following therapy. T cells were purified from spleens by negative selection using Miltenyi Biotec beads, and cytolytic activities were evaluated against autologous 3LL tumor cell line and the syngeneic control B16 melanoma tumor cell line. The T cell effectors were co-cultured with tumor cell targets (E:T of 20:1 and 40:1) in quadruplet wells in a 96-well plate, and 20 μl alamar blue was added to each well after 18 hours of incubation. Three hours after alamar blue addition, the plate was read with the Wallac 1420 fluorescence plate reader (Perkin-Elmer Life Science, Turku, Finland) with the excitation/emission set at 530/590 nm.

Example 1: Packaging CCL-21 into the Recombinant Vaults

A mouse chemokine CCL-21 was fused to a mouse mINT to create a CCL-21 fusion protein that was packaged into vault complexes. FIG. 1A shows a diagram of the CCL-21 and mCherry-INT constructs (SEQ ID NO:60) that were fused to create the mouse CCL-21-mCherry-mINT fusion protein (SEQ ID NO: 61). Mixing of lysates containing recombinant CCL-21-mINT and rat MVP generated in Sf-9 cells allowed the formation of a macromolecular vault complex containing the CCL-21 fusion protein that could be isolated by density gradient ultracentrifugation. The purified vault complexes contained both MVP as well as CCL-21-mINT (henceforth referred to as CCL-21 vault complex). FIG. 1B shows the incorporation of the recombinant CCL-21-mINT into a pFastBac expression vector by restriction digest and expression of CCL-21 fusion protein as analyzed on an electrophoresis gel. The MVP recombinant vaults containing packaged CCL-21-mCherry-mINT were purified on a sucrose gradient and the 40 and 45% fractions were analyzed by SDS-PAGE (FIG. 1C) and followed by staining with Coomassie (FIG. 1D). FIG. 1E shows a negative stain TEM image of vaults containing CCL-21-mCherry-mINT.

There was an estimated 20-30 molecules of the CCL-21-mINT protein in each vault complex is based on extrapolation from densitometric analysis of the Coomassie stained SDS-PAGE gels. This is consistent with previous studies in packaging multiple copies of other mINT fusion proteins into recombinant vault complexes [21]. With an estimate of 20-30 CCL-21-mINT proteins per vault, it is likely that this is at or near a saturating level for the packaging of this size protein. The CCL-21 vault complex also exhibited a very similar sedimentation profile on sucrose gradients as vault particles containing the INT domain fused to luciferase [6, 8, 21], suggesting that incorporation of CCL-21-mINT did not impact the normal structure of recombinant vault complexes. FIG. 1E shows purified vault complexes examined by negative stain transmission electron microscopy.

These results demonstrate that CCL-21 vaults complexes exhibit the characteristic barrel shaped morphology of vaults, consistent with the previously established morphology of vaults containing recombinant-INT fusion proteins [8, 26].

Example 2: CCL-21-Vault Complexes are Biologically Active and Induce the Migration of T2 Cells In Vitro

To determine whether CCL-21 retains its biological function when packaged inside the vault, a chemotaxis assay was used. The chemotactic activity of CCL-21 is mediated through its receptor CCR7 to induce the migration of T cells and dendritic cells. To evaluate the biological activity of CCL-21 in the vault, T2 hybridoma cells were used that constitutively express CCR7. Two different concentrations of CCL-21 vault complexes (200 ng and 600 ng), empty vaults (600 ng), and recombinant CCL-21 (600 ng) were placed in the bottom chamber of a 24-well transwell plates and 2×10⁵ T2 cells were loaded in the upper chamber.

In FIG. 2A, the number of cells that migrated to the lower chamber following incubation was determined by flow cytometry and represented as the % migration. 2.0×10⁵ T2 cells were plated in serum-free medium in the upper chamber. CCL-21-mCherry-vault complexes (200 ng/ml or 600 ng/ml), recombinant CCL-21 (600 ng/ml), control vaults (600 ng/ml) or neutralizing anti-CCL-21 recombinant antibody (5 μg/ml) were added to the lower chamber of the wells. Following a two hour incubation, migration of T2 cells were analyzed by flow cytometry. CCL-21 vault complexes effectively increased the T2 migration as compared with control, and anti-CCL-21 neutralizing Ab. abrogated the increase in migration suggesting that CCL-21 vault complexes are biological active and can mediate the chemotatic migration of T cells. Data in the panel are representative of 2 independent experiments. (Bars; Mean±SEM, *p<0.05 between the CCL-21 vault complexes and control vault or anti-CCL-21 antibody treatment groups.)

More than 7.5% of the T2 cells responded to 200 ng of CCL-21 vault complexes compared with <2.5% of the T2 cells incubated with 600 ng of recombinant CCL-21. This is a phenomenal response considering that the given concentration is of CCL-vault complexes and the actual concentration of CCL-21 inside of the vaults would be estimated to be <20 ng. It is possible that the increased bioactivity of CCL-21 vault complexes results from increased stabilization of CCL-21 resulting from packaging of the protein into the protective environment of the vault lumen. As the fusion protein non-covalently associates within vaults, it is plausible that vault breathing in solution releases CCL-21 in a gradient fashion and the number of cells migrated was higher than the recombinant CCL-21 because a steeper gradient is formed. To demonstrate that the migration of T2 cells was CCL-21 dependent, a neutralizing antibody (against CCL-21) was shown to efficiently block the chemotactic activity of both recombinant CCL-21 and CCL-21 vault complexes. This led to the conclusion that CCL-21 vault complexes were functionally active at inducing the migration of T2 cells in vitro.

These results demonstrate that CCL-21 cytokines retain their biological function when packaged inside the vault complex.

Example 3: CCL-21 Vault Complexes Enhance DC APC Activity

In order to determine the effect of CCL-21 vault complexes on dendritic cell (DC) antigen presenting cell (APC) activity, the impact of CCL-21-vault complexes on DC APC activity was studied in vitro. In comparison to control vaults, CCL-21-vault complexes augmented DC capacity to process and present ovalbumin and activate CD8 T cells to secrete IL-2 (FIG. 2B).

FIG. 2B shows CCL-21 vault complexes enhanced DC APC activity, and blocking CCL-21 reversed the increase in APC activity. B3Z cells (1×10⁵ cells/200 ul/well) were co-cultured with DC 2.4 (5×10⁴ cells/200 ul/well) and ovalbumin (350 ug/ml) in the presence or absence of CCL21 vaults (200 ng/ml) and anti-CCL-21 antibody (5 ug/ml) or control antibody (5 ug/ml goat IgG) for 24 hrs. Control vaults were used at concentration of 200 ng/ml. T cell activation was analyzed by measuring IL-2 production by ELISA. Data are representative of 2 independent experiments. (Bars; Mean±SEM, *p<0.05 between the CCL21 vault and control vault or anti-CCL21 antibody treatment groups.) Neutralization of CCL-21 abrogated the increase in DC APC activity to control levels.

These results demonstrate that CCL-21 vault complexes enhance DC APC activity in vitro.

Example 4: CCL-21 Vault Complexes Enhance the Recruitment of Antitumor Leukocytic Infiltrates and Reduce 3LL Tumor Burden In Vivo

To determine the anti-tumor activity of CCL-21 vault complexes in vivo, CCL-21 vault complexes were tested for effects on established tumor burden in 3LL tumor-bearing mice.

As shown in FIG. 3, a single intratumoral injection of CCL-21 vault complexes (200 ng) led to significant decrease in tumor burden compared to empty vaults. C57BL/6 mice (n=5) were injected s.c. with 1.5×10⁵ 3 LL tumor cells and tumor growth was monitored daily. After 5 days following tumor implantation, mice were treated with vaults containing CCL-21-mCherry-mINT (200 ng), vaults alone (200 ng) or normal saline (diluent) via intra tumoral injection and tumor growth was monitored for the duration of the experiment. Tumor size was measured and tumor volume calculated as described herein. Bisecting tumor diameters were measured with calipers. Intra-tumoral administration of vaults containing CCL-21-mCherry-mINT led to significant reduction in tumor volume compared with untreated tumor bearing mice (p<0.001).

FIGS. 4A-4B show that the CCL-21-vault complex treatment group (FIG. 4B) had enhanced leukocytic infiltrates compared to control vault (FIG. 4A), and immune staining showed that the infiltrates were mostly CD3 expressing T cells (FIG. 4B, bottom right panel). Sections from paraffin-embedded tissue were stained by hematoxylin-eosin (H&E) and CD3, CD4, CD8 and S-100 by immunohistochemistry using commercially available antibodies. Each panel of FIGS. 4A and 4B show photographs taken at 400× of representative areas within distinct primary tumors and Lymph nodes. Thus, CCL-21 vaults reduced tumor burden and increased the influx of CD3 expressing T cells in the tumor as compared to control vaults. (Data; Mean±SEM, *p<0.05 between CCL-21 vaults and control group, n=8 mice/group.)

In additional experiments, the antitumor efficacy of CCL-21-vault complexes was determined in a 7-day established orthotopic 3LL lung cancer model. CCL-21-vault complexes reduced tumor burden by 7-fold compared to controls. In FIGS. 5A-5C, H&E staining of lung tumor sections from diluent or control vaults showed increased tumor masses as compared to reduced tumor mass in the CCL-21 vault complex treatment group. FIG. 5A illustrates the effects of treatment of 3LL lung cancer cells with diluents only. FIG. 5B shows treatment with control vault, and FIG. 5C shows treatment with CCL-21 vault.

FIG. 6A shows the percentage tumor burden in naïve cells, and 3LL cells treated with diluents, control vault (CV), or CCL-21 vault complexes in a flow cytometry assay. Tumor burden was calculated on total percentage of GFP and Epcam expressing tumor cells in total lung digest. Naïve lung was used as control to set up the gate. CCL-21 vault complex treatment reduced tumor burden. FIG. 6B is a graph illustrating the percentage tumor burden in 3LL cells after treatment with diluents, control vault, or CCL-21 vault complexes.

Example 5: CCL-21-Vault Complexes Induce Tumor Infiltrating T Cell IFNγ but Reduce IL-10 and Augment Systemic T Cell Cytolytic Activity

The effect of CCL-21 vault complexes on inducing tumor infiltrates and IL-10 expression was studied in vivo.

Accompanying the reduced tumor burden, an evaluation of intratumoral leukocytic populations showed enhanced frequency of CD4, CD8, CD3 CXCR3, CD3 CCR7 and DEC205 but reduced levels of MDSC and Tregs (FIG. 7A-7D). In FIG. 7A, CCL-21 vault complexes augmented CD4, CD8, CXCR3⁺CD3⁻T, CCR7⁺CD3⁺T and DEC205⁺DC infiltrates and reduced MDSC and Tregs compared with treatment with diluents or control vault alone. FIGS. 7B and 7C show T cell infiltrates of CCL-21 vault complex treatment mice increased IFNγ and reduced IL-10 expression compared to controls. FIG. 7D illustrates that CCL-21 vault treatment enhanced the cytolytic activity of purified splenic T cells against parental 3LL tumors in vitro (E:T of 20:1 and 40:1).

FIGS. 6A-7D demonstrate that CCL-21 vaults reduced tumor burden and immune suppressors, increased T and DC infiltrates and induced systemic T cell antitumor activity. Specifically, CCL-21 vaults reduced tumor burden and immune suppressors (MDSC and Tregs) and enhanced intratumoral immune cell infiltrates in a 3LL orthotropic lung cancer model. For experiments shown in FIGS. 6A-7D, 5×10³ 3 LL-GFP tumor cells were injected in the left lung via transthoracic route. One week after tumor injections, mice were treated with diluent (NS), control vaults (2 ug) or CCL-21 vaults (2 ug) via transthoracic route in the left lung. Day 28 post tumor implantation, lung tumors were harvested for the analysis of tumor burden and tumor leukocytic infiltrates. (Data bars, mean±SEM, *p<0.05 between CCL-21 vaults and control vault groups, n=8 mice/group.).

These results demonstrate that CCL-21 vault complexes induce tumor infiltrating T cell IFNγ but reduce IL-10 and augment systemic T cell cytolytic activity.

Example 6: Use of CCL-21 Vault Complexes for Treatment of Cancer in Humans

For treatment of cancer in humans, the pharmaceutical compositions used in the present invention may be administered in a number of ways depending upon the invasiveness of treatment and based on whether local or systemic treatment is desired. The preferred initial treatment may be performed by intra-tumoral injection of the CCL-21 vault complex into a tumor of the patient. In some embodiments, intra-tumoral injection of a CCL-21 vault complex is performed on a tumor in the lung of the patient in need of treatment of lung cancer.

In certain embodiments, various dosages of the pharmaceutical composition comprising CCL-21 vault complexes can be administered to the patient.

While the invention has been particularly shown and described with reference to a preferred embodiment and various alternate embodiments, it will be understood by persons skilled in the relevant art that various changes in form and details can be made therein without departing from the spirit and scope of the invention.

All references, issued patents and patent applications cited within the body of the instant specification are hereby incorporated by reference in their entirety, for all purposes.

TABLE 1 Sequences SEQ ID NO: 1 Mouse CCL-21 Protein sequence MAQMMTLSLLSLVLALCIPWTQGSDGGGQDCCLKYSQKKIPYSIVRGYRKQEPSLGCPIP AILFSPRKHSKPELCANPEEGWVQNLMRRLDQPPAPGKQSPGCRKNRGTSKSGKKGKGSK GCKRTEQTQPSRG SEQ ID NO: 2 Human CCL-21 Protein sequence MAQSLALSLLILVLAFGIPRTQGSDGGAQDCCLKYSQRKIPAKVVRSYRKQEPSLGCSIP AILFLPRKRSQAELCADPKELWVQQLMQHLDKTPSPQKPAQGCRKDRGASKTGKKGKGSK GCKRTERSQTPKGP SEQ ID NO: 3 Mouse CCL-21 DNA cloned sequence ATGGCTCAGATGATGACTCTGAGCCTCCTTAGCCTGGTCCTGGCTCTCTGCATCCCCTGGACCCAAGGCA GTGATGGAGGGGGTCAGGACTGCTGCCTTAAGTACAGCCAGAAGAAAATTCCCTACAGTATTGTCCGAGG CTATAGGAAGCAAGAACCAAGTTTAGGCTGTCCCATCCCGGCAATCCTGTTCTCACCCCGGAAGCACTCT AAGCCTGAGCTATGTGCAAACCCTGAGGAAGGCTGGGTGCAGAACCTGATGCGCCGCCTGGACCAGCCTC CAGCCCCAGGGAAACAAAGCCCCGGCTGCAGGAAGAACCGGGGAACCTCTAAGTCTGGAAAGAAAGGAAA GGGCTCCAAGGGCTGCAAGAGAACTGAACAGACACAGCCCTCAAGAGGA SEQ ID NO: 4 Mouse CCL-21 DNA full sequence ATGGCTCAGATGATGACTCTGAGCCTCCTTAGCCTGGTCCTGGCTCTCTGCATCCCCTGGACCCAAGGCA GTGATGGAGGGGGTCAGGACTGCTGCCTTAAGTACAGCCAGAAGAAAATTCCCTACAGTATTGTCCGAGG CTATAGGAAGCAAGAACCAAGTTTAGGCTGTCCCATCCCGGCAATCCTGTTCTCACCCCGGAAGCACTCT AAGCCTGAGCTATGTGCAAACCCTGAGGAAGGCTGGGTGCAGAACCTGATGCGCCGCCTGGACCAGCCTC CAGCCCCAGGGAAACAAAGCCCCGGCTGCAGGAAGAACCGGGGAACCTCTAAGTCTGGAAAGAAAGGAAA GGGCTCCAAGGGCTGCAAGAGAACTGAACAGACACAGCCCTCAAGAGGATAG Human CCL-21 DNA sequence, Genbank SEQ ID NO: 5 #NP_002980 ATGGCTCAGTCACTGGCTCTGAGCCTCCTTATCCTGGTTCTGGCCTTTGGCATCCCCAGGACCCAAGGCA GTGATGGAGGGGCTCAGGACTGTTGCCTCAAGTACAGCCAAAGGAAGATTCCCGCCAAGGTTGTCCGCAG CTACCGGAAGCAGGAACCAAGCTTAGGCTGCTCCATCCCAGCTATCCTGTTCTTGCCCCGCAAGCGCTCT CAGGCAGAGCTATGTGCAGACCCAAAGGAGCTCTGGGTGCAGCAGCTGATGCAGCATCTGGACAAGACAC CATCCCCACAGAAACCAGCCCAGGGCTGCAGGAAGGACAGGGGGGCCTCCAAGACTGGCAAGAAAGGAAA GGGCTCCAAAGGCTGCAAGAGGACTGAGCGGTCACAGACCCCTAAAGGGCCATAG SEQ ID NO: 6 Mouse mINT DNA sequence TGC ACA CAA CAC TGG CAG GAT GCT GTG CCT TGG ACA GAA CTC CTC AGT CTA CAG ACA GAG GAT GGC TTC TGG AAA CTT ACA CCA GAA CTG GGA CTT ATA TTA AAT CTT AAT ACA AAT GGT TTG CAC AGC TTT CTT AAA CAA AAA GGC ATT CAA TCT CTA GGT GTA AAA GGA AGA GAA TGT CTC CTG GAC CTA ATT GCC ACA ATG CTG GTA CTA CAG TTT ATT CGC ACC AGG TTG GAA AAA GAG GGA ATA GTG TTC AAA TCA CTG ATG AAA ATG GAT GAC CCT TCT ATT TCC AGG AAT ATT CCC TGG GCT TTT GAG GCA ATA AAG CAA GCA AGT GAA TGG GTA AGA AGA ACT GAA GGA CAG TAC CCA TCT ATC TGC CCA CGG CTT GAA CTG GGG AAC GAC TGG GAC TCT GCC ACC AAG CAG TTG CTG GGA CTC CAG CCC ATA AGC ACT GTG TCC CCT CTT CAT AGA GTC CTC CAT TAC AGT CAA GGC TAA SEQ ID NO: 7 Human mINT DNA sequence TGC ACA CAA CAC TGG CAG GAT GCT GTG CCT TGG ACA GAA CTC CTC AGT CTA CAG ACA GAG GAT GGC TTC TGG AAA CTT ACA CCA GAA CTG GGA CTT ATA TTA AAT CTT AAT ACA AAT GGT TTG CAC AGC TTT CTT AAA CAA AAA GGC ATT CAA TCT CTA GGT GTA AAA GGA AGA GAA TGT CTC CTG GAC CTA ATT GCC ACA ATG CTG GTA CTA CAG TTT ATT CGC ACC AGG TTG GAA AAA GAG GGA ATA GTG TTC AAA TCA CTG ATG AAA ATG GAT GAC CCT TCT ATT TCC AGG AAT ATT CCC TGG GCT TTT GAG GCA ATA AAG CAA GCA AGT GAA TGG GTA AGA AGA ACT GAA GGA CAG TAC CCA TCT ATC TGC CCA CGG CTT GAA CTG GGG AAC GAC TGG GAC TCT GCC ACC AAG CAG TTG CTG GGA CTC CAG CCC ATA AGC ACT GTG TCC CCT CTT CAT AGA GTC CTC CAT TAC AGT CAA GGC TAA Human mINT protein sequence (residues 1563-1724 SEQ ID NO: 8 of the human VPARP protein sequence) ctqhwqdavpwtellslqtedgfwkltpelglilnlntnglhsflkqkgiqslgvkgreclldliatmlvlqfirtrlekegi vfkslmkmddpsisrnipwafeaikqasewvrrtegqypsicprlelgndwdsatkqllglqpistvsplhrvlhysqg SEQ ID NO: 9 Mouse mINT protein sequence CTQHWQDAVPWTELLSLQTEDGFWKLTPELGLILNLNTNGLHSFLKQKGIQSLGVKGRECLLDLIATMLVLQFIRTRLEKEGI VFKSLMKMDDPSISRNIPWAFEAIKQASEWVRRTEGQYPSICPRLELGNDWDSATKQLLGLQPISTVSPLHRVLHYSQG SEQ ID NO: 10 Mouse CCL-21-mINT fusion DNA sequence ATGGCTCAGATGATGACTCTGAGCCTCCTTAGCCTGGTCCTGGCTCTCTGCATCCCCTGGACCCAAGGCA GTGATGGAGGGGGTCAGGACTGCTGCCTTAAGTACAGCCAGAAGAAAATTCCCTACAGTATTGTCCGAGG CTATAGGAAGCAAGAACCAAGTTTAGGCTGTCCCATCCCGGCAATCCTGTTCTCACCCCGGAAGCACTCT AAGCCTGAGCTATGTGCAAACCCTGAGGAAGGCTGGGTGCAGAACCTGATGCGCCGCCTGGACCAGCCTC CAGCCCCAGGGAAACAAAGCCCCGGCTGCAGGAAGAACCGGGGAACCTCTAAGTCTGGAAAGAAAGGAAA GGGCTCCAAGGGCTGCAAGAGAACTGAACAGACACAGCCCTCAAGAGGA TGC ACA CAA CAC TGG CAG GAT GCT GTG CCT TGG ACA GAA CTC CTC AGT CTA CAG ACA GAG GAT GGC TTC TGG AAA CTT ACA CCA GAA CTG GGA CTT ATA TTA AAT CTT AAT ACA AAT GGT TTG CAC AGC TTT CTT AAA CAA AAA GGC ATT CAA TCT CTA GGT GTA AAA GGA AGA GAA TGT CTC CTG GAC CTA ATT GCC ACA ATG CTG GTA CTA CAG TTT ATT CGC ACC AGG TTG GAA AAA GAG GGA ATA GTG TTC AAA TCA CTG ATG AAA ATG GAT GAC CCT TCT ATT TCC AGG AAT ATT CCC TGG GCT TTT GAG GCA ATA AAG CAA GCA AGT GAA TGG GTA AGA AGA ACT GAA GGA CAG TAC CCA TCT ATC TGC CCA CGG CTT GAA CTG GGG AAC GAC TGG GAC TCT GCC ACC AAG CAG TTG CTG GGA CTC CAG CCC ATA AGC ACT GTG TCC CCT CTT CAT AGA GTC CTC CAT TAC AGT CAA GGC TAA SEQ ID NO: 11 Human CCL-21-mINT fusion DNA sequence ATGGCTCAGTCACTGGCTCTGAGCCTCCTTATCCTGGTTCTGGCCTTTGGCATCCCCAGGACCCAAGGCA GTGATGGAGGGGCTCAGGACTGTTGCCTCAAGTACAGCCAAAGGAAGATTCCCGCCAAGGTTGTCCGCAG CTACCGGAAGCAGGAACCAAGCTTAGGCTGCTCCATCCCAGCTATCCTGTTCTTGCCCCGCAAGCGCTCT CAGGCAGAGCTATGTGCAGACCCAAAGGAGCTCTGGGTGCAGCAGCTGATGCAGCATCTGGACAAGACAC CATCCCCACAGAAACCAGCCCAGGGCTGCAGGAAGGACAGGGGGGCCTCCAAGACTGGCAAGAAAGGAAA GGGCTCCAAAGGCTGCAAGAGGACTGAGCGGTCACAGACCCCTAAAGGGCCAGCTAGCTGC ACA CAA CAC TGG CAG GAT GCT GTG CCT TGG ACA GAA CTC CTC AGT CTA CAG ACA GAG GAT GGC TTC TGG AAA CTT ACA CCA GAA CTG GGA CTT ATA TTA AAT CTT AAT ACA AAT GGT TTG CAC AGC TTT CTT AAA CAA AAA GGC ATT CAA TCT CTA GGT GTA AAA GGA AGA GAA TGT CTC CTG GAC CTA ATT GCC ACA ATG CTG GTA CTA CAG TTT ATT CGC ACC AGG TTG GAA AAA GAG GGA ATA GTG TTC AAA TCA CTG ATG AAA ATG GAT GAC CCT TCT ATT TCC AGG AAT ATT CCC TGG GCT TTT GAG GCA ATA AAG CAA GCA AGT GAA TGG GTA AGA AGA ACT GAA GGA CAG TAC CCA TCT ATC TGC CCA CGG CTT GAA CTG GGG AAC GAC TGG GAC TCT GCC ACC AAG CAG TTG CTG GGA CTC CAG CCC ATA AGC ACT GTG TCC CCT CTT CAT AGA GTC CTC CAT TAC AGT CAA GGC TAA SEQ ID NO: 12 Mouse CCL-21-INT fusion Protein Sequence MAQMMTLSLLSLVLALCIPWTQGSDGGGQDCCLKYSQKKIPYSIVRGYRKQEPSLGCPIPAILFSPRKHSKPELCANPEEGWV QNLMRRLDQPPAPGKQSPGCRKNRGTSKSGKKGKGSKGCKRTEQTQPSRGCTQHWQDAVPWTELLSLQTEDGFWKLTPELGLI LNLNTNGLHSFLKQKGIQSLGVKGRECLLDLIATMLVLQFIRTRLEKEGIVFKSLMKMDDPSISRNIPWAFEAIKQASEWVRR TEGQYPSICPRLELGNDWDSATKQLLGLQPISTVSPLHRVLHYSQG SEQ ID NO: 13 Human CCL-21-INT fusion Protein Sequence MAQSLALSLLILVLAFGIPRTQGSDGGAQDCCLKYSQRKIPAKVVRSYRKQEPSLGCSIPAILFLPRKRSQAELCADPKELWV QQLMQHLDKTPSPQKPAQGCRKDRGASKTGKKGKGSKGCKRTERSQTPKGPASCTQHWQDAVPWTELLSLQTEDGFWKLTPEL GLILNLNTNGLHSFLKQKGIQSLGVKGRECLLDLIATMLVLQFIRTRLEKEGIVFKSLMKMDDPSISRNIPWAFEAIKQASEW VRRTEGQYPSICPRLELGNDWDSATKQLLGLQPISTVSPLHRVLHYSQG Human VPARP protein sequence Genbank SEQ ID NO: 14 #AAD47250 Met Val Met Gly Ile Phe Ala Asn Cys Ile Phe Cys Leu Lys Val Lys Tyr Leu Pro Gln Gln Gln Lys Lys Lys Leu Gln Thr Asp Ile Lys Glu Asn Gly Gly Lys Phe Ser Phe Ser Leu Asn Pro Gln Cys Thr His Ile Ile Leu Asp Asn Ala Asp Val Leu Ser Gln Tyr Gln Leu Asn Ser Ile Gln Lys Asn His Val His Ile Ala Asn Pro Asp Phe Ile Trp Lys Ser Ile Arg Glu Lys Arg Leu Leu Asp Val Lys Asn Tyr Asp Pro Tyr Lys Pro Leu Asp Ile Thr Pro Pro Pro Asp Gln Lys Ala Ser Ser Ser Glu Val Lys Thr Glu Gly Leu Cys Pro Asp Ser Ala Thr Glu Glu Glu Asp Thr Val Glu Leu Thr Glu Phe Gly Met Gln Asn Val Glu Ile Pro His Leu Pro Gln Asp Phe Glu Val Ala Lys Tyr Asn Thr Leu Glu Lys Val Gly Met Glu Gly Gly Gln Glu Ala Val Val Val Glu Leu Gln Cys Ser Arg Asp Ser Arg Asp Cys Pro Phe Leu Ile Ser Ser His Phe Leu Leu Asp Asp Gly Met Glu Thr Arg Arg Gln Phe Ala Ile Lys Lys Thr Ser Glu Asp Ala Ser Glu Tyr Phe Glu Asn Tyr Ile Glu Glu Leu Lys Lys Gln Gly Phe Leu Leu Arg Glu His Phe Thr Pro Glu Ala Thr Gln Leu Ala Ser Glu Gln Leu Gln Ala Leu Leu Leu Glu Glu Val Met Asn Ser Ser Thr Leu Ser Gln Glu Val Ser Asp Leu Val Glu Met Ile Trp Ala Glu Ala Leu Gly His Leu Glu His Met Leu Leu Lys Pro Val Asn Arg Ile Ser Leu Asn Asp Val Ser Lys Ala Glu Gly Ile Leu Leu Leu Val Lys Ala Ala Leu Lys Asn Gly Glu Thr Ala Glu Gln Leu Gln Lys Met Met Thr Glu Phe Tyr Arg Leu Ile Pro His Lys Gly Thr Met Pro Lys Glu Val Asn Leu Gly Leu Leu Ala Lys Lys Ala Asp Leu Cys Gln Leu Ile Arg Asp Met Val Asn Val Cys Glu Thr Asn Leu Ser Lys Pro Asn Pro Pro Ser Leu Ala Lys Tyr Arg Ala Leu Arg Cys Lys Ile Glu His Val Glu Gln Asn Thr Glu Glu Phe Leu Arg Val Arg Lys Glu Val Leu Gln Asn His His Ser Lys Ser Pro Val Asp Val Leu Gln Ile Phe Arg Val Gly Arg Val Asn Glu Thr Thr Glu Phe Leu Ser Lys Leu Gly Asn Val Arg Pro Leu Leu His Gly Ser Pro Val Gln Asn Ile Val Gly Ile Leu Cys Arg Gly Leu Leu Leu Pro Lys Val Val Glu Asp Arg Gly Val Gln Arg Thr Asp Val Gly Asn Leu Gly Ser Gly Ile Tyr Phe Ser Asp Ser Leu Ser Thr Ser Ile Lys Tyr Ser His Pro Gly Glu Thr Asp Gly Thr Arg Leu Leu Leu Ile Cys Asp Val Ala Leu Gly Lys Cys Met Asp Leu His Glu Lys Asp Phe Pro Leu Thr Glu Ala Pro Pro Gly Tyr Asp Ser Val His Gly Val Ser Gln Thr Ala Ser Val Thr Thr Asp Phe Glu Asp Asp Glu Phe Val Val Tyr Lys Thr Asn Gln Val Lys Met Lys Tyr Ile Ile Lys Phe Ser Met Pro Gly Asp Gln Ile Lys Asp Phe His Pro Ser Asp His Thr Glu Leu Glu Glu Tyr Arg Pro Glu Phe Ser Asn Phe Ser Lys Val Glu Asp Tyr Gln Leu Pro Asp Ala Lys Thr Ser Ser Ser Thr Lys Ala Gly Leu Gln Asp Ala Ser Gly Asn Leu Val Pro Leu Glu Asp Val His Ile Lys Gly Arg Ile Ile Asp Thr Val Ala Gln Val Ile Val Phe Gln Thr Tyr Thr Asn Lys Ser His Val Pro Ile Glu Ala Lys Tyr Ile Phe Pro Leu Asp Asp Lys Ala Ala Val Cys Gly Phe Glu Ala Phe Ile Asn Gly Lys His Ile Val Gly Glu Ile Lys Glu Lys Glu Glu Ala Gln Gln Glu Tyr Leu Glu Ala Val Thr Gln Gly His Gly Ala Tyr Leu Met Ser Gln Asp Ala Pro Asp Val Phe Thr Val Ser Val Gly Asn Leu Pro Pro Lys Ala Lys Val Leu Ile Lys Ile Thr Tyr Ile Thr Glu Leu Ser Ile Leu Gly Thr Val Gly Val Phe Phe Met Pro Ala Thr Val Ala Pro Trp Gln Gln Asp Lys Ala Leu Asn Glu Asn Leu Gln Asp Thr Val Glu Lys Ile Cys Ile Lys Glu Ile Gly Thr Lys Gln Ser Phe Ser Leu Thr Met Ser Ile Glu Met Pro Tyr Val Ile Glu Phe Ile Phe Ser Asp Thr His Glu Leu Lys Gln Lys Arg Thr Asp Cys Lys Ala Val Ile Ser Thr Met Glu Gly Ser Ser Leu Asp Ser Ser Gly Phe Ser Leu His Ile Gly Leu Ser Ala Ala Tyr Leu Pro Arg Met Trp Val Glu Lys His Pro Glu Lys Glu Ser Glu Ala Cys Met Leu Val Phe Gln Pro Asp Leu Asp Val Asp Leu Pro Asp Leu Ala Ser Glu Ser Glu Val Ile Ile Cys Leu Asp Cys Ser Ser Ser Met Glu Gly Val Thr Phe Leu Gln Ala Lys Gln Ile Thr Leu His Ala Leu Ser Leu Val Gly Glu Lys Gln Lys Val Asn Ile Ile Gln Phe Gly Thr Gly Tyr Lys Glu Leu Phe Ser Tyr Pro Lys His Ile Thr Ser Asn Thr Thr Ala Ala Glu Phe Ile Met Ser Ala Thr Pro Thr Met Gly Asn Thr Asp Phe Trp Lys Thr Leu Arg Tyr Leu Ser Leu Leu Tyr Pro Ala Arg Gly Ser Arg Asn Ile Leu Leu Val Ser Asp Gly His Leu Gln Asp Glu Ser Leu Thr Leu Gln Leu Val Lys Arg Ser Arg Pro His Thr Arg Leu Phe Ala Cys Gly Ile Gly Ser Thr Ala Asn Arg His Val Leu Arg Ile Leu Ser Gln Cys Gly Ala Gly Val Phe Glu Tyr Phe Asn Ala Lys Ser Lys His Ser Trp Arg Lys Gln Ile Glu Asp Gln Met Thr Arg Leu Cys Ser Pro Ser Cys His Ser Leu Gln Ala Pro Ala Gln Val Pro Ser Leu Phe Arg Asn Asp Arg Leu Leu Val Tyr Gly Phe Ile Pro His Cys Thr Gln Ala Thr Leu Cys Ala Leu Ile Gln Glu Lys Glu Phe Cys Thr Met Val Ser Thr Thr Glu Leu Gln Lys Thr Thr Gly Thr Met Ile His Lys Leu Ala Ala Arg Ala Leu Ile Arg Asp Tyr Glu Asp Gly Ile Leu His Glu Asn Glu Thr Ser His Glu Met Lys Lys Gln Thr Leu Lys Ser Leu Ile Ile Lys Leu Ser Lys Glu Asn Ser Leu Ile Thr Gln Phe Thr Ser Phe Val Ala Val Glu Lys Arg Asp Glu Asn Glu Ser Pro Phe Pro Asp Ile Pro Lys Val Ser Glu Leu Ile Ala Lys Glu Asp Val Asp Phe Leu Pro Tyr Met Ser Trp Gln Gly Glu Pro Gln Glu Ala Val Arg Asn Gln Ser Leu Leu Ala Ser Ser Glu Trp Pro Glu Leu Arg Leu Ser Lys Arg Lys His Arg Lys Ile Pro Phe Ser Lys Arg Lys Met Glu Leu Ser Gln Pro Glu Val Ser Glu Asp Phe Glu Glu Asp Gly Leu Gly Val Leu Pro Ala Phe Thr Ser Asn Leu Glu Arg Gly Gly Val Glu Lys Leu Leu Asp Leu Ser Trp Thr Glu Ser Cys Lys Pro Thr Ala Thr Glu Pro Leu Phe Lys Lys Val Ser Pro Trp Glu Thr Ser Thr Ser Ser Phe Phe Pro Ile Leu Ala Pro Ala Val Gly Ser Tyr Leu Thr Pro Thr Thr Arg Ala His Ser Pro Ala Ser Leu Ser Phe Ala Ser Tyr Arg Gln Val Ala Ser Phe Gly Ser Ala Ala Pro Pro Arg Gln Phe Asp Ala Ser Gln Phe Ser Gln Gly Pro Val Pro Gly Thr Cys Ala Asp Trp Ile Pro Gln Ser Ala Ser Cys Pro Thr Gly Pro Pro Gln Asn Pro Pro Ser Ala Pro Tyr Cys Gly Ile Val Phe Ser Gly Ser Ser Leu Ser Ser Ala Gln Ser Ala Pro Leu Gln His Pro Gly Gly Phe Thr Thr Arg Pro Ser Ala Gly Thr Phe Pro Glu Leu Asp Ser Pro Gln Leu His Phe Ser Leu Pro Thr Asp Pro Asp Pro Ile Arg Gly Phe Gly Ser Tyr His Pro Ser Ala Tyr Ser Pro Phe His Phe Gln Pro Ser Ala Ala Ser Leu Thr Ala Asn Leu Arg Leu Pro Met Ala Ser Ala Leu Pro Glu Ala Leu Cys Ser Gln Ser Arg Thr Thr Pro Val Asp Leu Cys Leu Leu Glu Glu Ser Val Gly Ser Leu Glu Gly Ser Arg Cys Pro Val Phe Ala Phe Gln Ser Ser Asp Thr Glu Ser Asp Glu Leu Ser Glu Val Leu Gln Asp Ser Cys Phe Leu Gln Ile Lys Cys Asp Thr Lys Asp Asp Ser Ile Pro Cys Phe Leu Glu Leu Lys Glu Glu Asp Glu Ile Val Cys Thr Gln His Trp Gln Asp Ala Val Pro Trp Thr Glu Leu Leu Ser Leu Gln Thr Glu Asp Gly Phe Trp Lys Leu Thr Pro Glu Leu Gly Leu Ile Leu Asn Leu Asn Thr Asn Gly Leu His Ser Phe Leu Lys Gln Lys Gly Ile Gln Ser Leu Gly Val Lys Gly Arg Glu Cys Leu Leu Asp Leu Ile Ala Thr Met Leu Val Leu Gln Phe Ile Arg Thr Arg Leu Glu Lys Glu Gly Ile Val Phe Lys Ser Leu Met Lys Met Asp Asp Pro Ser Ile Ser Arg Asn Ile Pro Trp Ala Phe Glu Ala Ile Lys Gln Ala Ser Glu Trp Val Arg Arg Thr Glu Gly Gln Tyr Pro Ser Ile Cys Pro Arg Leu Glu Leu Gly Asn Asp Trp Asp Ser Ala Thr Lys Gln Leu Leu Gly Leu Gln Pro Ile Ser Thr Val Ser Pro Leu His Arg Val Leu His Tyr Ser Gln Gly SEQ ID NO: 15 Human VPARP cDNA, Genbank #AF158255 atggtgatgg gaatctttgc aaattgtatc ttctgtttga aagtgaagta cttacctcag cagcagaaga aaaagctaca aactgacatt aaggaaaatg gcggaaagtt ttccttttcg ttaaatcctc agtgcacaca tataatctta gataatgctg atgttctgag tcagtaccaa ctgaattcta tccaaaagaa ccacgttcat attgcaaacc cagattttat atggaaatct atcagagaaa agagactctt ggatgtaaag aattatgatc cttataagcc cctggacatc acaccacctc ctgatcagaa ggcgagcagt tctgaagtga aaacagaagg tctatgcccg gacagtgcca cagaggagga agacactgtg gaactcactg agtttggtat gcagaatgtt gaaattcctc atcttcctca agattttgaa gttgcaaaat ataacacctt ggagaaagtg ggaatggagg gaggccagga agctgtggtg gtggagcttc agtgttcgcg ggactccagg gactgtcctt tcctgatatc ctcacacttc ctcctggatg atggcatgga gactagaaga cagtttgcta taaagaaaac ctctgaagat gcaagtgaat actttgaaaa ttacattgaa gaactgaaga aacaaggatt tctactaaga gaacatttca cacctgaagc aacccaatta gcatctgaac aattgcaagc attgcttttg gaggaagtca tgaattcaag cactctgagc caagaggtga gcgatttagt agagatgatt tgggcagagg ccctgggcca cctggaacac atgcttctca agccagtgaa caggattagc ctcaacgatg tgagcaaggc agaggggatt ctccttctag taaaggcagc actgaaaaat ggagaaacag cagagcaatt gcaaaagatg atgacagagt tttacagact gatacctcac aaaggcacaa tgcccaaaga agtgaacctg ggactattgg ctaagaaagc agacctctgc cagctaataa gagacatggt taatgtctgt gaaactaatt tgtccaaacc caacccacca tccctggcca aataccgagc tttgaggtgc aaaattgagc atgttgaaca gaatactgaa gaatttctca gggttagaaa agaggttttg cagaatcatc acagtaagag cccagtggat gtcttgcaga tatttagagt tggcagagtg aatgaaacca cagagttttt gagcaaactt ggtaatgtga ggcccttgtt gcatggttct cctgtacaaa acatcgtggg aatcttgtgt cgagggttgc ttttacccaa agtagtggaa gatcgtggtg tgcaaagaac agacgtcgga aaccttggaa gtgggattta tttcagtgat tcgctcagta caagtatcaa gtactcacac ccgggagaga cagatggcac cagactcctg ctcatttgtg acgtagccct cggaaagtgt atggacttac atgagaagga ctttccctta actgaagcac caccaggcta cgacagtgtg catggagttt cacaaacagc ctctgtcacc acagactttg aggatgatga atttgttgtc tataaaacca atcaggttaa aatgaaatat attattaaat tttccatgcc tggagatcag ataaaggact ttcatcctag tgatcatact gaattagagg aatacagacc tgagttttca aatttttcaa aggttgaaga ttaccagtta ccagatgcca aaacttccag cagcaccaag gccggcctcc aggatgcctc tgggaacttg gttcctctgg aggatgtcca catcaaaggg agaatcatag acactgtagc ccaggtcatt gtttttcaga catacacaaa taaaagtcac gtgcccattg aggcaaaata tatctttcct ttggatgaca aggccgctgt gtgtggcttc gaagccttca tcaatgggaa gcacatagtt ggagagatta aagagaagga agaagcccag caagagtacc tagaagccgt gacccagggc catggcgctt acctgatgag tcaggatgct ccggacgttt ttactgtaag tgttggaaac ttacccccta aggctaaggt tcttataaaa attacctaca tcacagaact cagcatcctg ggcactgttg gtgtcttttt catgcccgcc accgtagcac cctggcaaca ggacaaggct ttgaatgaaa accttcagga tacagtagag aagatttgta taaaagaaat aggaacaaag caaagcttct ctttgactat gtctattgag atgccgtatg tgattgaatt cattttcagt gatacacatg aactgaaaca aaagcgcaca gactgcaaag ctgtcattag caccatggaa ggcagctcct tagacagcag tggattttct ctccacatcg gtttgtctgc tgcctatctc ccaagaatgt gggttgaaaa acatccagaa aaagaaagcg aggcttgcat gcttgtcttt caacccgatc tcgatgtcga cctccctgac ctagccagtg agagcgaagt gattatttgt cttgactgct ccagttccat ggagggtgtg acattcttgc aagccaagca aatcaccttg catgcgctgt ccttggtggg tgagaagcag aaagtaaata ttatccagtt cggcacaggt tacaaggagc tattttcgta tcctaagcat atcacaagca ataccacggc agcagagttc atcatgtctg ccacacctac catggggaac acagacttct ggaaaacact ccgatatctt agcttattgt accctgctcg agggtcacgg aacatcctcc tggtgtctga tgggcacctc caggatgaga gcctgacatt acagctcgtg aagaggagcc gcccgcacac caggttattc gcctgcggta tcggttctac agcaaatcgt cacgtcttaa ggattttgtc ccagtgtggt gccggagtat ttgaatattt taatgcaaaa tccaagcata gttggagaaa acagatagaa gaccaaatga ccaggctatg ttctccgagt tgccactctg tctccgtcaa atggcagcaa ctcaatccag atgcgcccga ggccctgcag gccccagccc aggtgccatc cttgtttcgc aatgatcgac tccttgtcta tggattcatt cctcactgca cacaagcaac tctgtgtgca ctaattcaag agaaagaatt ttgtacaatg gtgtcgacta ctgagcttca gaagacaact ggaactatga tccacaagct ggcagcccga gctctaatca gagattatga agatggcatt cttcacgaaa atgaaaccag tcatgagatg aaaaaacaaa ccttgaaatc tctgattatt aaactcagta aagaaaactc tctcataaca caatttacaa gctttgtggc agttgagaaa agggatgaga atgagtcgcc ttttcctgat attccaaaag tttctgaact tattgccaaa gaagatgtag acttcctgcc ctacatgagc tggcaggggg agccccaaga agccgtcagg aaccagtctc ttttagcatc ctctgagtgg ccagaattac gtttatccaa acgaaaacat aggaaaattc cattttccaa aagaaaaatg gaattatctc agccagaagt ttctgaagat tttgaagagg atggcttagg tgtactacca gctttcacat caaatttgga acgtggaggt gtggaaaagc tattggattt aagttggaca gagtcatgta aaccaacagc aactgaacca ctatttaaga aagtcagtcc atgggaaaca tctacttcta gcttttttcc tattttggct ccggccgttg gttcctatct taccccgact acccgcgctc acagtcctgc ttccttgtct tttgcctcat atcgtcaggt agctagtttc ggttcagctg ctcctcccag acagtttgat gcatctcaat tcagccaagg ccctgtgcct ggcacttgtg ctgactggat cccacagtcg gcgtcttgtc ccacaggacc tccccagaac ccaccttctg caccctattg tggcattgtt ttttcaggga gctcattaag ctctgcacag tctgctccac tgcaacatcc tggaggcttt actaccaggc cttctgctgg caccttccct gagctggatt ctccccagct tcatttctct cttcctacag accctgatcc catcagaggt tttgggtctt atcatccctc tgcttactct ccttttcatt ttcaaccttc cgcagcctct ttgactgcca accttaggct gccaatggcc tctgctttac ctgaggctct ttgcagtcag tcccggacta ccccagtaga tctctgtctt ctagaagaat cagtaggcag tctcgaagga agtcgatgtc ctgtctttgc ttttcaaagt tctgacacag aaagtgatga gctatcagaa gtacttcaag acagctgctt tttacaaata aagtgtgata caaaagatga cagtatcccg tgctttctgg aattaaaaga agaggatgaa atagtgtgca cacaacactg gcaggatgct gtgccttgga cagaactcct cagtctacag acagaggatg gcttctggaa acttacacca gaactgggac ttatattaaa tcttaataca aatggtttgc acagctttct taaacaaaaa ggcattcaat ctctaggtgt aaaaggaaga gaatgtctcc tggacctaat tgccacaatg ctggtactac agtttattcg caccaggttg gaaaaagagg gaatagtgtt caaatcactg atgaaaatgg atgacccttc tatttccagg aatattccct gggcttttga ggcaataaag caagcaagtg aatgggtaag aagaactgaa ggacagtacc catctatctg cccacggctt gaactgggga acgactggga ctctgccacc aagcagttgc tgggactcca gcccataagc actgtgtccc ctcttcatag agtcctccat tacagtcaag gctaa  SEQ ID NO: 16 Human MVP, Genbank #CAA56256 Met Ala Thr Glu Glu Phe Ile Ile Arg Ile Pro Pro Tyr His Tyr Ile His Val Leu Asp Gln Asn Ser Asn Val Ser Arg Val Glu Val Gly Pro Lys Thr Tyr Ile Arg Gln Asp Asn Glu Arg Val Leu Phe Ala Pro Met Arg Met Val Thr Val Pro Pro Arg His Tyr Cys Thr Val Ala Asn Pro Val Ser Arg Asp Ala Gln Gly Leu Val Leu Phe Asp Val Thr Gly Gln Val Arg Leu Arg His Ala Asp Leu Glu Ile Arg Leu Ala Gln Asp Pro Phe Pro Leu Tyr Pro Gly Glu Val Leu Glu Lys Asp Ile Thr Pro Leu Gln Val Val Leu Pro Asn Thr Ala Leu His Leu Lys Ala Leu Leu Asp Phe Glu Asp Lys Asp Gly Asp Lys Val Val Ala Gly Asp Glu Trp Leu Phe Glu Gly Pro Gly Thr Tyr Ile Pro Arg Lys Glu Val Glu Val Val Glu Ile Ile Gln Ala Thr Ile Ile Arg Gln Asn Gln Ala Leu Arg Leu Arg Ala Arg Lys Glu Cys Trp Asp Arg Asp Gly Lys Glu Arg Val Thr Gly Glu Glu Trp Leu Val Thr Thr Val Gly Ala Tyr Leu Pro Ala Val Phe Glu Glu Val Leu Asp Leu Val Asp Ala Val Ile Leu Thr Glu Lys Thr Ala Leu His Leu Arg Ala Arg Arg Asn Phe Arg Asp Phe Arg Gly Val Ser Arg Arg Thr Gly Glu Glu Trp Leu Val Thr Val Gln Asp Thr Glu Ala His Val Pro Asp Val His Glu Glu Val Leu Gly Val Val Pro Ile Thr Thr Leu Gly Pro His Asn Tyr Cys Val Ile Leu Asp Pro Val Gly Pro Asp Gly Lys Asn Gln Leu Gly Gln Lys Arg Val Val Lys Gly Glu Lys Ser Phe Phe Leu Gln Pro Gly Glu Gln Leu Glu Gln Gly Ile Gln Asp Val Tyr Val Leu Ser Glu Gln Gln Gly Leu Leu Leu Arg Ala Leu Gln Pro Leu Glu Glu Gly Glu Asp Glu Glu Lys Val Ser His Gln Ala Gly Asp His Trp Leu Ile Arg Gly Pro Leu Glu Tyr Val Pro Ser Ala Lys Val Glu Val Val Glu Glu Arg Gln Ala Ile Pro Leu Asp Glu Asn Glu Gly Ile Tyr Val Gln Asp Val Lys Thr Gly Lys Val Arg Ala Val Ile Gly Ser Thr Tyr Met Leu Thr Gln Asp Glu Val Leu Trp Glu Lys Glu Leu Pro Pro Gly Val Glu Glu Leu Leu Asn Lys Gly Gln Asp Pro Leu Ala Asp Arg Gly Glu Lys Asp Thr Ala Lys Ser Leu Gln Pro Leu Ala Pro Arg Asn Lys Thr Arg Val Val Ser Tyr Arg Val Pro His Asn Ala Ala Val Gln Val Tyr Asp Tyr Arg Glu Lys Arg Ala Arg Val Val Phe Gly Pro Glu Leu Val Ser Leu Gly Pro Glu Glu Gln Phe Thr Val Leu Ser Leu Ser Ala Gly Arg Pro Lys Arg Pro His Ala Arg Arg Ala Leu Cys Leu Leu Leu Gly Pro Asp Phe Phe Thr Asp Val Ile Thr Ile Glu Thr Ala Asp His Ala Arg Leu Gln Leu Gln Leu Ala Tyr Asn Trp His Phe Glu Val Asn Asp Arg Lys Asp Pro Gln Glu Thr Ala Lys Leu Phe Ser Val Pro Asp Phe Val Gly Asp Ala Cys Lys Ala Ile Ala Ser Arg Val Arg Gly Ala Val Ala Ser Val Thr Phe Asp Asp Phe His Lys Asn Ser Ala Arg Ile Ile Arg Thr Ala Val Phe Gly Phe Glu Thr Ser Glu Ala Lys Gly Pro Asp Gly Met Ala Leu Pro Arg Pro Arg Asp Gln Ala Val Phe Pro Gln Asn Gly Leu Val Val Ser Ser Val Asp Val Gln Ser Val Glu Pro Val Asp Gln Arg Thr Arg Asp Ala Leu Gln Arg Ser Val Gln Leu Ala Ile Glu Ile Thr Thr Asn Ser Gln Glu Ala Ala Ala Lys His Glu Ala Gln Arg Leu Glu Gln Glu Ala Arg Gly Arg Leu Glu Arg Gln Lys Ile Leu Asp Gln Ser Glu Ala Glu Lys Ala Arg Lys Glu Leu Leu Glu Leu Glu Ala Leu Ser Met Ala Val Glu Ser Thr Gly Thr Ala Lys Ala Glu Ala Glu Ser Arg Ala Glu Ala Ala Arg Ile Glu Gly Glu Gly Ser Val Leu Gln Ala Lys Leu Lys Ala Gln Ala Leu Ala Ile Glu Thr Glu Ala Glu Leu Gln Arg Val Gln Lys Val Arg Glu Leu Glu Leu Val Tyr Ala Arg Ala Gln Leu Glu Leu Glu Val Ser Lys Ala Gln Gln Leu Ala Glu Val Glu Val Lys Lys Phe Lys Gln Met Thr Glu Ala Ile Gly Pro Ser Thr Ile Arg Asp Leu Ala Val Ala Gly Pro Glu Met Gln Val Lys Leu Leu Gln Ser Leu Gly Leu Lys Ser Thr Leu Ile Thr Asp Gly Ser Thr Pro Ile Asn Leu Phe Asn Thr Ala Phe Gly Leu Leu Gly Met Gly Pro Glu Gly Gln Pro Leu Gly Arg Arg Val Ala Ser Gly Pro Ser Pro Gly Glu Gly Ile Ser Pro Gln Ser Ala Gln Ala Pro Gln Ala Pro Gly Asp Asn His Val Val Pro Val Leu Arg SEQ ID NO: 17 Human MVP cDNA, Genbank #X79882 atggcaactg aagagttcat catccgcatc cccccatacc actatatcca tgtgctggac cagaacagca acgtgtcccg tgtggaggtc gggccaaaga cctacatccg gcaggacaat gagagggtac tgtttgcccc catgcgcatg gtgaccgtcc ccccacgtca ctactgcaca gtggccaacc ctgtgtctcg ggatgcccag ggcttggtgc tgtttgatgt cacagggcaa gttcggcttc gccacgctga cctcgagatc cggctggccc aggacccctt ccccctgtac ccaggggagg tgctggaaaa ggacatcaca cccctgcagg tggttctgcc caacactgcc ctccatctaa aggcgctgct tgattttgag gataaagatg gagacaaggt ggtggcagga gatgagtggc ttttcgaggg acctggcacg tacatccccc ggaaggaagt ggaggtcgtg gagatcattc aggccaccat catcaggcag aaccaggctc tgcggctcag ggcccgcaag gagtgctggg accgggacgg caaggagagg gtgacagggg aagaatggct ggtcaccaca gtaggggcgt acctcccagc ggtgtttgag gaggttctgg atttggtgga cgccgtcatc cttacggaaa agacagccct gcacctccgg gctcggcgga acttccggga cttcagggga gtgtcccgcc gcactgggga ggagtggctg gtaacagtgc aggacacaga ggcccacgtg ccagatgtcc acgaggaggt gctgggggtt gtgcccatca ccaccctggg cccccacaac tactgcgtga ttctcgaccc tgtcggaccg gatggcaaga atcagctggg gcagaagcgc gtggtcaagg gagagaagtc ttttttcctc cagccaggag agcagctgga acaaggcatc caggatgtgt atgtgctgtc ggagcagcag gggctgctgc tgagggccct gcagcccctg gaggaggggg aggatgagga gaaggtctca caccaggctg gggaccactg gctcatccgc ggacccctgg agtatgtgcc atctgccaaa gtggaggtgg tggaggagcg ccaggccatc cctctagacg agaacgaggg catctatgtg caggatgtca agaccggaaa ggtgcgcgct gtgattggaa gcacctacat gctgacccag gacgaagtcc tgtgggagaa agagctgcct cccggggtgg aggagctgct gaacaagggg caggaccctc tggcagacag gggtgagaag gacacagcta agagcctcca gcccttggcg ccccggaaca agacccgtgt ggtcagctac cgcgtgcccc acaacgctgc ggtgcaggtg tacgactacc gagagaagcg agcccgcgtg gtcttcgggc ctgagctggt gtcgctgggt cctgaggagc agttcacagt gttgtccctc tcagctgggc ggcccaagcg tccccatgcc cgccgtgcgc tctgcctgct gctggggcct gacttcttca cagacgtcat caccatcgaa acggcggatc atgccaggct gcaactgcag ctggcctaca actggcactt tgaggtgaat gaccggaagg acccccaaga gacggccaag ctcttttcag tgccagactt tgtaggtgat gcctgcaaag ccatcgcatc ccgggtgcgg ggggccgtgg cctctgtcac tttcgatgac ttccataaga actcagcccg catcattcgc actgctgtct ttggctttga gacctcggaa gcgaagggcc ccgatggcat ggccctgccc aggccccggg accaggctgt cttcccccaa aacgggctgg tggtcagcag tgtggacgtg cagtcagtgg agcctgtgga tcagaggacc cgggacgccc tgcaacgcag cgtccagctg gccatcgaga tcaccaccaa ctcccaggaa gcggcggcca agcatgaggc tcagagactg gagcaggaag cccgcggccg gcttgagcgg cagaagatcc tggaccagtc agaagccgag aaagctcgca aggaactttt ggagctggag gctctgagca tggccgtgga gagcaccggg actgccaagg cggaggccga gtcccgtgcg gaggcagccc ggattgaggg agaagggtcc gtgctgcagg ccaagctaaa agcacaggcc ttggccattg aaacggaggc tgagctccag agggtccaga aggtccgaga gctggaactg gtctatgccc gggcccagct ggagctggag gtgagcaagg ctcagcagct ggctgaggtg gaggtgaaga agttcaagca gatgacagag gccataggcc ccagcaccat cagggacctt gctgtggctg ggcctgagat gcaggtaaaa ctgctccagt ccctgggcct gaaatcaacc ctcatcaccg atggctccac tcccatcaac ctcttcaaca cagcctttgg gctgctgggg atggggcccg agggtcagcc cctgggcaga agggtggcca gtgggcccag ccctggggag gggatatccc cccagtctgc tcaggcccct caagctcctg gagacaacca cgtggtgcct gtactgcgct aa SEQ ID NO: 18 Rat MVP, Genbank #AAC52161 Met Ala Thr Glu Glu Ala Ile Ile Arg Ile Pro Pro Tyr His Tyr Ile His Val Leu Asp Gln Asn Ser Asn Val Ser Arg Val Glu Val Gly Pro Lys Thr Tyr Ile Arg Gln Asp Asn Glu Arg Val Leu Phe Ala Pro Val Arg Met Val Thr Val Pro Pro Arg His Tyr Cys Ile Val Ala Asn Pro Val Ser Arg Asp Thr Gln Ser Ser Val Leu Phe Asp Ile Thr Gly Gln Val Arg Leu Arg His Ala Asp Gln Glu Ile Arg Leu Ala Gln Asp Pro Phe Pro Leu Tyr Pro Gly Glu Val Leu Glu Lys Asp Ile Thr Pro Leu Gln Val Val Leu Pro Asn Thr Ala Leu His Leu Lys Ala Leu Leu Asp Phe Glu Asp Lys Asn Gly Asp Lys Val Met Ala Gly Asp Glu Trp Leu Phe Glu Gly Pro Gly Thr Tyr Ile Pro Gln Lys Glu Val Glu Val Val Glu Ile Ile Gln Ala Thr Val Ile Lys Gln Asn Gln Ala Leu Arg Leu Arg Ala Arg Lys Glu Cys Phe Asp Arg Glu Gly Lys Gly Arg Val Thr Gly Glu Glu Trp Leu Val Arg Ser Val Gly Ala Tyr Leu Pro Ala Val Phe Glu Glu Val Leu Asp Leu Val Asp Ala Val Ile Leu Thr Glu Lys Thr Ala Leu His Leu Arg Ala Leu Gln Asn Phe Arg Asp Leu Arg Gly Val Leu His Arg Thr Gly Glu Glu Trp Leu Val Thr Val Gln Asp Thr Glu Ala His Val Pro Asp Val Tyr Glu Glu Val Leu Gly Val Val Pro Ile Thr Thr Leu Gly Pro Arg His Tyr Cys Val Ile Leu Asp Pro Met Gly Pro Asp Gly Lys Asn Gln Leu Gly Gln Lys Arg Val Val Lys Gly Glu Lys Ser Phe Phe Leu Gln Pro Gly Glu Arg Leu Glu Arg Gly Ile Gln Asp Val Tyr Val Leu Ser Glu Gln Gln Gly Leu Leu Leu Lys Ala Leu Gln Pro Leu Glu Glu Gly Glu Ser Glu Glu Lys Val Ser His Gln Ala Gly Asp Cys Trp Leu Ile Arg Gly Pro Leu Glu Tyr Val Pro Ser Ala Lys Val Glu Val Val Glu Glu Arg Gln Ala Ile Pro Leu Asp Gln Asn Glu Gly Ile Tyr Val Gln Asp Val Lys Thr Gly Lys Val Arg Ala Val Ile Gly Ser Thr Tyr Met Leu Thr Gln Asp Glu Val Leu Trp Glu Lys Glu Leu Pro Ser Gly Val Glu Glu Leu Leu Asn Leu Gly His Asp Pro Leu Ala Asp Arg Gly Gln Lys Gly Thr Ala Lys Pro Leu Gln Pro Ser Ala Pro Arg Asn Lys Thr Arg Val Val Ser Tyr Arg Val Pro His Asn Ala Ala Val Gln Val Tyr Asp Tyr Arg Ala Lys Arg Ala Arg Val Val Phe Gly Pro Glu Leu Val Thr Leu Asp Pro Glu Glu Gln Phe Thr Val Leu Ser Leu Ser Ala Gly Arg Pro Lys Arg Pro His Ala Arg Arg Ala Leu Cys Leu Leu Leu Gly Pro Asp Phe Phe Thr Asp Val Ile Thr Ile Glu Thr Ala Asp His Ala Arg Leu Gln Leu Gln Leu Ala Tyr Asn Trp His Phe Glu Leu Lys Asn Arg Asn Asp Pro Ala Glu Ala Ala Lys Leu Phe Ser Val Pro Asp Phe Val Gly Asp Ala Cys Lys Ala Ile Ala Ser Arg Val Arg Gly Ala Val Ala Ser Val Thr Phe Asp Asp Phe His Lys Asn Ser Ala Arg Ile Ile Arg Met Ala Val Phe Gly Phe Glu Met Ser Glu Asp Thr Gly Pro Asp Gly Thr Leu Leu Pro Lys Ala Arg Asp Gln Ala Val Phe Pro Gln Asn Gly Leu Val Val Ser Ser Val Asp Val Gln Ser Val Glu Pro Val Asp Gln Arg Thr Arg Asp Ala Leu Gln Arg Ser Val Gln Leu Ala Ile Glu Ile Thr Thr Asn Ser Gln Glu Ala Ala Ala Lys His Glu Ala Gln Arg Leu Glu Gln Glu Ala Arg Gly Arg Leu Glu Arg Gln Lys Ile Leu Asp Gln Ser Glu Ala Glu Lys Ala Arg Lys Glu Leu Leu Glu Leu Glu Ala Met Ser Met Ala Val Glu Ser Thr Gly Asn Ala Lys Ala Glu Ala Glu Ser Arg Ala Glu Ala Ala Arg Ile Glu Gly Glu Gly Ser Val Leu Gln Ala Lys Leu Lys Ala Gln Ala Leu Ala Ile Glu Thr Glu Ala Glu Leu Glu Arg Val Lys Lys Val Arg Glu Met Glu Leu Ile Tyr Ala Arg Ala Gln Leu Glu Leu Glu Val Ser Lys Ala Gln Gln Leu Ala Asn Val Glu Ala Lys Lys Phe Lys Glu Met Thr Glu Ala Leu Gly Pro Gly Thr Ile Arg Asp Leu Ala Val Ala Gly Pro Glu Met Gln Val Lys Leu Leu Gln Ser Leu Gly Leu Lys Ser Thr Leu Ile Thr Asp Gly Ser Ser Pro Ile Asn Leu Phe Ser Thr Ala Phe Gly Leu Leu Gly Leu Gly Ser Asp Gly Gln Pro Pro Ala Gln Lys SEQ ID NO: 19 Rat MVP cDNA, Genbank #U09870 atggcaactg aagaggccat catccgcatc cccccatacc actacatcca tgtgctggac cagaacagta atgtgtcccg tgtggaggtt ggaccaaaga cctacatccg gcaggacaat gagagggtac tgtttgcccc agttcgcatg gtgaccgtcc ccccacgcca ctactgcata gtggccaacc ctgtgtcccg ggacacccag agttctgtgt tatttgacat cacaggacaa gtccgactcc ggcacgctga ccaggagatc cgactagccc aggacccctt ccccctgtat ccaggggagg tgctggaaaa ggacatcacc ccactgcagg tggttctgcc caacacagca ctgcatctta aggcgttgct ggactttgag gataagaatg gagacaaggt catggcagga gacgagtggc tatttgaggg acctggcacc tacatcccac agaaggaagt ggaagtcgtg gagatcattc aggccacagt catcaaacag aaccaagcac tgcggctaag ggcccgaaag gagtgctttg accgggaggg caaggggcgc gtgacaggtg aggagtggct ggtccgatcc gtgggggctt acctcccagc tgtctttgaa gaggtgctgg atctggtgga tgctgtgatc cttacagaaa agactgccct gcacctccgg gctctgcaga acttcaggga ccttcgggga gtgctccacc gcaccgggga ggaatggtta gtgacagtgc aggacacaga agcccatgtt ccagatgtct atgaggaggt gcttggggta gtacccatca ccaccctggg acctcgacac tactgtgtca ttcttgaccc aatgggacca gacggcaaga accagctggg acaaaagcgt gttgtcaagg gagagaagtc ctttttcctc cagccaggag agaggctgga gcgaggcatc caggatgtgt atgtgctgtc agagcagcag gggctgctac tgaaggcact gcagcccctg gaggagggag agagcgagga gaaggtctcc catcaggccg gagactgctg gctcatccgt gggcccctgg agtatgtgcc atctgcaaaa gtggaggtgg tggaggagcg tcaggctatc cctctggacc aaaatgaggg catctatgtg caggatgtca agacggggaa ggtgcgggct gtgattggaa gcacctacat gctgactcag gatgaagtcc tgtgggaaaa ggagctgcct tctggggtgg aggagctgct gaacttgggg catgaccctc tggcagacag gggtcagaag ggcacagcca agccccttca gccctcagct ccaaggaaca agacccgagt ggtcagctac cgtgtcccgc acaatgcagc ggtgcaggtc tatgactaca gagccaagag agcccgtgtg gtctttgggc ccgagctagt gacactggat cctgaggagc agttcacagt attgtccctt tctgccgggc gacccaagcg tcctcatgcc cgccgtgcac tctgcctact gctgggacct gatttcttta ctgatgtcat caccatcgaa actgcagatc atgccaggtt gcagctgcag cttgcctaca actggcactt tgaactgaag aaccggaatg accctgcaga ggcagccaag cttttctccg tgcctgactt cgtgggtgac gcctgcaagg ccattgcatc ccgagtccgg ggggctgtag cctctgtcac ctttgatgac ttccataaaa actcagcccg gatcattcga atggctgttt ttggctttga gatgtctgaa gacacaggtc ctgatggcac actcctgccc aaggctcgag accaggcagt ctttccccaa aacgggctgg tagtcagcag tgtggatgtg cagtcagtgg agcccgtgga ccagaggacc cgggatgccc ttcagcgcag cgttcagctg gccatcgaaa ttaccaccaa ctcccaggag gcagcagcca agcacgaggc tcagagactg gaacaggaag cccgtggtcg gcttgagagg cagaagatct tggaccagtc agaagctgaa aaagcccgca aggaactctt ggagcttgag gctatgagca tggctgtgga gagcacgggt aatgccaaag cagaggctga gtcccgtgca gaggcagcga ggatcgaagg agaaggctct gtgctgcagg ccaagctcaa ggcacaggcg ctagccattg agacggaggc tgagttggag cgagtaaaga aagtacgaga gatggaactg atctatgccc gggcccagtt ggagctggag gtgagcaagg cgcagcagct tgccaatgtg gaggcaaaga agttcaagga gatgacagag gcactgggcc ccggcaccat cagggacctg gctgtggccg ggccagagat gcaggtgaaa cttctccagt ccctgggcct gaaatccact ctcatcaccg atggctcgtc tcccatcaac ctcttcagca cagccttcgg gttgctgggg ctggggtctg atggtcagcc gccagcacag aagtga SEQ ID NO: 20 CP Peptide Met Ala Gly Cys Gly Cys Pro Cys Gly Cys Gly Ala SEQ ID NO: 21 Human CP-MVP Met Ala Gly Cys Gly Cys Pro Cys Gly Cys Gly Ala Met Ala Thr Glu Glu Phe Ile Ile Arg Ile Pro Pro Tyr His Tyr Ile His Val Leu Asp Gln Asn Ser Asn Val Ser Arg Val Glu Val Gly Pro Lys Thr Tyr Ile Arg Gln Asp Asn Glu Arg Val Leu Phe Ala Pro Met Arg Met Val Thr Val Pro Pro Arg His Tyr Cys Thr Val Ala Asn Pro Val Ser Arg Asp Ala Gln Gly Leu Val Leu Phe Asp Val Thr Gly Gln Val Arg Leu Arg His Ala Asp Leu Glu Ile Arg Leu Ala Gln Asp Pro Phe Pro Leu Tyr Pro Gly Glu Val Leu Glu Lys Asp Ile Thr Pro Leu Gln Val Val Leu Pro Asn Thr Ala Leu His Leu Lys Ala Leu Leu Asp Phe Glu Asp Lys Asp Gly Asp Lys Val Val Ala Gly Asp Glu Trp Leu Phe Glu Gly Pro Gly Thr Tyr Ile Pro Arg Lys Glu Val Glu Val Val Glu Ile Ile Gln Ala Thr Ile Ile Arg Gln Asn Gln Ala Leu Arg Leu Arg Ala Arg Lys Glu Cys Trp Asp Arg Asp Gly Lys Glu Arg Val Thr Gly Glu Glu Trp Leu Val Thr Thr Val Gly Ala Tyr Leu Pro Ala Val Phe Glu Glu Val Leu Asp Leu Val Asp Ala Val Ile Leu Thr Glu Lys Thr Ala Leu His Leu Arg Ala Arg Arg Asn Phe Arg Asp Phe Arg Gly Val Ser Arg Arg Thr Gly Glu Glu Trp Leu Val Thr Val Gln Asp Thr Glu Ala His Val Pro Asp Val His Glu Glu Val Leu Gly Val Val Pro Ile Thr Thr Leu Gly Pro His Asn Tyr Cys Val Ile Leu Asp Pro Val Gly Pro Asp Gly Lys Asn Gln Leu Gly Gln Lys Arg Val Val Lys Gly Glu Lys Ser Phe Phe Leu Gln Pro Gly Glu Gln Leu Glu Gln Gly Ile Gln Asp Val Tyr Val Leu Ser Glu Gln Gln Gly Leu Leu Leu Arg Ala Leu Gln Pro Leu Glu Glu Gly Glu Asp Glu Glu Lys Val Ser His Gln Ala Gly Asp His Trp Leu Ile Arg Gly Pro Leu Glu Tyr Val Pro Ser Ala Lys Val Glu Val Val Glu Glu Arg Gln Ala Ile Pro Leu Asp Glu Asn Glu Gly Ile Tyr Val Gln Asp Val Lys Thr Gly Lys Val Arg Ala Val Ile Gly Ser Thr Tyr Met Leu Thr Gln Asp Glu Val Leu Trp Glu Lys Glu Leu Pro Pro Gly Val Glu Glu Leu Leu Asn Lys Gly Gln Asp Pro Leu Ala Asp Arg Gly Glu Lys Asp Thr Ala Lys Ser Leu Gln Pro Leu Ala Pro Arg Asn Lys Thr Arg Val Val Ser Tyr Arg Val Pro His Asn Ala Ala Val Gln Val Tyr Asp Tyr Arg Glu Lys Arg Ala Arg Val Val Phe Gly Pro Glu Leu Val Ser Leu Gly Pro Glu Glu Gln Phe Thr Val Leu Ser Leu Ser Ala Gly Arg Pro Lys Arg Pro His Ala Arg Arg Ala Leu Cys Leu Leu Leu Gly Pro Asp Phe Phe Thr Asp Val Ile Thr Ile Glu Thr Ala Asp His Ala Arg Leu Gln Leu Gln Leu Ala Tyr Asn Trp His Phe Glu Val Asn Asp Arg Lys Asp Pro Gln Glu Thr Ala Lys Leu Phe Ser Val Pro Asp Phe Val Gly Asp Ala Cys Lys Ala Ile Ala Ser Arg Val Arg Gly Ala Val Ala Ser Val Thr Phe Asp Asp Phe His Lys Asn Ser Ala Arg Ile Ile Arg Thr Ala Val Phe Gly Phe Glu Thr Ser Glu Ala Lys Gly Pro Asp Gly Met Ala Leu Pro Arg Pro Arg Asp Gln Ala Val Phe Pro Gln Asn Gly Leu Val Val Ser Ser Val Asp Val Gln Ser Val Glu Pro Val Asp Gln Arg Thr Arg Asp Ala Leu Gln Arg Ser Val Gln Leu Ala Ile Glu Ile Thr Thr Asn Ser Gln Glu Ala Ala Ala Lys His Glu Ala Gln Arg Leu Glu Gln Glu Ala Arg Gly Arg Leu Glu Arg Gln Lys Ile Leu Asp Gln Ser Glu Ala Glu Lys Ala Arg Lys Glu Leu Leu Glu Leu Glu Ala Leu Ser Met Ala Val Glu Ser Thr Gly Thr Ala Lys Ala Glu Ala Glu Ser Arg Ala Glu Ala Ala Arg Ile Glu Gly Glu Gly Ser Val Leu Gln Ala Lys Leu Lys Ala Gln Ala Leu Ala Ile Glu Thr Glu Ala Glu Leu Gln Arg Val Gln Lys Val Arg Glu Leu Glu Leu Val Tyr Ala Arg Ala Gln Leu Glu Leu Glu Val Ser Lys Ala Gln Gln Leu Ala Glu Val Glu Val Lys Lys Phe Lys Gln Met Thr Glu Ala Ile Gly Pro Ser Thr Ile Arg Asp Leu Ala Val Ala Gly Pro Glu Met Gln Val Lys Leu Leu Gln Ser Leu Gly Leu Lys Ser Thr Leu Ile Thr Asp Gly Ser Thr Pro Ile Asn Leu Phe Asn Thr Ala Phe Gly Leu Leu Gly Met Gly Pro Glu Gly Gln Pro Leu Gly Arg Arg Val Ala Ser Gly Pro Ser Pro Gly Glu Gly Ile Ser Pro Gln Ser Ala Gln Ala Pro Gln Ala Pro Gly Asp Asn His Val Val Pro Val Leu Arg SEQ ID NO: 22 Human CP-MVP cDNA atggcaggct gcggttgtcc atgcggttgt ggcgccatgg caactgaaga gttcatcatc cgcatccccc cataccacta tatccatgtg ctggaccaga acagcaacgt gtcccgtgtg gaggtcgggc caaagaccta catccggcag gacaatgaga gggtactgtt tgcccccatg cgcatggtga ccgtcccccc acgtcactac tgcacagtgg ccaaccctgt gtctcgggat gcccagggct tggtgctgtt tgatgtcaca gggcaagttc ggcttcgcca cgctgacctc gagatccggc tggcccagga ccccttcccc ctgtacccag gggaggtgct ggaaaaggac atcacacccc tgcaggtggt tctgcccaac actgccctcc atctaaaggc gctgcttgat tttgaggata aagatggaga caaggtggtg gcaggagatg agtggctttt cgagggacct ggcacgtaca tcccccggaa ggaagtggag gtcgtggaga tcattcaggc caccatcatc aggcagaacc aggctctgcg gctcagggcc cgcaaggagt gctgggaccg ggacggcaag gagagggtga caggggaaga atggctggtc accacagtag gggcgtacct cccagcggtg tttgaggagg ttctggattt ggtggacgcc gtcatcctta cggaaaagac agccctgcac ctccgggctc ggcggaactt ccgggacttc aggggagtgt cccgccgcac tggggaggag tggctggtaa cagtgcagga cacagaggcc cacgtgccag atgtccacga ggaggtgctg ggggttgtgc ccatcaccac cctgggcccc cacaactact gcgtgattct cgaccctgtc ggaccggatg gcaagaatca gctggggcag aagcgcgtgg tcaagggaga gaagtctttt ttcctccagc caggagagca gctggaacaa ggcatccagg atgtgtatgt gctgtcggag cagcaggggc tgctgctgag ggccctgcag cccctggagg agggggagga tgaggagaag gtctcacacc aggctgggga ccactggctc atccgcggac ccctggagta tgtgccatct gccaaagtgg aggtggtgga ggagcgccag gccatccctc tagacgagaa cgagggcatc tatgtgcagg atgtcaagac cggaaaggtg cgcgctgtga ttggaagcac ctacatgctg acccaggacg aagtcctgtg ggagaaagag ctgcctcccg gggtggagga gctgctgaac aaggggcagg accctctggc agacaggggt gagaaggaca cagctaagag cctccagccc ttggcgcccc ggaacaagac ccgtgtggtc agctaccgcg tgccccacaa cgctgcggtg caggtgtacg actaccgaga gaagcgagcc cgcgtggtct tcgggcctga gctggtgtcg ctgggtcctg aggagcagtt cacagtgttg tccctctcag ctgggcggcc caagcgtccc catgcccgcc gtgcgctctg cctgctgctg gggcctgact tcttcacaga cgtcatcacc atcgaaacgg cggatcatgc caggctgcaa ctgcagctgg cctacaactg gcactttgag gtgaatgacc ggaaggaccc ccaagagacg gccaagctct tttcagtgcc agactttgta ggtgatgcct gcaaagccat cgcatcccgg gtgcgggggg ccgtggcctc tgtcactttc gatgacttcc ataagaactc agcccgcatc attcgcactg ctgtctttgg ctttgagacc tcggaagcga agggccccga tggcatggcc ctgcccaggc cccgggacca ggctgtcttc ccccaaaacg ggctggtggt cagcagtgtg gacgtgcagt cagtggagcc tgtggatcag aggacccggg acgccctgca acgcagcgtc cagctggcca tcgagatcac caccaactcc caggaagcgg cggccaagca tgaggctcag agactggagc aggaagcccg cggccggctt gagcggcaga agatcctgga ccagtcagaa gccgagaaag ctcgcaagga acttttggag ctggaggctc tgagcatggc cgtggagagc accgggactg ccaaggcgga ggccgagtcc cgtgcggagg cagcccggat tgagggagaa gggtccgtgc tgcaggccaa gctaaaagca caggccttgg ccattgaaac ggaggctgag ctccagaggg tccagaaggt ccgagagctg gaactggtct atgcccgggc ccagctggag ctggaggtga gcaaggctca gcagctggct gaggtggagg tgaagaagtt caagcagatg acagaggcca taggccccag caccatcagg gaccttgctg tggctgggcc tgagatgcag gtaaaactgc tccagtccct gggcctgaaa tcaaccctca tcaccgatgg ctccactccc atcaacctct tcaacacagc ctttgggctg ctggggatgg ggcccgaggg tcagcccctg ggcagaaggg tggccagtgg gcccagccct ggggagggga tatcccccca gtctgctcag gcccctcaag ctcctggaga caaccacgtg gtgcctgtac tgcgctaa SEQ ID NO: 23 Rat CP-MVP Met Ala Gly Cys Gly Cys Pro Cys Gly Cys Gly Ala Met Ala Thr Glu Glu Ala Ile Ile Arg Ile Pro Pro Tyr His Tyr Ile His Val Leu Asp Gln Asn Ser Asn Val Ser Arg Val Glu Val Gly Pro Lys Thr Tyr Ile Arg Gln Asp Asn Glu Arg Val Leu Phe Ala Pro Val Arg Met Val Thr Val Pro Pro Arg His Tyr Cys Ile Val Ala Asn Pro Val Ser Arg Asp Thr Gln Ser Ser Val Leu Phe Asp Ile Thr Gly Gln Val Arg Leu Arg His Ala Asp Gln Glu Ile Arg Leu Ala Gln Asp Pro Phe Pro Leu Tyr Pro Gly Glu Val Leu Glu Lys Asp Ile Thr Pro Leu Gln Val Val Leu Pro Asn Thr Ala Leu His Leu Lys Ala Leu Leu Asp Phe Glu Asp Lys Asn Gly Asp Lys Val Met Ala Gly Asp Glu Trp Leu Phe Glu Gly Pro Gly Thr Tyr Ile Pro Gln Lys Glu Val Glu Val Val Gly Ile Ile Gln Ala Thr Val Ile Lys Gln Asn Gln Ala Leu Arg Leu Arg Ala Arg Lys Glu Cys Phe Asp Arg Glu Gly Lys Gly Arg Val Thr Gly Glu Glu Trp Leu Val Arg Ser Val Gly Ala Tyr Leu Pro Ala Val Phe Glu Glu Val Leu Asp Leu Val Asp Ala Val Ile Leu Thr Glu Lys Thr Ala Leu His Leu Arg Ala Leu Gln Asn Phe Arg Asp Leu Arg Gly Val Leu His Arg Thr Gly Glu Glu Trp Leu Val Thr Val Gln Asp Thr Glu Ala His Val Pro Asp Val Tyr Glu Glu Val Leu Gly Val Val Pro Ile Thr Thr Leu Gly Pro Arg His Tyr Cys Val Ile Leu Asp Pro Met Gly Pro Asp Gly Lys Asn Gln Leu Gly Gln Lys Arg Val Val Lys Gly Glu Lys Ser Phe Phe Leu Gln Pro Gly Glu Arg Leu Glu Arg Gly Ile Gln Asp Val Tyr Val Leu Ser Glu Gln Gln Gly Leu Leu Leu Lys Ala Leu Gln Pro Leu Glu Glu Gly Glu Ser Glu Glu Lys Val Ser His Gln Ala Gly Asp Cys Trp Leu Ile Arg Gly Pro Leu Glu Tyr Val Pro Ser Ala Lys Val Glu Val Val Glu Glu Arg Gln Ala Ile Pro Leu Asp Gln Asn Glu Gly Ile Tyr Val Gln Asp Val Lys Thr Gly Lys Val Arg Ala Val Ile Gly Ser Thr Tyr Met Leu Thr Gln Asp Glu Val Leu Trp Glu Lys Glu Leu Pro Ser Gly Val Glu Glu Leu Leu Asn Leu Gly His Asp Pro Leu Ala Asp Arg Gly Gln Lys Gly Thr Ala Lys Pro Leu Gln Pro Ser Ala Pro Arg Asn Lys Thr Arg Val Val Ser Tyr Arg Val Pro His Asn Ala Ala Val Gln Val Tyr Asp Tyr Arg Ala Lys Arg Ala Arg Val Val Phe Gly Pro Glu Leu Val Thr Leu Asp Pro Glu Glu Gln Phe Thr Val Leu Ser Leu Ser Ala Gly Arg Pro Lys Arg Pro His Ala Arg Arg Ala Leu Cys Leu Leu Leu Gly Pro Asp Phe Phe Thr Asp Val Ile Thr Ile Glu Thr Ala Asp His Ala Arg Leu Gln Leu Gln Leu Ala Tyr Asn Trp His Phe Glu Leu Lys Asn Arg Asn Asp Pro Ala Glu Ala Ala Lys Leu Phe Ser Val Pro Asp Phe Val Gly Asp Ala Cys Lys Ala Ile Ala Ser Arg Val Arg Gly Ala Val Ala Ser Val Thr Phe Asp Asp Phe His Lys Asn Ser Ala Arg Ile Ile Arg Met Ala Val Phe Gly Phe Glu Met Ser Glu Asp Thr Gly Pro Asp Gly Thr Leu Leu Pro Lys Ala Arg Asp Gln Ala Val Phe Pro Gln Asn Gly Leu Val Val Ser Ser Val Asp Val Gln Ser Val Glu Pro Val Asp Gln Arg Thr Arg Asp Ala Leu Gln Arg Ser Val Gln Leu Ala Ile Glu Ile Thr Thr Asn Ser Gln Glu Ala Ala Ala Lys His Glu Ala Gln Arg Leu Glu Gln Glu Ala Arg Gly Arg Leu Glu Arg Gln Lys Ile Leu Asp Gln Ser Glu Ala Glu Lys Ala Arg Lys Glu Leu Leu Glu Leu Glu Ala Met Ser Met Ala Val Glu Ser Thr Gly Asn Ala Lys Ala Glu Ala Glu Ser Arg Ala Glu Ala Ala Arg Ile Glu Gly Glu Gly Ser Val Leu Gln Ala Lys Leu Lys Ala Gln Ala Leu Ala Ile Glu Thr Glu Ala Glu Leu Glu Arg Val Lys Lys Val Arg Glu Met Glu Leu Ile Tyr Ala Arg Ala Gln Leu Glu Leu Glu Val Ser Lys Ala Gln Gln Leu Ala Asn Val Glu Ala Lys Lys Phe Lys Glu Met Thr Glu Ala Leu Gly Pro Gly Thr Ile Arg Asp Leu Ala Val Ala Gly Pro Glu Met Gln Val Lys Leu Leu Gln Ser Leu Gly Leu Lys Ser Thr Leu Ile Thr Asp Gly Ser Ser Pro Ile Asn Leu Phe Ser Thr Ala Phe Gly Leu Leu Gly Leu Gly Ser Asp Gly Gln Pro Pro Ala Gln Lys SEQ ID NO: 24 Rat CP-MVP cDNA atggcaggct gcggttgtcc atgcggttgt ggcgccatgg caactgaaga ggccatcatc cgcatccccc cataccacta catccatgtg ctggaccaga acagtaatgt gtcccgtgtg gaggttggac caaagaccta catccggcag gacaatgaga gggtactgtt tgccccagtt cgcatggtga ccgtcccccc acgccactac tgcatagtgg ccaaccctgt gtcccgggac acccagagtt ctgtgttatt tgacatcaca ggacaagtcc gactccggca cgctgaccag gagatccgac tagcccagga ccccttcccc ctgtatccag gggaggtgct ggaaaaggac atcaccccac tgcaggtggt tctgcccaac acagcactgc atcttaaggc gttgctggac tttgaggata agaatggaga caaggtcatg gcaggagacg agtggctatt tgagggacct ggcacctaca tcccacagaa ggaagtggaa gtcgtggaga tcattcaggc cacagtcatc aaacagaacc aagcactgcg gctaagggcc cgaaaggagt gctttgaccg ggagggcaag gggcgcgtga caggtgagga gtggctggtc cgatccgtgg gggcttacct cccagctgtc tttgaagagg tgctggatct ggtggatgct gtgatcctta cagaaaagac tgccctgcac ctccgggctc tgcagaactt cagggacctt cggggagtgc tccaccgcac cggggaggaa tggttagtga cagtgcagga cacagaagcc catgttccag atgtctatga ggaggtgctt ggggtagtac ccatcaccac cctgggacct cgacactact gtgtcattct tgacccaatg ggaccagacg gcaagaacca gctgggacaa aagcgtgttg tcaagggaga gaagtccttt ttcctccagc caggagagag gctggagcga ggcatccagg atgtgtatgt gctgtcagag cagcaggggc tgctactgaa ggcactgcag cccctggagg agggagagag cgaggagaag gtctcccatc aggccggaga ctgctggctc atccgtgggc ccctggagta tgtgccatct gcaaaagtgg aggtggtgga ggagcgtcag gctatccctc tggaccaaaa tgagggcatc tatgtgcagg atgtcaagac ggggaaggtg cgggctgtga ttggaagcac ctacatgctg actcaggatg aagtcctgtg ggaaaaggag ctgccttctg gggtggagga gctgctgaac ttggggcatg accctctggc agacaggggt cagaagggca cagccaagcc ccttcagccc tcagctccaa ggaacaagac ccgagtggtc agctaccgtg tcccgcacaa tgcagcggtg caggtctatg actacagagc caagagagcc cgtgtggtct ttgggcccga gctagtgaca ctggatcctg aggagcagtt cacagtattg tccctttctg ccgggcgacc caagcgtcct catgcccgcc gtgcactctg cctactgctg ggacctgatt tctttactga tgtcatcacc atcgaaactg cagatcatgc caggttgcag ctgcagcttg cctacaactg gcactttgaa ctgaagaacc ggaatgaccc tgcagaggca gccaagcttt tctccgtgcc tgacttcgtg ggtgacgcct gcaaggccat tgcatcccga gtccgggggg ctgtagcctc tgtcaccttt gatgacttcc ataaaaactc agcccggatc attcgaatgg ctgtttttgg ctttgagatg tctgaagaca caggtcctga tggcacactc ctgcccaagg ctcgagacca ggcagtcttt ccccaaaacg ggctggtagt cagcagtgtg gatgtgcagt cagtggagcc cgtggaccag aggacccggg atgcccttca gcgcagcgtt cagctggcca tcgaaattac caccaactcc caggaggcag cagccaagca cgaggctcag agactggaac aggaagcccg tggtcggctt gagaggcaga agatcttgga ccagtcagaa gctgaaaaag cccgcaagga actcttggag cttgaggcta tgagcatggc tgtggagagc acgggtaatg ccaaagcaga ggctgagtcc cgtgcagagg cagcgaggat cgaaggagaa ggctctgtgc tgcaggccaa gctcaaggca caggcgctag ccattgagac ggaggctgag ttggagcgag taaagaaagt acgagagatg gaactgatct atgcccgggc ccagttggag ctggaggtga gcaaggcgca gcagcttgcc aatgtggagg caaagaagtt caaggagatg acagaggcac tgggccccgg caccatcagg gacctggctg tggccgggcc agagatgcag gtgaaacttc tccagtccct gggcctgaaa tccactctca tcaccgatgg ctcgtctccc atcaacctct tcagcacagc cttcgggttg ctggggctgg ggtctgatgg tcagccgcca gcacagaagt ga SEQ ID NO: 25 Human TEP1, Genbank #AAC51107 Met Glu Lys Leu His Gly His Val Ser Ala His Pro Asp Ile Leu Ser Leu Glu Asn Arg Cys Leu Ala Met Leu Pro Asp Leu Gln Pro Leu Glu Lys Leu His Gln His Val Ser Thr His Ser Asp Ile Leu Ser Leu Lys Asn Gln Cys Leu Ala Thr Leu Pro Asp Leu Lys Thr Met Glu Lys Pro His Gly Tyr Val Ser Ala His Pro Asp Ile Leu Ser Leu Glu Asn Gln Cys Leu Ala Thr Leu Ser Asp Leu Lys Thr Met Glu Lys Pro His Gly His Val Ser Ala His Pro Asp Ile Leu Ser Leu Glu Asn Arg Cys Leu Ala Thr Leu Pro Ser Leu Lys Ser Thr Val Ser Ala Ser Pro Leu Phe Gln Ser Leu Gln Ile Ser His Met Thr Gln Ala Asp Leu Tyr Arg Val Asn Asn Ser Asn Cys Leu Leu Ser Glu Pro Pro Ser Trp Arg Ala Gln His Phe Ser Lys Gly Leu Asp Leu Ser Thr Cys Pro Ile Ala Leu Lys Ser Ile Ser Ala Thr Glu Thr Ala Gln Glu Ala Thr Leu Gly Arg Trp Phe Asp Ser Glu Glu Lys Lys Gly Ala Glu Thr Gln Met Pro Ser Tyr Ser Leu Ser Leu Gly Glu Glu Glu Glu Val Glu Asp Leu Ala Val Lys Leu Thr Ser Gly Asp Ser Glu Ser His Pro Glu Pro Thr Asp His Val Leu Gln Glu Lys Lys Met Ala Leu Leu Ser Leu Leu Cys Ser Thr Leu Val Ser Glu Val Asn Met Asn Asn Thr Ser Asp Pro Thr Leu Ala Ala Ile Phe Glu Ile Cys Arg Glu Leu Ala Leu Leu Glu Pro Glu Phe Ile Leu Lys Ala Ser Leu Tyr Ala Arg Gln Gln Leu Asn Val Arg Asn Val Ala Asn Asn Ile Leu Ala Ile Ala Ala Phe Leu Pro Ala Cys Arg Pro His Leu Arg Arg Tyr Phe Cys Ala Ile Val Gln Leu Pro Ser Asp Trp Ile Gln Val Ala Glu Leu Tyr Gln Ser Leu Ala Glu Gly Asp Lys Asn Lys Leu Val Pro Leu Pro Ala Cys Leu Arg Thr Ala Met Thr Asp Lys Phe Ala Gln Phe Asp Glu Tyr Gln Leu Ala Lys Tyr Asn Pro Arg Lys His Arg Ala Lys Arg His Pro Arg Arg Pro Pro Arg Ser Pro Gly Met Glu Pro Pro Phe Ser His Arg Cys Phe Pro Arg Tyr Ile Gly Phe Leu Arg Glu Glu Gln Arg Lys Phe Glu Lys Ala Gly Asp Thr Val Ser Glu Lys Lys Asn Pro Pro Arg Phe Thr Leu Lys Lys Leu Val Gln Arg Leu His Ile His Lys Pro Ala Gln His Val Gln Ala Leu Leu Gly Tyr Arg Tyr Pro Ser Asn Leu Gln Leu Phe Ser Arg Ser Arg Leu Pro Gly Pro Trp Asp Ser Ser Arg Ala Gly Lys Arg Met Lys Leu Ser Arg Pro Glu Thr Trp Glu Arg Glu Leu Ser Leu Arg Gly Asn Lys Ala Ser Val Trp Glu Glu Leu Ile Glu Asn Gly Lys Leu Pro Phe Met Ala Met Leu Arg Asn Leu Cys Asn Leu Leu Arg Val Gly Ile Ser Ser Arg His His Glu Leu Ile Leu Gln Arg Leu Gln His Gly Lys Ser Val Ile His Ser Arg Gln Phe Pro Phe Arg Phe Leu Asn Ala His Asp Ala Ile Asp Ala Leu Glu Ala Gln Leu Arg Asn Gln Ala Leu Pro Phe Pro Ser Asn Ile Thr Leu Met Arg Arg Ile Leu Thr Arg Asn Glu Lys Asn Arg Pro Arg Arg Arg Phe Leu Cys His Leu Ser Arg Gln Gln Leu Arg Met Ala Met Arg Ile Pro Val Leu Tyr Glu Gln Leu Lys Arg Glu Lys Leu Arg Val His Lys Ala Arg Gln Trp Lys Tyr Asp Gly Glu Met Leu Asn Arg Tyr Arg Gln Ala Leu Glu Thr Ala Val Asn Leu Ser Val Lys His Ser Leu Pro Leu Leu Pro Gly Arg Thr Val Leu Val Tyr Leu Thr Asp Ala Asn Ala Asp Arg Leu Cys Pro Lys Ser Asn Pro Gln Gly Pro Pro Leu Asn Tyr Ala Leu Leu Leu Ile Gly Met Met Ile Thr Arg Ala Glu Gln Val Asp Val Val Leu Cys Gly Gly Asp Thr Leu Lys Thr Ala Val Leu Lys Ala Glu Glu Gly Ile Leu Lys Thr Ala Ile Lys Leu Gln Ala Gln Val Gln Glu Phe Asp Glu Asn Asp Gly Trp Ser Leu Asn Thr Phe Gly Lys Tyr Leu Leu Ser Leu Ala Gly Gln Arg Val Pro Val Asp Arg Val Ile Leu Leu Gly Gln Ser Met Asp Asp Gly Met Ile Asn Val Ala Lys Gln Leu Tyr Trp Gln Arg Val Asn Ser Lys Cys Leu Phe Val Gly Ile Leu Leu Arg Arg Val Gln Tyr Leu Ser Thr Asp Leu Asn Pro Asn Asp Val Thr Leu Ser Gly Cys Thr Asp Ala Ile Leu Lys Phe Ile Ala Glu His Gly Ala Ser His Leu Leu Glu His Val Gly Gln Met Asp Lys Ile Phe Lys Ile Pro Pro Pro Pro Gly Lys Thr Gly Val Gln Ser Leu Arg Pro Leu Glu Glu Asp Thr Pro Ser Pro Leu Ala Pro Val Ser Gln Gln Gly Trp Arg Ser Ile Arg Leu Phe Ile Ser Ser Thr Phe Arg Asp Met His Gly Glu Arg Asp Leu Leu Leu Arg Ser Val Leu Pro Ala Leu Gln Ala Arg Ala Ala Pro His Arg Ile Ser Leu His Gly Ile Asp Leu Arg Trp Gly Val Thr Glu Glu Glu Thr Arg Arg Asn Arg Gln Leu Glu Val Cys Leu Gly Glu Val Glu Asn Ala Gln Leu Phe Val Gly Ile Leu Gly Ser Arg Tyr Gly Tyr Ile Pro Pro Ser Tyr Asn Leu Pro Asp His Pro His Phe His Trp Ala Gln Gln Tyr Pro Ser Gly Arg Ser Val Thr Glu Met Glu Val Met Gln Phe Leu Asn Arg Asn Gln Arg Leu Gln Pro Ser Ala Gln Ala Leu Ile Tyr Phe Arg Asp Ser Ser Phe Leu Ser Ser Val Pro Asp Ala Trp Lys Ser Asp Phe Val Ser Glu Ser Glu Glu Ala Ala Cys Arg Ile Ser Glu Leu Lys Ser Tyr Leu Ser Arg Gln Lys Gly Ile Thr Cys Arg Arg Tyr Pro Cys Glu Trp Gly Gly Val Ala Ala Gly Arg Pro Tyr Val Gly Gly Leu Glu Glu Phe Gly Gln Leu Val Leu Gln Asp Val Trp Asn Met Ile Gln Lys Leu Tyr Leu Gln Pro Gly Ala Leu Leu Glu Gln Pro Val Ser Ile Pro Asp Asp Asp Leu Val Gln Ala Thr Phe Gln Gln Leu Gln Lys Pro Pro Ser Pro Ala Arg Pro Arg Leu Leu Gln Asp Thr Val Gln Gln Leu Met Leu Pro His Gly Arg Leu Ser Leu Val Thr Gly Gln Ser Gly Gln Gly Lys Thr Ala Phe Leu Ala Ser Leu Val Ser Ala Leu Gln Ala Pro Asp Gly Ala Lys Val Ala Pro Leu Val Phe Phe His Phe Ser Gly Ala Arg Pro Asp Gln Gly Leu Ala Leu Thr Leu Leu Arg Arg Leu Cys Thr Tyr Leu Arg Gly Gln Leu Lys Glu Pro Gly Ala Leu Pro Ser Thr Tyr Arg Ser Leu Val Trp Glu Leu Gln Gln Arg Leu Leu Pro Lys Ser Ala Glu Ser Leu His Pro Gly Gln Thr Gln Val Leu Ile Ile Asp Gly Ala Asp Arg Leu Val Asp Gln Asn Gly Gln Leu Ile Ser Asp Trp Ile Pro Lys Lys Leu Pro Arg Cys Val His Leu Val Leu Ser Val Ser Ser Asp Ala Gly Leu Gly Glu Thr Leu Glu Gln Ser Gln Gly Ala His Val Leu Ala Leu Gly Pro Leu Glu Ala Ser Ala Arg Ala Arg Leu Val Arg Glu Glu Leu Ala Leu Tyr Gly Lys Arg Leu Glu Glu Ser Pro Phe Asn Asn Gln Met Arg Leu Leu Leu Val Lys Arg Glu Ser Gly Arg Pro Leu Tyr Leu Arg Leu Val Thr Asp His Leu Arg Leu Phe Thr Leu Tyr Glu Gln Val Ser Glu Arg Leu Arg Thr Leu Pro Ala Thr Val Pro Leu Leu Leu Gln His Ile Leu Ser Thr Leu Glu Lys Glu His Gly Pro Asp Val Leu Pro Gln Ala Leu Thr Ala Leu Glu Val Thr Arg Ser Gly Leu Thr Val Asp Gln Leu His Gly Val Leu Ser Val Trp Arg Thr Leu Pro Lys Gly Thr Lys Ser Trp Glu Glu Ala Val Ala Ala Gly Asn Ser Gly Asp Pro Tyr Pro Met Gly Pro Phe Ala Cys Leu Val Gln Ser Leu Arg Ser Leu Leu Gly Glu Gly Pro Leu Glu Arg Pro Gly Ala Arg Leu Cys Leu Pro Asp Gly Pro Leu Arg Thr Ala Ala Lys Arg Cys Tyr Gly Lys Arg Pro Gly Leu Glu Asp Thr Ala His Ile Leu Ile Ala Ala Gln Leu Trp Lys Thr Cys Asp Ala Asp Ala Ser Gly Thr Phe Arg Ser Cys Pro Pro Glu Ala Leu Gly Asp Leu Pro Tyr His Leu Leu Gln Ser Gly Asn Arg Gly Leu Leu Ser Lys Phe Leu Thr Asn Leu His Val Val Ala Ala His Leu Glu Leu Gly Leu Val Ser Arg Leu Leu Glu Ala His Ala Leu Tyr Ala Ser Ser Val Pro Lys Glu Glu Gln Lys Leu Pro Glu Ala Asp Val Ala Val Phe Arg Thr Phe Leu Arg Gln Gln Ala Ser Ile Leu Ser Gln Tyr Pro Arg Leu Leu Pro Gln Gln Ala Ala Asn Gln Pro Leu Asp Ser Pro Leu Cys His Gln Ala Ser Leu Leu Ser Arg Arg Trp His Leu Gln His Thr Leu Arg Trp Leu Asn Lys Pro Arg Thr Met Lys Asn Gln Gln Ser Ser Ser Leu Ser Leu Ala Val Ser Ser Ser Pro Thr Ala Val Ala Phe Ser Thr Asn Gly Gln Arg Ala Ala Val Gly Thr Ala Asn Gly Thr Val Tyr Leu Leu Asp Leu Arg Thr Trp Gln Glu Glu Lys Ser Val Val Ser Gly Cys Asp Gly Ile Ser Ala Cys Leu Phe Leu Ser Asp Asp Thr Leu Phe Leu Thr Ala Phe Asp Gly Leu Leu Glu Leu Trp Asp Leu Gln His Gly Cys Arg Val Leu Gln Thr Lys Ala His Gln Tyr Gln Ile Thr Gly Cys Cys Leu Ser Pro Asp Cys Arg Leu Leu Ala Thr Val Cys Leu Gly Gly Cys Leu Lys Leu Trp Asp Thr His Ala Gly Cys Gln Leu Leu Thr Ala Gly Glu Asp Gly Lys Val Gln Val Trp Ser Gly Ser Leu Gly Arg Pro Arg Gly His Leu Gly Ser Leu Ser Leu Ser Pro Ala Leu Ser Val Ala Leu Ser Pro Asp Gly Asp Arg Val Ala Val Gly Tyr Arg Ala Asp Gly Ile Arg Ile Tyr Lys Ile Ser Ser Gly Ser Gln Gly Ala Gln Gly Gln Ala Leu Asp Val Ala Val Ser Ala Leu Ala Trp Leu Ser Pro Lys Val Leu Val Ser Gly Ala Glu Asp Gly Ser Leu Gln Gly Trp Ala Leu Lys Glu Cys Ser Leu Gln Ser Leu Trp Leu Leu Ser Arg Phe Gln Lys Pro Val Leu Gly Leu Ala Thr Ser Gln Glu Leu Leu Ala Ser Ala Ser Glu Asp Phe Thr Val Gln Leu Trp Pro Arg Gln Leu Leu Thr Arg Pro His Lys Ala Glu Asp Phe Pro Cys Gly Thr Glu Leu Arg Gly His Glu Gly Pro Val Ser Cys Cys Ser Phe Ser Thr Asp Gly Gly Ser Leu Ala Thr Gly Gly Arg Asp Arg Ser Leu Leu Cys Trp Asp Val Arg Thr Pro Lys Thr Pro Val Leu Ile His Ser Phe Pro Ala Cys His Arg Asp Trp Val Thr Gly Cys Ala Trp Thr Lys Asp Asn Leu Leu Ile Ser Cys Ser Ser Asp Gly Ser Val Gly Leu Trp Asp Pro Glu Ser Gly Gln Arg Leu Gly Gln Phe Leu Gly His Gln Ser Ala Val Ser Ala Val Ala Ala Val Glu Glu His Val Val Ser Val Ser Arg Asp Gly Thr Leu Lys Val Trp Asp His Gln Gly Val Glu Leu Thr Ser Ile Pro Ala His Ser Gly Pro Ile Ser His Cys Ala Ala Ala Met Glu Pro Arg Ala Ala Gly Gln Pro Gly Ser Glu Leu Leu Val Val Thr Val Gly Leu Asp Gly Ala Thr Arg Leu Trp His Pro Leu Leu Val Cys Gln Thr His Thr Leu Leu Gly His Ser Gly Pro Val Arg Ala Ala Ala Val Ser Glu Thr Ser Gly Leu Met Leu Thr Ala Ser Glu Asp Gly Ser Val Arg Leu Trp Gln Val Pro Lys Glu Ala Asp Asp Thr Cys Ile Pro Arg Ser Ser Ala Ala Val Thr Ala Val Ala Trp Ala Pro Asp Gly Ser Met Ala Val Ser Gly Asn Gln Ala Gly Glu Leu Ile Leu Trp Gln Glu Ala Lys Ala Val Ala Thr Ala Gln Ala Pro Gly His Ile Gly Ala Leu Ile Trp Ser Ser Ala His Thr Phe Phe Val Leu Ser Ala Asp Glu Lys Ile Ser Glu Trp Gln Val Lys Leu Arg Lys Gly Ser Ala Pro Gly Asn Leu Ser Leu His Leu Asn Arg Ile Leu Gln Glu Asp Leu Gly Val Leu Thr Ser Leu Asp Trp Ala Pro Asp Gly His Phe Leu Ile Leu Ala Lys Ala Asp Leu Lys Leu Leu Cys Met Lys Pro Gly Asp Ala Pro Ser Glu Ile Trp Ser Ser Tyr Thr Glu Asn Pro Met Ile Leu Ser Thr His Lys Glu Tyr Gly Ile Phe Val Leu Gln Pro Lys Asp Pro Gly Val Leu Ser Phe Leu Arg Gln Lys Glu Ser Gly Glu Phe Glu Glu Arg Leu Asn Phe Asp Ile Asn Leu Glu Asn Pro Ser Arg Thr Leu Ile Ser Ile Thr Gln Ala Lys Pro Glu Ser Glu Ser Ser Phe Leu Cys Ala Ser Ser Asp Gly Ile Leu Trp Asn Leu Ala Lys Cys Ser Pro Glu Gly Glu Trp Thr Thr Gly Asn Met Trp Gln Lys Lys Ala Asn Thr Pro Glu Thr Gln Thr Pro Gly Thr Asp Pro Ser Thr Cys Arg Glu Ser Asp Ala Ser Met Asp Ser Asp Ala Ser Met Asp Ser Glu Pro Thr Pro His Leu Lys Thr Arg Gln Arg Arg Lys Ile His Ser Gly Ser Val Thr Ala Leu His Val Leu Pro Glu Leu Leu Val Thr Ala Ser Lys Asp Arg Asp Val Lys Leu Trp Glu Arg Pro Ser Met Gln Leu Leu Gly Leu Phe Arg Cys Glu Gly Ser Val Ser Cys Leu Glu Pro Trp Leu Gly Ala Asn Ser Thr Leu Gln Leu Ala Val Gly Asp Val Gln Gly Asn Val Tyr Phe Leu Asn Trp Glu SEQ ID NO: 26 Human TEP1 cDNA, Genbank #U86136 atggaaaaac tccatgggca tgtgtctgcc catccagaca tcctctcctt ggagaaccgg tgcctggcta tgctccctga cttacagccc ttggagaaac tacatcagca tgtatctacc cactcagata tcctctcctt gaagaaccag tgcctagcca cgcttcctga cctgaagacc atggaaaaac cacatggata tgtgtctgcc cacccagaca tcctctcctt ggagaaccag tgcctggcca cactttctga cctgaagacc atggagaaac cacatggaca tgtttctgcc cacccagaca tcctctcctt ggagaaccgg tgcctggcca ccctccctag tctaaagagc actgtgtctg ccagcccctt gttccagagt ctacagatat ctcacatgac gcaagctgat ttgtaccgtg tgaacaacag caattgcctg ctctctgagc ctccaagttg gagggctcag catttctcta agggactaga cctttcaacc tgccctatag ccctgaaatc catctctgcc acagagacag ctcaggaagc aactttgggt cgttggtttg attcagaaga gaagaaaggg gcagagaccc aaatgccttc ttatagtctg agcttgggag aggaggagga ggtggaggat ctggccgtga agctcacctc tggagactct gaatctcatc cagagcctac tgaccatgtc cttcaggaaa agaagatggc tctactgagc ttgctgtgct ctactctggt ctcagaagta aacatgaaca atacatctga ccccaccctg gctgccattt ttgaaatctg tcgtgaactt gccctcctgg agcctgagtt tatcctcaag gcatctttgt atgccaggca gcagctgaac gtccggaatg tggccaataa catcttggcc attgctgctt tcttgccggc gtgtcgcccc cacctgcgac gatatttctg tgccattgtc cagctgcctt ctgactggat ccaggtggct gagctttacc agagcctggc tgagggagat aagaataagc tggtgcccct gcccgcctgt ctccgtactg ccatgacgga caaatttgcc cagtttgacg agtaccagct ggctaagtac aaccctcgga agcaccgggc caagagacac ccccgccggc caccccgctc tccagggatg gagcctccat tttctcacag atgttttcca aggtacatag ggtttctcag agaagagcag agaaagtttg agaaggccgg tgatacagtg tcagagaaaa agaatcctcc aaggttcacc ctgaagaagc tggttcagcg actgcacatc cacaagcctg cccagcacgt tcaagccctg ctgggttaca gatacccctc caacctacag ctcttttctc gaagtcgcct tcctgggcct tgggattcta gcagagctgg gaagaggatg aagctgtcta ggccagagac ctgggagcgg gagctgagcc tacgggggaa caaagcgtcg gtctgggagg aactcattga aaatgggaag cttcccttca tggccatgct tcggaacctg tgcaacctgc tgcgggttgg aatcagttcc cgccaccatg agctcattct ccagagactc cagcatggga agtcggtgat ccacagtcgg cagtttccat tcagatttct taacgcccat gatgccattg atgccctcga ggctcaactc agaaatcaag cattgccctt tccttcgaat ataacactga tgaggcggat actaactaga aatgaaaaga accgtcccag gcggaggttt ctttgccacc taagccgtca gcagcttcgt atggcaatga ggatacctgt gttgtatgag cagctcaaga gggagaagct gagagtacac aaggccagac agtggaaata tgatggtgag atgctgaaca ggtaccgaca ggccctagag acagctgtga acctctctgt gaagcacagc ctgcccctgc tgccaggccg cactgtcttg gtctatctga cagatgctaa tgcagacagg ctctgtccaa agagcaaccc acaagggccc ccgctgaact atgcactgct gttgattggg atgatgatca cgagggcgga gcaggtggac gtcgtgctgt gtggaggtga cactctgaag actgcagtgc ttaaggcaga agaaggcatc ctgaagactg ccatcaagct ccaggctcaa gtccaggagt ttgatgaaaa tgatggatgg tccctgaata cttttgggaa atacctgctg tctctggctg gccaaagggt tcctgtggac agggtcatcc tccttggcca aagcatggat gatggaatga taaatgtggc caaacagctt tactggcagc gtgtgaattc caagtgcctc tttgttggta tcctcctaag aagggtacaa tacctgtcaa cagatttgaa tcccaatgat gtgacactct caggctgtac tgatgcgata ctgaagttca ttgcagagca tggggcctcc catcttctgg aacatgtggg ccaaatggac aaaatattca agattccacc acccccagga aagacagggg tccagtctct ccggccactg gaagaggaca ctccaagccc cttggctcct gtttcccagc aaggatggcg cagcatccgg cttttcattt catccacttt ccgagacatg cacggggagc gggacctgct gctgaggtct gtgctgccag cactgcaggc ccgagcggcc cctcaccgta tcagccttca cggaatcgac ctccgctggg gcgtcactga ggaggagacc cgtaggaaca gacaactgga agtgtgcctt ggggaggtgg agaacgcaca gctgtttgtg gggattctgg gctcccgtta tggatacatt ccccccagct acaaccttcc tgaccatcca cacttccact gggcccagca gtacccttca gggcgctctg tgacagagat ggaggtgatg cagttcctga accggaacca acgtctgcag ccctctgccc aagctctcat ctacttccgg gattccagct tcctcagctc tgtgccagat gcctggaaat ctgactttgt ttctgagtct gaagaggccg catgtcggat ctcagaactg aagagctacc taagcagaca gaaagggata acctgccgca gatacccctg tgagtggggg ggtgtggcag ctggccggcc ctatgttggc gggctggagg agtttgggca gttggttctg caggatgtat ggaatatgat ccagaagctc tacctgcagc ctggggccct gctggagcag ccagtgtcca tcccagacga tgacttggtc caggccacct tccagcagct gcagaagcca ccgagtcctg cccggccacg ccttcttcag gacacagtgc aacagctgat gctgccccac ggaaggctga gcctggtgac ggggcagtca ggacagggca agacagcctt cctggcatct cttgtgtcag ccctgcaggc tcctgatggg gccaaggtgg caccattagt cttcttccac ttttctgggg ctcgtcctga ccagggtctt gccctcactc tgctcagacg cctctgtacc tatctgcgtg gccaactaaa agagccaggt gccctcccca gcacctaccg aagcctggtg tgggagctgc agcagaggct gctgcccaag tctgctgagt ccctgcatcc tggccagacc caggtcctga tcatcgatgg ggctgatagg ttagtggacc agaatgggca gctgatttca gactggatcc caaagaagct tccccggtgt gtacacctgg tgctgagtgt gtctagtgat gcaggcctag gggagaccct tgagcagagc cagggtgccc acgtgctggc cttggggcct ctggaggcct ctgctcgggc ccggctggtg agagaggagc tggccctgta cgggaagcgg ctggaggagt caccatttaa caaccagatg cgactgctgc tggtgaagcg ggaatcaggc cggccgctct acctgcgctt ggtcaccgat cacctgaggc tcttcacgct gtatgagcag gtgtctgaga gactccggac cctgcctgcc actgtccccc tgctgctgca gcacatcctg agcacactgg agaaggagca cgggcctgat gtccttcccc aggccttgac tgccctagaa gtcacacgga gtggtttgac tgtggaccag ctgcacggag tgctgagtgt gtggcggaca ctaccgaagg ggactaagag ctgggaagaa gcagtggctg ctggtaacag tggagacccc taccccatgg gcccgtttgc ctgcctcgtc cagagtctgc gcagtttgct aggggagggc cctctggagc gccctggtgc ccggctgtgc ctccctgatg ggcccctgag aacagcagct aaacgttgct atgggaagag gccagggcta gaggacacgg cacacatcct cattgcagct cagctctgga agacatgtga cgctgatgcc tcaggcacct tccgaagttg ccctcctgag gctctgggag acctgcctta ccacctgctc cagagcggga accgtggact tctttcgaag ttccttacca acctccatgt ggtggctgca cacttggaat tgggtctggt ctctcggctc ttggaggccc atgccctcta tgcttcttca gtccccaaag aggaacaaaa gctccccgag gctgacgttg cagtgtttcg caccttcctg aggcagcagg cttcaatcct cagccagtac ccccggctcc tgccccagca ggcagccaac cagcccctgg actcacctct ttgccaccaa gcctcgctgc tctcccggag atggcacctc caacacacac tacgatggct taataaaccc cggaccatga aaaatcagca aagctccagc ctgtctctgg cagtttcctc atcccctact gctgtggcct tctccaccaa tgggcaaaga gcagctgtgg gcactgccaa tgggacagtt tacctgttgg acctgagaac ttggcaggag gagaagtctg tggtgagtgg ctgtgatgga atctctgctt gtttgttcct ctccgatgat acactctttc ttactgcctt cgacgggctc ctggagctct gggacctgca gcatggttgt cgggtgctgc agactaaggc tcaccagtac caaatcactg gctgctgcct gagcccagac tgccggctgc tagccaccgt gtgcttggga ggatgcctaa agctgtggga cacagtccgt gggcagctgg ccttccagca cacctacccc aagtccctga actgtgttgc cttccaccca gaggggcagg taatagccac aggcagctgg gctggcagca tcagcttctt ccaggtggat gggctcaaag tcaccaagga cctgggggca cccggagcct ctatccgtac cttggccttc aatgtgcctg ggggggttgt ggctgtgggc cggctggaca gtatggtgga gctgtgggcc tggcgagaag gggcacggct ggctgccttc cctgcccacc atggctttgt tgctgctgcg cttttcctgc atgcgggttg ccagttactg acggctggag aggatggcaa ggttcaggtg tggtcagggt ctctgggtcg gccccgtggg cacctgggtt ccctttctct ctctcctgcc ctctctgtgg cactcagccc agatggtgat cgggtggctg ttggatatcg agcggatggc attaggatct acaaaatctc ttcaggttcc cagggggctc agggtcaggc actggatgtg gcagtgtccg ccctggcctg gctaagcccc aaggtattgg tgagtggtgc agaagatggg tccttgcagg gctgggcact caaggaatgc tcccttcagt ccctctggct cctgtccaga ttccagaagc ctgtgctagg actggccact tcccaggagc tcttggcttc tgcctcagag gatttcacag tgcagctgtg gccaaggcag ctgctgacgc ggccacacaa ggcagaagac tttccctgtg gcactgagct gcggggacat gagggccctg tgagctgctg tagtttcagc actgatggag gcagcctggc caccgggggc cgggatcgga gtctcctctg ctgggacgtg aggacaccca aaacccctgt tttgatccac tccttccctg cctgtcaccg tgactgggtc actggctgtg cctggaccaa agataaccta ctgatatcct gctccagtga tggctctgtg gggctctggg acccagagtc aggacagcgg cttggtcagt tcctgggtca tcagagtgct gtgagcgctg tggcagctgt ggaggagcac gtggtgtctg tgagccggga tgggaccttg aaagtgtggg accatcaagg cgtggagctg accagcatcc ctgctcactc aggacccatt agccactgtg cagctgccat ggagccccgt gcagctggac agcctgggtc agagcttctg gtggtaaccg tcgggctaga tggggccaca cggttatggc atccactctt ggtgtgccaa acccacaccc tcctgggaca cagcggccca gtccgtgctg ctgctgtttc agaaacctca ggcctcatgc tgaccgcctc tgaggatggt tctgtacggc tctggcaggt tcctaaggaa gcagatgaca catgtatacc aaggagttct gcagccgtca ctgctgtggc ttgggcacca gatggttcca tggcagtatc tggaaatcaa gctggggaac taatcttgtg gcaggaagct aaggctgtgg ccacagcaca ggctccaggc cacattggtg ctctgatctg gtcctcggca cacacctttt ttgtcctcag tgctgatgag aaaatcagcg agtggcaagt gaaactgcgg aagggttcgg cacccggaaa tttgagtctt cacctgaacc gaattctaca ggaggactta ggggtgctga caagtctgga ttgggctcct gatggtcact ttctcatctt ggccaaagca gatttgaagt tactttgcat gaagccaggg gatgctccat ctgaaatctg gagcagctat acagaaaatc ctatgatatt gtccacccac aaggagtatg gcatatttgt cctgcagccc aaggatcctg gagttctttc tttcttgagg caaaaggaat caggagagtt tgaagagagg ctgaactttg atataaactt agagaatcct agtaggaccc taatatcgat aactcaagcc aaacctgaat ctgagtcctc atttttgtgt gccagctctg atgggatcct atggaacctg gccaaatgca gcccagaagg agaatggacc acaggtaaca tgtggcagaa aaaagcaaac actccagaaa cccaaactcc agggacagac ccatctacct gcagggaatc tgatgccagc atggatagtg atgccagcat ggatagtgag ccaacaccac atctaaagac acggcagcgt agaaagattc actcgggctc tgtcacagcc ctccatgtgc tacctgagtt gctggtgaca gcttcgaagg acagagatgt taagctatgg gagagaccca gtatgcagct gctgggcctg ttccgatgcg aagggtcagt gagctgcctg gaaccttggc tgggcgctaa ctccaccctg cagcttgccg tgggagacgt gcagggcaat gtgtactttc tgaattggga atga SEQ ID NO: 27 Rat TEP1, Genbank #AAB51690 Met Glu Lys Leu Cys Gly Tyr Val Pro Val His Pro Asp Ile Leu Ser Leu Lys Asn Arg Cys Leu Thr Met Leu Ser Asp Ile Gln Pro Leu Glu Lys Ile His Gly Gln Arg Ser Val Asn Pro Asp Ile Leu Ser Leu Glu Asn Arg Cys Leu Thr Leu Leu Pro Asp Leu Gln Pro Met Glu Lys Ile His Gly Gln Arg Ser Val His Pro Asp Ile Leu Ser Ser Glu Asn Arg Cys Leu Thr Leu Leu Pro Asp Leu Gln Ser Leu Glu Lys Leu Cys Gly His Met Ser Ser His Pro Asp Val Leu Ser Leu Glu Asn Arg Cys Leu Ala Thr Leu Pro Thr Val Lys Arg Thr Val Ser Ser Gly Pro Leu Leu Gln Cys Leu His Arg Ser His Thr Ala Gln Ala Asp Leu Arg Asp Pro Asn Phe Arg Asn Cys Leu Phe Pro Glu Pro Pro Thr Ile Glu Ala Pro Cys Phe Leu Lys Glu Leu Asp Leu Pro Thr Gly Pro Arg Ala Leu Lys Ser Met Ser Ala Thr Ala Arg Val Gln Glu Val Ala Leu Gly Gln Arg Cys Val Ser Glu Gly Lys Glu Leu Gln Glu Glu Lys Glu Ser Ala Glu Val Pro Met Pro Leu Tyr Ser Leu Ser Leu Gly Gly Glu Glu Glu Glu Val Val Gly Ala Pro Val Leu Lys Leu Thr Ser Gly Asp Ser Asp Ser His Pro Glu Thr Thr Asp Gln Ile Leu Gln Glu Lys Lys Met Ala Leu Leu Thr Leu Leu Cys Ser Ala Met Ala Ser Ser Val Asn Val Lys Asp Ala Ser Asp Pro Thr Arg Ala Ser Ile His Glu Val Cys Ser Ala Leu Ala Pro Leu Glu Pro Glu Phe Ile Leu Lys Ala Ser Leu Tyr Ala Arg Gln Gln Leu Asn Leu Arg Asp Ile Ala Asn Ile Val Leu Ala Val Ala Ala Leu Leu Pro Ala Cys Arg Pro His Val Arg Arg Tyr Tyr Ser Ala Ile Val His Leu Pro Ser Asp Trp Ile Gln Val Ala Glu Phe Tyr Gln Ser Leu Ala Glu Gly Asp Glu Lys Lys Leu Val Pro Leu Pro Ala Cys Leu Arg Ala Ala Met Thr Asp Lys Phe Ala Gln Phe Asp Glu Tyr Gln Leu Ala Lys Tyr Asn Pro Arg Lys His Arg Ser Lys Thr Arg Ser Arg Gln Pro Pro Arg Pro Gln Arg Thr Lys Pro Pro Phe Ser Glu Ser Gly Lys Cys Phe Pro Lys Ser Val Trp Pro Leu Lys Asn Glu Gln Ile Ser Phe Glu Ala Ala Tyr Asn Ala Val Ser Glu Lys Lys Arg Leu Pro Arg Phe Thr Leu Lys Lys Leu Val Glu Gln Leu His Ile His Glu Pro Ala Gln His Val Gln Ala Leu Leu Gly Tyr Arg Tyr Pro Ser Thr Leu Glu Leu Phe Ser Arg Ser His Leu Pro Gly Pro Trp Asp Ser Ser Arg Ala Gly Gln Arg Met Lys Leu Gln Arg Pro Glu Thr Trp Glu Arg Glu Leu Ser Leu Arg Gly Asn Arg Ala Ser Val Trp Glu Glu Leu Ile Asp Asn Gly Lys Leu Pro Phe Met Ala Met Leu Arg Asn Leu Cys Asn Leu Leu Arg Thr Gly Ile Ser Ala His His His Glu Leu Val Leu Gln Arg Leu Gln His Glu Lys Ser Val Ile His Ser Arg Gln Phe Pro Phe Arg Phe Leu Asn Ala His Asp Ser Leu Asp Arg Leu Glu Ala Gln Leu Arg Ser Lys Ala Ser Pro Phe Pro Ser Asn Thr Thr Leu Met Lys Arg Ile Met Ile Arg Asn Ser Lys Lys Ile Lys Arg Pro Ala Asn Pro Arg Tyr Leu Cys Thr Leu Thr Gln Arg Gln Leu Arg Ala Ala Met Ala Ile Pro Val Met Tyr Glu His Leu Lys Arg Glu Lys Leu Arg Leu His Lys Ala Arg Gln Trp Thr Cys Asp Leu Glu Leu Leu Glu Arg Tyr Arg Gln Ala Leu Glu Thr Ala Val Asn Ile Ser Val Lys His Asn Leu Pro Pro Leu Pro Gly Arg Thr Leu Leu Val Tyr Leu Thr Asp Ala Asn Ala Asn Arg Leu Cys Pro Lys Ser His Leu Gln Gly Pro Pro Leu Asn Tyr Val Leu Leu Leu Ile Gly Met Met Met Ala Arg Ala Glu Gln Thr Thr Val Trp Leu Cys Gly Thr Gly Thr Val Lys Thr Pro Val Leu Thr Ala Asp Glu Gly Ile Leu Lys Thr Ala Ile Lys Leu Gln Ala Gln Val Gln Glu Leu Glu Glu Asn Asp Glu Trp Pro Leu Glu Thr Phe Glu Lys Tyr Leu Leu Ser Leu Ala Val Arg Arg Thr Pro Ile Asp Arg Val Ile Leu Phe Gly Gln Arg Met Asp Thr Glu Leu Leu Asn Val Ala Lys Gln Ile Ile Trp Gln His Val Asn Ser Lys Cys Leu Phe Val Ser Val Leu Leu Arg Lys Met Gln Tyr Met Ser Pro Asn Leu Asn Pro Asn Asp Val Thr Leu Ser Gly Cys Thr Asp Gly Ile Leu Lys Phe Ile Ala Glu His Gly Ala Ser Arg Leu Leu Glu His Val Gly Gln Leu Asp Lys Ile Phe Lys Ile Pro Pro Pro Pro Gly Lys Thr Lys Val Ser Pro Leu Arg Pro Leu Glu Glu Asn Asn Pro Gly Pro Phe Val Pro Ile Ser Gln His Gly Trp Arg Asn Ile Arg Leu Phe Ile Ser Ser Thr Phe Arg Asp Met His Gly Glu Arg Asp Leu Leu Met Arg Ser Val Leu Pro Ala Leu Gln Ala Arg Ala Phe Pro His Arg Ile Ser Leu His Ala Ile Asp Leu Arg Trp Gly Ile Thr Glu Glu Glu Thr Arg Arg Asn Arg Gln Leu Glu Val Cys Leu Gly Glu Val Glu Asn Ser Gln Leu Phe Val Gly Ile Leu Gly Ser Arg Tyr Gly Tyr Thr Pro Pro Ser Tyr Asp Leu Pro Asp His Pro His Phe His Trp Thr Gln Arg Tyr Pro Ser Gly Arg Ser Val Thr Glu Met Glu Val Met Gln Phe Leu Asn Arg Gly Gln Arg Ser Glu Pro Ser Asp Gln Ala Leu Ile Tyr Phe Arg Asp Pro Gly Phe Leu Ser Ser Val Pro Asp  Val Trp Lys Pro Asp Phe Ile Ser Glu Ser Glu Glu Ala Ala His  Arg Val Ser Glu Leu Lys Arg Phe Leu Gln Glu Gln Lys Glu Val  Thr Cys Arg Arg Tyr Ser Cys Glu Trp Gly Gly Val Ala Ala Gly  Arg Pro Tyr Thr Gly Gly Leu Glu Glu Phe Gly Gln Leu Val Leu  Gln Asp Val Trp Ser Val Ile Gln Lys Arg Tyr Leu Gln Pro Gly  Ala Gln Leu Glu Gln Pro Gly Ser Ile Ser Glu Glu Asp Leu Ile  Gln Ala Ser Phe Gln Gln Leu Lys Ser Pro Pro Ser Pro Ala Arg  Pro Arg Leu Leu Gln Asp Thr Val Gln Gln Leu Met Leu Pro His  Gly Arg Leu Ser Leu Val Ile Gly Gln Ala Gly Gln Gly Lys Thr  Ala Phe Leu Ala Ser Leu Val Ser Ala Leu Lys Val Pro Asp Gln  Pro Asn Val Ala Pro Phe Val Phe Phe His Phe Ser  His Val Val Ala Ala Tyr Leu Glu Val Gly Leu Val Pro Asp Leu  Leu Glu Ala Tyr Glu Leu Tyr Ala Ser Ser Lys Pro Glu Val Asn  Gln Lys Leu Pro Glu Ala Asp Val Ala Val Phe His Asn Phe Leu  Lys Gln Gln Ala Ser Leu Leu Thr Gln Tyr Pro Leu Leu Leu Leu  Gln Gln Ala Ala Ser Gln Pro Glu Glu Ser Pro Val Cys Cys Gln  Ala Pro Leu Leu Thr Gln Arg Trp His Asn Gln Cys Ile Leu Lys  Trp Ile Asn Lys Pro Gln Thr Leu Lys Gly Gln Gln Ser Leu Ser  Leu Pro Ile Ser Ser Ser Pro Thr Ala Val Ala Phe Ser Pro Asn  Gly Gln Arg Ala Ala Val Gly Thr Ala Gly Gly Thr Ile Tyr Leu  Leu Asn Leu Arg Thr Trp Gln Glu Glu Lys Ala Leu Val Ser Gly  Cys Asp Gly Ile Ser Ser Phe Ala Phe Leu Ser Asp Thr Ala Leu  Phe Leu Thr Thr Phe Asp Gly Leu Leu Glu Leu Trp Asp Leu Gln  His Gly Cys Trp Val Phe Gln Thr Lys Ala His Gln Tyr Gln Ile  Thr Gly Cys Cys Leu Ser Pro Asp Arg Arg Leu Leu Ala Thr Val  Cys Leu Gly Gly Tyr Val Lys Leu Trp Asp Thr Val Gln Gly Gln  Leu Ala Phe Gln Tyr Thr His Pro Lys Ser Leu Asn Cys Ile Thr  Phe His Pro Glu Gly Gln Val Val Ala Thr Gly Asn Trp Ser Gly  Ile Val Thr Phe Phe Gln Ala Asp Gly Leu Lys Val Thr Lys Glu  Leu Gly Gly Pro Gly Pro Ser Val Arg Thr Leu Ala Phe Ser Ala  Pro Gly Lys Val Val Ala Leu Gly Arg Ile Asp Gly Thr Val Glu  Leu Trp Ala Trp Gln Glu Gly Thr Arg Leu Ala Ala Phe Pro Ala  Gln Cys Gly Gly Val Ser Thr Val Leu Phe Leu His Ala Gly Gly  Arg Phe Leu Thr Ala Gly Glu Asp Gly Lys Ala Gln Leu Trp Ser  Gly Phe Leu Gly Arg Pro Arg Gly Cys Leu Gly Ser Leu Tyr Leu  Ser Pro Ala Leu Ser Val Ala Leu Asn Pro Asp Gly Asp Gln Val  Ala Val Gly Tyr Arg Gly Asp Gly Ile Lys Ile Tyr Arg Ile Ser  Ser Gly Pro Gln Glu Ala Gln Cys Gln Glu Leu Asn Val Ala Val  Ser Ala Leu Val Trp Leu Ser Pro Ser Val Leu Val Ser Gly Ala  Glu Asp Gly Ser Leu His Gly Trp Met Leu Arg Arg Asn Ser Leu  Gln Ser Leu Trp Leu Ser Ser Val Cys Gln Lys Pro Val Leu Gly  Leu Ala Ala Ser Gln Glu Phe Leu Ala Ser Ala Ser Glu Asp Phe  Thr Val Arg Leu Trp Pro Arg Gln Leu Leu Thr Gln Pro His Ala  Val Glu Glu Leu Pro Cys Ala Ala Glu Leu Arg Gly His Glu Gly  Pro Val Cys Cys Cys Ser Phe Ser Pro Asp Gly Arg Ile Leu Ala  Thr Ala  SEQ ID NO: 28 Rat TEP1 cDNA, Genbank #U89282 atggagaaac tctgtggtta tgtgcctgtc cacccagaca tcctctcctt gaagaatcgg tgcctgacca tgctctctga catccaaccc ctggagaaaa tacatggaca gagatctgtc aacccagaca tcctgtcctt ggagaaccgg tgcctgacct tgctccctga tctccagccc atggagaaaa tacatggaca gagatctgtc cacccagaca tcctctcctc agagaaccgg tgtctgacct tgctccctga cctccagtcc ctggagaagc tatgtggaca tatgtctagt cacccagacg tcctctcttt ggagaaccga tgtcttgcta ccctcccgac tgtaaagaga actgtttcga gtggcccctt gctccagtgt cttcacagat ctcatacggc acaagctgat ctgcgtgacc cgaactttcg caactgcctg ttccctgagc ctcctaccat agaggctcca tgtttcttga aggaactaga ccttccaact ggacccaggg ccctgaaatc catgtctgct acagctcgag ttcaggaagt agctttgggt cagcggtgcg tctcagaagg aaaggaattg caggaagaaa aagaaagcgc agaagtcccg atgcctttgt acagtctaag cttgggggga gaagaagaag aagtggtggg ggcaccggtc ctaaaactca catctggaga ctctgactct caccctgaaa ccactgacca gatcctgcag gagaagaaga tggctctctt gaccttgctg tgctcagcta tggcctcaag tgtgaatgtg aaagatgcct ccgatcctac ccgggcatct atccatgaag tctgcagtgc gctggccccc ttggaacctg agttcatcct taaggcatct ttgtatgcta ggcagcagct taacctccgg gacatagcca atatagtgtt ggccgtggct gccctcttgc cagcctgccg cccccatgta cgacggtatt actctgccat tgttcacctg ccttcagact ggatccaggt agccgagttc taccagagcc tggcagaagg ggatgagaag aagttggtgc ccctgcctgc ctgcctccgt gctgccatga ctgacaaatt tgcccagttt gatgagtacc agctagcgaa gtacaaccca cggaaacacc gatccaagac acgttcccgc cagccacccc gccctcaaag gacaaaacct ccattttcag agagtgggaa atgttttcca aagagcgttt ggccccttaa aaacgaacag atttcgttcg aagcagctta taatgcagtg tcagagaaga aaaggctacc aaggttcact ctgaagaagt tggtagagca actgcatatc catgagcctg cgcagcatgt ccaggccctg ctgggctaca ggtacccatc caccctagag ctcttttctc ggagtcatct ccctgggcca tgggactcta gcagggctgg gcaacggatg aagctccaaa ggccagagac ctgggagcgg gagctgagct tacgtggaaa cagagcttct gtgtgggagg aactcataga caatgggaaa ctccccttca tggccatgct ccggaacctg tgtaacctgc tgcggactgg gatcagtgcc caccaccatg aactcgttct ccagagactc cagcatgaga aatctgtgat tcacagtcgg cagtttccat tcagattcct taatgctcac gactctctcg atagactcga ggctcagctc agaagtaaag catcgccctt cccttccaat acaacattga tgaagcggat aatgattaga aactcaaaaa aaatcaagag acctgccaac ccgaggtacc tgtgcaccct gacgcagcgg cagcttcggg cggcaatggc tatcccggtg atgtatgagc atctcaagcg ggagaaactg aggctgcaca aggccagaca gtggacctgt gaccttgagt tgctggagcg gtatcgccag gccctggaaa cggccgtgaa catctctgta aagcacaacc tacccccgct gccaggccga accctcttgg tctatctcac agatgcaaat gccaacagac tttgtcccaa gagtcacttg caagggcctc ccctgaacta tgtgctgctg ttgatcggga tgatgatggc tcgggcggag cagacgacag tttggctgtg tgggacagga actgtgaaga caccagtact tacagccgac gaaggtatcc tgaagactgc catcaaactt caggctcaag tccaggagtt agaagaaaat gatgagtggc ccctggaaac ttttgagaag tacctgctat ctctggctgt gcgaaggacc cctattgaca gggtcatcct gttcggccaa aggatggata cggagctgct gaatgtagcc aaacagatta tctggcagca tgtgaattcc aagtgcctct tcgtcagtgt cctcctacgg aaaatgcagt acatgtcacc aaatttgaat cccaatgatg tgacgctctc gggctgcact gacgggatcc tgaagttcat tgcggagcat ggagcctctc gtcttctgga acatgtgggc caactagata agatattcaa gatccctcca cccccaggaa agacaaaggt ctcacctctc cggccgctgg aggagaacaa ccctggtccc ttcgttccta tttcccagca tggatggcgc aacatccggc ttttcatttc gtccactttc cgagacatgc atggggaacg agacttgctg atgcgatctg ttctgccagc gctgcaggcc cgagcgttcc cccaccgcat cagccttcac gccattgacc tgcgctgggg aatcacggag gaagagaccc gcaggaacag acaactggaa gtgtgccttg gggaggtgga gaactctcag ctgttcgtgg ggatcctggg ctcccgctat ggctatactc cccccagcta tgatctgcct gaccaccccc actttcactg gacccagcga tacccttcgg ggcgctctgt aacagagatg gaggtgatgc agttcctgaa ccgtggccaa cgctcggaac cctctgacca agctctcatc tacttccgag atcctggttt ccttagctct gtgccagatg tctggaaacc tgactttatt tccgagtcag aagaggctgc acatcgggtc tcagaactga agagattcct acaggaacag aaagaggtta cctgccgcag gtactcctgt gaatggggag gcgtagcagc cggccggccc tatactgggg gcctggagga gtttggacag ttggttctcc aagatgtgtg gagcgtgatc cagaagcgtt acctgcagcc tggggcccag ttggagcagc caggatccat ctcagaagag gatttgatcc aggccagctt tcagcagctg aagagcccac cgagtcccgc acggccacgc cttcttcagg ataccgtgca acagctgatg ctgccccacg ggaggctgag cctagtgatt gggcaggcag gacagggaaa gactgccttc ctggcatccc ttgtgtcggc cctgaaggtt cccgaccagc ccaatgtggc cccgttcgtt ttcttccact tttcagcagc ccgccctgac cagtgtcttg ctttcaacct cctcagacgc ctctgtaccc atctgcatca aaaactggga gagccgagcg ctctccccag cacttacaga ggcctggtgt gggaactgca gcagaagctg ctcctcaaat ctgcccagtg gctgcaacca ggccagactt tggtccttat tatcgacggg gcagataagt tggtggacca taatggacag ctgatttcag actggatccc caagtctctt ccgcggcgag tacacctggt gctgagtgtg tctagtgact caggcctggg agagaccctt cagcaaagtc agagtgctta tgtggtggcc ttggggtctt tggtcccgtc ttcaagggct cagcttgtga gagaagagct agcactgtat gggaaacggc tggaggagtc accttttaac aaccagatgc ggctgctgct ggcaaagcag gggtcaagcc tgccactgta cctgcacctc gtcactgact acctgaggct tttcacactg tacgaacagg tgtctgagag acttcgaacc ctgcccgcca ctctcccact gctgctgcag cacatcctga gcaccttgga gcaagagcat ggccataacg tccttcctca agctttgact gcccttgagg tcacgcacag tggtctgact gtggaccagc tgcatgcagt cctgagcacg tggttgactt tgcccaagga gactaagagc tgggaagagg cagtggctgc cagtcacagt ggaaacctct accccttggc tccatttgcc taccttgtcc agagtctacg cagtttacta ggcgagggcc ccgtggagcg ccctggcgcc cgtctctgcc tctctgatgg gcctctgagg acagcagtta aacgtcgcta tgggaaaagg ctggggctag agaagactgc gcatgtcctc attgcagctc acctctggaa gatgtgtgac cctgatgcct caggcacctt ccgaagttgc cctcccgagg ctctgaaaga tttaccttac cacctgctcc agagcgggaa ccatggtctc cttgcaaagt tccttaccaa cctccatgtg gtggctgcat atctggaagt gggtctagtc ccggacctct tggaggctta cgagctctat gcttcttcaa agcctgaagt gaaccagaag ctcccggagg cagatgttgc tgtattccac aacttcctga aacaacaggc ttcactcctt acccagtatc ctttgctcct gctccagcag gcagctagcc agcctgaaga gtcacctgtt tgctgccagg cccccctgct cacccagcgg tggcacaacc agtgcatact gaaatggatt aataaacccc agaccttgaa gggtcagcaa agcttgtctc tgccaatttc ctcatcccca actgctgtgg ccttctctcc taatgggcaa agagcagctg tggggactgc tggtgggaca atttacctgt tgaacttgag aacctggcag gaggagaagg ctctggtgag tggctgtgat gggatttcct ctttcgcgtt cctgtcagac actgctcttt tccttaccac cttcgatggg ctcctggagc tttgggacct gcaacatggt tgttgggtgt tccagaccaa ggcccaccag taccaaatca ctggctgctg cctgagccca gaccgccgcc tgctggccac cgtgtgtttg ggaggatacg taaagctgtg ggacacagtc cagggccagc tggctttcca gtacacccat cccaagtctc taaactgcat caccttccac ccagaggggc aggtggtagc cacaggcaac tggtctggca tcgtgacctt cttccaggca gatggactca aagtcaccaa ggaactaggg ggcccaggac cctctgttcg tacgctggca ttcagtgcac ccgggaaggt tgtggctcta ggccggatag atgggacagt ggagctgtgg gcctggcaag agggcacacg gctggcagcc ttccctgcac agtgtggcgg tgtctccacc gttcttttct tgcatgctgg aggccggttc ctgacggctg gggaagatgg caaggctcag ttatggtcag gatttcttgg ccggcccagg ggttgcctgg gctctcttta tctttctcct gcgctctctg tggctctcaa cccagacggt gaccaggtgg ctgttgggta ccgaggagat ggcattaaaa tctacagaat ttcttcaggt ccccaggagg ctcaatgcca agagctaaat gtggcggtgt ctgcactggt ctggctgagt cccagcgtct tggtgagtgg tgcagaagat ggctccctgc atggctggat gctcaggaga aactcccttc agtccctgtg gctgtcatcc gtgtgccaga agcctgtgct ggggctggct gcctcccagg agttcttggc ttctgcctca gaggacttca cggtgcgact gtggccaaga cagctgctga cacagccaca tgcagtagaa gagttgccct gtgcggctga actccgggga cacgaggggc cggtgtgctg ctgtagcttc agcccggatg gacgcatctt ggccacagcg ggcagggatc ggaatctcct ctgctgggac gtcaaggtag cccaagcccc tctcctgatt cacacgttct cgtcctgtca tcgagactgg atcactggct gtacgtggac caaagacaac atcctgatct cctgctctag tgatggctct gtgggactct ggaacccaga ggcaggacag caacttggcc agttcccagg tcaccagagt gccgtgagcg ctgtggttgc tgtggaggaa cacattgtat ctgtgagtcg ggatgggacc ttgaaagtgt gggaccgtca gggtgtggag ctgaccagca tccctgccca ttccggaccc attagccagt gtgcggctgc tctggaaccc cgtccagctg gacagcctgg atcagagctt atggtggtga ctgttggact ggatggggcc acaaagctgt ggcatcccct gttggtgtgc caaatacata ccctgcaggg acacagtggt ccagtcacag ctgctgctgc ttcagaggcc tcaggcctcc tgctgacctc agacaatagc tctgtacgac tctggcagat ccctaaggaa gcagatgata cctgcaaacc taggagttct gcggtcatca ccgctgtggc gtgggcacca gatggttctc tggtggtgtc tggaaatgaa gctggggaac taacgctgtg gcagaaagcg caggctgtgg ctacggcacg ggctccaggc cgcgtcagtg acctgatctg gtgctccgca aatgcattct ttgttctcag tgctaatgaa aatgtcagtg agtggcaagt ggaactgagg aaaggttcaa catgcaccaa tttcagactt tatctgaaga gagttctgca ggaggacttg ggagtcttga caggtatggc cctggcgcct gacggccagt ctctcatttt gatgaaagag gatgtagaat tgctacagat gaagcccggg tctactccat cttcgatctg caggaggtat gcagtgcatt cttctatact gtgcaccagc aaagactatg gcctgtttta cctgcagcag ggaaactctg gatctctttc tatcttggag caggaggagt cagggaagtt tgaaaagacc ctggacttca atctgaactt aaataatcct aatgggtccc cagtatcaat cactcaggct gaacctgagt ctgggtcctc gcttttgtgt gctacctctg atgggatgct gtggaactta tctgagtgta ccccagaagg agagtgggtc gtagataaca tctggcagaa aaaatcaaga aaccctaaaa gtcgaactcc ggggacagat tcgtccccag gcttattctg catggatagc tgggtagaac ccacacattt aaaggcacgg cagtgtaaaa agattcactt gggctctgtc acggccctcc atgtgctgcc cggattgctg gtgactgctt cagaggacag agatgttaag ctgtgggaga gacccagtat gcagctgctc ggcttgttcc gatgtgaagg gccggtgagc tgtctggaac cttggatgga gcccagctct cccctgcagc ttgctgtggg agatgcacaa ggaaacttgt attttctatc ttgggaatga SEQ ID NO: 29 Human vRNA, Genbank #AF045143 ggcuggcuuu agcucagcgg uuacuucgac aguucuuuaa uugaaacaag caaccugucu ggguuguucg agacccgcgg gcgcucucca guccuuuu SEQ ID NO: 30 Human vRNA, Genbank #AF045144 ggcuggcuuu agcucagcgg uuacuucgag uacauuguaa ccaccucucu gggugguucg agacccgcgg gugcuuucca gcucuuuu SEQ ID NO: 31 Human vRNA, Genbank #AF045145 ggcuggcuuu agcucagcgg uuacuucgcg ugucaucaaa ccaccucucu ggguuguucg agacccgcgg gcgcucucca gcccucuu SEQ ID NO: 32 Rat vRNA, Genbank #Z1171 ggccagcuuu agcucagcgg uuacuucgac gugcuccagu uugagcaggc uauguaacgu ggucgguucg agcaacacaa ccagccgcuu gccuaucugg ugagugguug guucgagacc cgcgggcgcu cucuggcccu uuu Human IL-2 cDNA Sequence, Genbank  SEQ ID NO: 33 #BC070338.1, coding sequence: 48-509   1 atcactctct ttaatcacta ctcacagtaa cctcaactcc tgccacaatg tacaggatgc  61 aactcctgtc ttgcattgca ctaagtcttg cacttgtcac aaacagtgca cctacttcaa 121 gttctacaaa gaaaacacag ctacaactgg agcatttact gctggattta cagatgattt 181 tgaatggaat taataattac aagaatccca aactcaccag gatgctcaca tttaagtttt 241 acatgcccaa gaaggccaca gaactgaaac atcttcagtg tctagaagaa gaactcaaac 301 ctctggagga agtgctaaat ttagctcaaa gcaaaaactt tcacttaaga cccagggact 361 taatcagcaa tatcaacgta atagttctgg aactaaaggg atctgaaaca acattcatgt 421 gtgaatatgc tgatgagaca gcaaccattg tagaatttct gaacagatgg attacctttt 481 gtcaaagcat catctcaaca ctgacttgat aattaagtgc ttcccactta aaacgtatca 541 ggccttctat ttatttaaat atttaaattt tatatttatt gttgaatgta tggtttgcta 601 cctattgtaa ctattattct taatcttaaa actataaata tggatctttt atgattcttt 661 ttgtaagccc taggggctct aaaatggttt cacttattta tcccaaaata tttattatta 721 tgttgaatgt taaatatagt atctatgtag attggttagt aaaactattt aataaatttg 781 ataaatataa aaaaaaaaaa aaaaaaaaaa aaaa SEQ ID NO: 34 Human IL-2 Protein sequence, Genbank #AAH70338.1 MYRMQLLSCIALSLALVTNSAPTSSSTKKTQLQLEHLLLDLQMILNGINNYKNPKLTRMLTFKFYMPKKA TELKHLQCLEEELKPLEEVLNLAQSKNFHLRPRDLISNINVIVLELKGSETTFMCEYADETATIVEFLNR WITFCQSIISTLT Human IL-7 cDNA sequence, Genbank #J04156.1; coding SEQ ID NO: 35 sequence: 385-918    1 gaattcctct ggtcctcatc caggtgcgcg ggaagcaggt gcccaggaga gaggggataa   61  tgaagattcc atgctgatga tcccaaagat tgaacctgca gaccaagcgc aaagtagaaa  121 ctgaaagtac actgctggcg gatcctacgg aagttatgga aaaggcaaag cgcagagcca  181 cgccgtagtg tgtgccgccc cccttgggat ggatgaaact gcagtcgcgg cgtgggtaag  241 aggaaccagc tgcagagatc accctgccca acacagactc ggcaactccg cggaagacca  301 gggtcctggg agtgactatg ggcggtgaga gcttgctcct gctccagttg cggtcatcat  361 gactacgccc gcctcccgca gaccatgttc catgtttctt ttaggtatat ctttggactt  421 cctcccctga tccttgttct gttgccagta gcatcatctg attgtgatat tgaaggtaaa  481 gatggcaaac aatatgagag tgttctaatg gtcagcatcg atcaattatt ggacagcatg  541 aaagaaattg gtagcaattg cctgaataat gaatttaact tttttaaaag acatatctgt  601 gatgctaata aggaaggtat gtttttattc cgtgctgctc gcaagttgag gcaatttctt  661 aaaatgaata gcactggtga ttttgatctc cacttattaa aagtttcaga aggcacaaca  721 atactgttga actgcactgg ccaggttaaa ggaagaaaac cagctgccct gggtgaagcc  781 caaccaacaa agagtttgga agaaaataaa tctttaaagg aacagaaaaa actgaatgac  841 ttgtgtttcc taaagagact attacaagag ataaaaactt gttggaataa aattttgatg  901 ggcactaaag aacactgaaa aatatggagt ggcaatatag aaacacgaac tttagctgca  961 tcctccaaga atctatctgc ttatgcagtt tttcagagtg gaatgcttcc tagaagttac 1021 tgaatgcacc atggtcaaaa cggattaggg catttgagaa atgcatattg tattactaga 1081 agatgaatac aaacaatgga aactgaatgc tccagtcaac aaactatttc ttatatatgt 1141 gaacatttat caatcagtat aattctgtac tgatttttgt aagacaatcc atgtaaggta 1201 tcagttgcaa taatacttct caaacctgtt taaatatttc aagacattaa atctatgaag 1261 tatataatgg tttcaaagat tcaaaattga cattgcttta ctgtcaaaat aattttatgg 1321 ctcactatga atctattata ctgtattaag agtgaaaatt gtcttcttct gtgctggaga 1381 tgttttagag ttaacaatga tatatggata atgccggtga gaataagaga gtcataaacc 1441 ttaagtaagc aacagcataa caaggtccaa gatacctaaa agagatttca agagatttaa 1501 ttaatcatga atgtgtaaca cagtgccttc aataaatggt atagcaaatg ttttgacatg 1561 aaaaaaggac aatttcaaaa aaataaaat SEQ ID NO: 36 Human IL-7 Protein sequence, Genbank #AAA59156.1 MFHVSFRYIFGLPPLILVLLPVASSDCDIEGKDGKQYESVLMVSIDQLLDSMKEIGSNCLNNEFNFFKRH ICDANKEGMFLFRAARKLRQFLKMNSTGDFDLHLLKVSEGTTILLNCTGQVKGRKPAALGEAQPTKSLEE NKSLKEQKKLNDLCFLKRLLQEIKTCWNKILMGTKEH Human IL-15 cDNA sequence, Genbank #BC018149.2; SEQ ID NO: 37 coding sequence: 845-1333    1 actccgggtg gcaggcgccc gggggaatcc cagctgactc gctcactgcc ttcgaagtcc   61 ggcgcccccc gggagggaac tgggtggccg caccctcccg gctgcggtgg ctgtcgcccc  121 ccaccctgca gccaggactc gatggaggta cagagctcgg cttctttgcc ttgggagggg  181 agtggtggtg gttgaaaggg cgatggaatt ttccccgaaa gcctacgccc agggcccctc  241 ccagctccag cgttaccctc cggtctatcc tactggccga gctgccccgc cttctcatgg  301 ggaaaactta gccgcaactt caatttttgg tttttccttt aatgacactt ctgaggctct  361 cctagccatc ctcccgcttc cggaggagcg cagatcgcag gtccctttgc ccctggcgtg  421 cgactcccta ctgcgctgcg ctcttacggc gttccaggct gctggctagc gcaaggcggg  481 ccgggcaccc cgcgctccgc tgggagggtg agggacgcgc gtctggcggc cccagccaag  541 ctgcgggttt ctgagaagac gctgtcccgc agccctgagg gctgagttct gcacccagtc  601 aagctcagga aggccaagaa aagaatccat tccaatatat ggccatgtgg ctctttggag  661 caatgttcca tcatgttcca tgctgctgac gtcacatgga gcacagaaat caatgttagc  721 agatagccag cccatacaag atcgtattgt attgtaggag gcatcgtgga tggatggctg  781 ctggaaaccc cttgccatag ccagctcttc ttcaatactt aaggatttac cgtggctttg  841 agtaatgaga atttcgaaac cacatttgag aagtatttcc atccagtgct acttgtgttt  901 acttctaaac agtcattttc taactgaagc tggcattcat gtcttcattt tgggctgttt  961 cagtgcaggg cttcctaaaa cagaagccaa ctgggtgaat gtaataagtg atttgaaaaa 1021 aattgaagat cttattcaat ctatgcatat tgatgctact ttatatacgg aaagtgatgt 1081 tcaccccagt tgcaaagtaa cagcaatgaa gtgctttctc ttggagttac aagttatttc 1141 acttgagtcc ggagatgcaa gtattcatga tacagtagaa aatctgatca tcctagcaaa 1201 caacagtttg tcttctaatg ggaatgtaac agaatctgga tgcaaagaat gtgaggaact 1261 ggaggaaaaa aatattaaag aatttttgca gagttttgta catattgtcc aaatgttcat 1321 caacacttct tgattgcaat tgattctttt taaagtgttt ctgttattaa caaacatcac 1381 tctgctgctt agacataaca aaacactcgg catttcaaat gtgctgtcaa aacaagtttt 1441 tctgtcaaga agatgatcag accttggatc agatgaactc ttagaaatga aggcagaaaa 1501 atgtcattga gtaatatagt gactatgaac ttctctcaga cttactttac tcattttttt 1561 aatttattat tgaaattgta catatttgtg gaataatgta aaatgttgaa taaaaatatg 1621 tacaagtgtt gttttttaag ttgcactgat attttacctc ttattgcaaa atagcatttg 1681 tttaagggtg atagtcaaat tatgtattgg tggggctggg taccaatgct gcaggtcaac 1741 agctatgctg gtaggctcct gcctgtgtgg aaccactgac tactggctct cattgacttc 1801 cttactaagc atagcaaaca gaggaagaat ttgttatcag taagaaaaag aagaactata 1861 tgtgaatcct cttctttaca ctgtaattta gttattgatg tataaagcaa ctgttatgaa 1921 ataaagaaat tgcaataact ggcaaaaaaa aaaaaaaaaa aaaaaaaa SEQ ID NO: 38 Human IL-15 protein sequence, Genbank #AAH18149.1 MRISKPHLRSISIQCYLCLLLNSHFLTEAGIHVFILGCFSAGLPKTEANWVNVISDLKKIEDLIQSMHIDATLYTESDVHPSC KVTAMKCFLLELQVISLESGDASIHDTVENLIILANNSLSSNGNVTESGCKECEELEEKNIKEFLQSFVHIVQMFIN Human IL-12B cDNA Sequence, Genbank #NM_002187.2; SEQ ID NO: 39 coding sequence: 43-1029    1 ctgtttcagg gccattggac tctccgtcct gcccagagca agatgtgtca ccagcagttg   61 gtcatctctt ggttttccct ggtttttctg gcatctcccc tcgtggccat atgggaactg  121 aagaaagatg tttatgtcgt agaattggat tggtatccgg atgcccctgg agaaatggtg  181 gtcctcacct gtgacacccc tgaagaagat ggtatcacct ggaccttgga ccagagcagt  241 gaggtcttag gctctggcaa aaccctgacc atccaagtca aagagtttgg agatgctggc  301 cagtacacct gtcacaaagg aggcgaggtt ctaagccatt cgctcctgct gcttcacaaa  361 aaggaagatg gaatttggtc cactgatatt ttaaaggacc agaaagaacc caaaaataag  421 acctttctaa gatgcgaggc caagaattat tctggacgtt tcacctgctg gtggctgacg  481 acaatcagta ctgatttgac attcagtgtc aaaagcagca gaggctcttc tgacccccaa  541 ggggtgacgt gcggagctgc tacactctct gcagagagag tcagagggga caacaaggag  601 tatgagtact cagtggagtg ccaggaggac agtgcctgcc cagctgctga ggagagtctg  661 cccattgagg tcatggtgga tgccgttcac aagctcaagt atgaaaacta caccagcagc  721 ttcttcatca gggacatcat caaacctgac ccacccaaga acttgcagct gaagccatta  781 aagaattctc ggcaggtgga ggtcagctgg gagtaccctg acacctggag tactccacat  841 tcctacttct ccctgacatt ctgcgttcag gtccagggca agagcaagag agaaaagaaa  901 gatagagtct tcacggacaa gacctcagcc acggtcatct gccgcaaaaa tgccagcatt  961 agcgtgcggg cccaggaccg ctactatagc tcatcttgga gcgaatgggc atctgtgccc 1021 tgcagttagg ttctgatcca ggatgaaaat ttggaggaaa agtggaagat attaagcaaa 1081 atgtttaaag acacaacgga atagacccaa aaagataatt tctatctgat ttgctttaaa 1141 acgttttttt aggatcacaa tgatatcttt gctgtatttg tatagttaga tgctaaatgc 1201 tcattgaaac aatcagctaa tttatgtata gattttccag ctctcaagtt gccatgggcc 1261 ttcatgctat ttaaatattt aagtaattta tgtatttatt agtatattac tgttatttaa 1321 cgtttgtctg ccaggatgta tggaatgttt catactctta tgacctgatc catcaggatc 1381 agtccctatt atgcaaaatg tgaatttaat tttatttgta ctgacaactt ttcaagcaag 1441 gctgcaagta catcagtttt atgacaatca ggaagaatgc agtgttctga taccagtgcc 1501 atcatacact tgtgatggat gggaacgcaa gagatactta catggaaacc tgacaatgca 1561 aacctgttga gaagatccag gagaacaaga tgctagttcc catgtctgtg aagacttcct 1621 ggagatggtg ttgataaagc aatttagggc cacttacact tctaagcaag tttaatcttt 1681 ggatgcctga attttaaaag ggctagaaaa aaatgattga ccagcctggg aaacataaca 1741 agaccccgtc tctacaaaaa aaatttaaaa ttagccaggc gtggtggctc atgcttgtgg 1801 tcccagctgt tcaggaggat gaggcaggag gatctcttga gcccaggagg tcaaggctat 1861 ggtgagccgt gattgtgcca ctgcatacca gcctaggtga cagaatgaga ccctgtctca 1921 aaaaaaaaaa tgattgaaat taaaattcag ctttagcttc catggcagtc ctcaccccca 1981 cctctctaaa agacacagga ggatgacaca gaaacaccgt aagtgtctgg aaggcaaaaa 2041 gatcttaaga ttcaagagag aggacaagta gttatggcta aggacatgaa attgtcagaa 2101 tggcaggtgg cttcttaaca gccctgtgag aagcagacag atgcaaagaa aatctggaat 2161 ccctttctca ttagcatgaa tgaacctgat acacaattat gaccagaaaa tatggctcca 2221 tgaaggtgct acttttaagt aatgtatgtg cgctctgtaa agtgattaca tttgtttcct 2281 gtttgtttat ttatttattt atttttgcat tctgaggctg aactaataaa aactcttctt 2341 tgtaatc SEQ ID NO: 40 Human IL-12B Protein Sequence, Genbank #NP_002178.2 MCHQQLVISWFSLVFLASPLVAIWELKKDVYVVELDWYPDAPGEMVVLTCDTPEEDGITWTLDQSSEVLGSGKT LTIQVKEFGDAGQYTCHKGGEVLSHSLLLLHKKEDGIWSTDILKDQKEPKNKTFLRCEAKNYSGRFTCWWLTTI STDLTFSVKSSRGSSDPQGVTCGAATLSAERVRGDNKEYEYSVECQEDSACPAAEESLPIEVMVDAVHKLKYEN YTSSFFIRDIIKPDPPKNLQLKPLKNSRQVEVSWEYPDTWSTPHSYFSLTFCVQVQGKSKREKKDRVFTDKTSA TVICRKNASISVRAQDRYYSSSWSEWASVPCS Human IL-12A cDNA sequence, Genbank SEQ ID NO: 41 #NM_000882.2; coding sequence: 216-977    1 tttcattttg ggccgagctg gaggcggcgg ggccgtcccg gaacggctgc ggccgggcac   61 cccgggagtt aatccgaaag cgccgcaagc cccgcgggcc ggccgcaccg cacgtgtcac  121 cgagaagctg atgtagagag agacacagaa ggagacagaa agcaagagac cagagtcccg  181 ggaaagtcct gccgcgcctc gggacaatta taaaaatgtg gccccctggg tcagcctccc  241 agccaccgcc ctcacctgcc gcggccacag gtctgcatcc agcggctcgc cctgtgtccc  301 tgcagtgccg gctcagcatg tgtccagcgc gcagcctcct ccttgtggct accctggtcc  361 tcctggacca cctcagtttg gccagaaacc tccccgtggc cactccagac ccaggaatgt  421 tcccatgcct tcaccactcc caaaacctgc tgagggccgt cagcaacatg ctccagaagg  481 ccagacaaac tctagaattt tacccttgca cttctgaaga gattgatcat gaagatatca  541 caaaagataa aaccagcaca gtggaggcct gtttaccatt ggaattaacc aagaatgaga  601 gttgcctaaa ttccagagag acctctttca taactaatgg gagttgcctg gcctccagaa  661 agacctcttt tatgatggcc ctgtgcctta gtagtattta tgaagacttg aagatgtacc  721 aggtggagtt caagaccatg aatgcaaagc ttctgatgga tcctaagagg cagatctttc  781 tagatcaaaa catgctggca gttattgatg agctgatgca ggccctgaat ttcaacagtg  841 agactgtgcc acaaaaatcc tcccttgaag aaccggattt ttataaaact aaaatcaagc  901 tctgcatact tcttcatgct ttcagaattc gggcagtgac tattgataga gtgatgagct  961 atctgaatgc ttcctaaaaa gcgaggtccc tccaaaccgt tgtcattttt ataaaacttt 1021 gaaatgagga aactttgata ggatgtggat taagaactag ggagggggaa agaaggatgg 1081 gactattaca tccacatgat acctctgatc aagtattttt gacatttact gtggataaat 1141 tgtttttaag ttttcatgaa tgaattgcta agaagggaaa atatccatcc tgaaggtgtt 1201 tttcattcac tttaatagaa gggcaaatat ttataagcta tttctgtacc aaagtgtttg 1261 tggaaacaaa catgtaagca taacttattt taaaatattt atttatataa cttggtaatc 1321 atgaaagcat ctgagctaac ttatatttat ttatgttata tttattaaat tatttatcaa 1381 gtgtatttga aaaatatttt taagtgttct aaaaataaaa gtattgaatt aaagtgaaaa 1441 aaaa SEQ ID NO: 42 Human IL-12A Protein sequence, Genbank #NP_000873.2 MWPPGSASQPPPSPAAATGLHPAARPVSLQCRLSMCPARSLLLVATLVLLDHLSLARNLPVATPDPGMFPCLHH SQNLLRAVSNMLQKARQTLEFYPCTSEEIDHEDITKDKTSTVEACLPLELTKNESCLNSRETSFITNGSCLASR KTSFMMALCLSSIYEDLKMYQVEFKTMNAKLLMDPKRQIFLDQNMLAVIDELMQALNFNSETVPQKSSLEEPDF YKTKIKLCILLHAFRIRAVTIDRVMSYLNAS Human CSF2 cDNA Sequence, Genbank #BC108724.1; SEQ ID NO: 43 coding sequence: 20-454   1 ggctaaagtt ctctggagga tgtggctgca gagcctgctg ctcttgggca ctgtggcctg  61 cagcatctct gcacccgccc gctcgcccag ccccagcacg cagccctggg agcatgtgaa 121 tgccatccag gaggcccggc gtctcctgaa cctgagtaga gacactgctg ctgagatgaa 181 tgaaacagta gaagtcatct cagaaatgtt tgacctccag gagccgacct gcctacagac 241 ccgcctggag ctgtacaagc agggcctgcg gggcagcctc accaagctca agggcccctt 301 gaccatgatg gccagccact acaagcagca ctgccctcca accccggaaa cttcctgtgc 361 aacccagatt atcacctttg aaagtttcaa agagaacctg aaggactttc tgcttgtcat 421 cccctttgac tgctgggagc cagtccagga gtgagaccgg ccagatgagg ctggccaagc 481 cggggagctg ctctctcatg aaacaagagc tagaaactca ggatggtcat cttggaggga 541 ccaaggggtg ggccacagcc atggtgggag tggcctggac ctgccctggg ccacactgac 601 cctgatacag gcatggcaga agaatgggaa tattttatac tgacagaaat cagtaatatt 661 tatatattta tatttttaaa atatttattt atttatttat ttaagttcat attccatatt 721 tattcaagat gttttaccgt aataattatt attaaaaata tgcttctact tgaaaaaaaa 781 aaaaaaa SEQ ID NO: 44 Human CSF2 Protein Sequence, Genbank #AAI08725.1 MWLQSLLLLGTVACSISAPARSPSPSTQPWEHVNAIQEARRLLNLSRDTAAEMNETVEVIEMFDLQEPTCLQT RLELYKQGLRGSLTKLKGPLTMMASHYKQHCPPTPETSCATQIITFESFKENLKDFLLVIPFDCWEPVQE Human CXCL9 cDNA Sequence, Genbank SEQ ID NO: 45 #NP_002416.1; coding sequence: 40-417    1 atccaataca ggagtgactt ggaactccat tctatcacta tgaagaaaag tggtgttctt   61 ttcctcttgg gcatcatctt gctggttctg attggagtgc aaggaacccc agtagtgaga  121 aagggtcgct gttcctgcat cagcaccaac caagggacta tccacctaca atccttgaaa  181 gaccttaaac aatttgcccc aagcccttcc tgcgagaaaa ttgaaatcat tgctacactg  241 aagaatggag ttcaaacatg tctaaaccca gattcagcag atgtgaagga actgattaaa  301 aagtgggaga aacaggtcag ccaaaagaaa aagcaaaaga atgggaaaaa acatcaaaaa  361 aagaaagttc tgaaagttcg aaaatctcaa cgttctcgtc aaaagaagac tacataagag  421 accacttcac caataagtat tctgtgttaa aaatgttcta ttttaattat accgctatca  481 ttccaaagga ggatggcata taatacaaag gcttattaat ttgactagaa aatttaaaac  541 attactctga aattgtaact aaagttagaa agttgatttt aagaatccaa acgttaagaa  601 ttgttaaagg ctatgattgt ctttgttctt ctaccaccca ccagttgaat ttcatcatgc  661 ttaaggccat gattttagca atacccatgt ctacacagat gttcacccaa ccacatccca  721 ctcacaacag ctgcctggaa gagcagccct aggcttccac gtactgcagc ctccagagag  781 tatctgaggc acatgtcagc aagtcctaag cctgttagca tgctggtgag ccaagcagtt  841 tgaaattgag ctggacctca ccaagctgct gtggccatca acctctgtat ttgaatcagc  901 ctacaggcct cacacacaat gtgtctgaga gattcatgct gattgttatt gggtatcacc  961 actggagatc accagtgtgt ggctttcaga gcctcctttc tggctttgga agccatgtga 1021 ttccatcttg cccgctcagg ctgaccactt tatttctttt tgttcccctt tgcttcattc 1081 aagtcagctc ttctccatcc taccacaatg cagtgccttt cttctctcca gtgcacctgt 1141 catatgctct gatttatctg agtcaactcc tttctcatct tgtccccaac accccacaga 1201 agtgctttct tctcccaatt catcctcact cagtccagct tagttcaagt cctgcctctt 1261 aaataaacct ttttggacac acaaattatc ttaaaactcc tgtttcactt ggttcagtac 1321 cacatgggtg aacactcaat ggttaactaa ttcttgggtg tttatcctat ctctccaacc 1381 agattgtcag ctccttgagg gcaagagcca cagtatattt ccctgtttct tccacagtgc 1441 ctaataatac tgtggaacta ggttttaata attttttaat tgatgttgtt atgggcagga 1501 tggcaaccag accattgtct cagagcaggt gctggctctt tcctggctac tccatgttgg 1561 ctagcctctg gtaacctctt acttattatc ttcaggacac tcactacagg gaccagggat 1621 gatgcaacat ccttgtcttt ttatgacagg atgtttgctc agcttctcca acaataagaa 1681 gcacgtggta aaacacttgc ggatattctg gactgttttt aaaaaatata cagtttaccg 1741 aaaatcatat aatcttacaa tgaaaaggac tttatagatc agccagtgac caaccttttc 1801 ccaaccatac aaaaattcct tttcccgaag gaaaagggct ttctcaataa gcctcagctt 1861 tctaagatct aacaagatag ccaccgagat ccttatcgaa actcatttta ggcaaatatg 1921 agttttattg tccgtttact tgtttcagag tttgtattgt gattatcaat taccacacca 1981 tctcccatga agaaagggaa cggtgaagta ctaagcgcta gaggaagcag ccaagtcggt 2041 tagtggaagc atgattggtg cccagttagc ctctgcagga tgtggaaacc tccttccagg 2101 ggaggttcag tgaattgtgt aggagaggtt gtctgtggcc agaatttaaa cctatactca 2161 ctttcccaaa ttgaatcact gctcacactg ctgatgattt agagtgctgt ccggtggaga 2221 tcccacccga acgtcttatc taatcatgaa actccctagt tccttcatgt aacttccctg 2281 aaaaatctaa gtgtttcata aatttgagag tctgtgaccc acttaccttg catctcacag 2341 gtagacagta tataactaac aaccaaagac tacatattgt cactgacaca cacgttataa 2401 tcatttatca tatatataca tacatgcata cactctcaaa gcaaataatt tttcacttca 2461 aaacagtatt gacttgtata ccttgtaatt tgaaatattt tctttgttaa aatagaatgg 2521 tatcaataaa tagaccatta atcag SEQ ID NO: 46 Human CXCL9 Protein Sequence, Genbank #NP_002407.1 MKKSGVLFLLGIILLVLIGVQGTPVVRKGRCSCISTNQGTIHLQSLKDLKQFAPSPSCEKIEIIATLKNGVQTCLNPDSADVK ELIKKWEKQVSQKKKQKNGKKHQKKKVLKVRKSQRSRQKKTT Human CXCL10 cDNA Sequence, Genbank SEQ ID NO: 47 #NM_001565.2; coding sequence: 71-367    1 gggggagaca ttcctcaatt gcttagacat attctgagcc tacagcagag gaacctccag   61 tctcagcacc atgaatcaaa ctgccattct gatttgctgc cttatctttc tgactctaag  121 tggcattcaa ggagtacctc tctctagaac tgtacgctgt acctgcatca gcattagtaa  181 tcaacctgtt aatccaaggt ctttagaaaa acttgaaatt attcctgcaa gccaattttg  241 tccacgtgtt gagatcattg ctacaatgaa aaagaagggt gagaagagat gtctgaatcc  301 agaatcgaag gccatcaaga atttactgaa agcagttagc aaggaaaggt ctaaaagatc  361 tccttaaaac cagaggggag caaaatcgat gcagtgcttc caaggatgga ccacacagag  421 gctgcctctc ccatcacttc cctacatgga gtatatgtca agccataatt gttcttagtt  481 tgcagttaca ctaaaaggtg accaatgatg gtcaccaaat cagctgctac tactcctgta  541 ggaaggttaa tgttcatcat cctaagctat tcagtaataa ctctaccctg gcactataat  601 gtaagctcta ctgaggtgct atgttcttag tggatgttct gaccctgctt caaatatttc  661 cctcaccttt cccatcttcc aagggtacta aggaatcttt ctgctttggg gtttatcaga  721 attctcagaa tctcaaataa ctaaaaggta tgcaatcaaa tctgcttttt aaagaatgct  781 ctttacttca tggacttcca ctgccatcct cccaaggggc ccaaattctt tcagtggcta  841 cctacataca attccaaaca catacaggaa ggtagaaata tctgaaaatg tatgtgtaag  901 tattcttatt taatgaaaga ctgtacaaag tagaagtctt agatgtatat atttcctata  961 ttgttttcag tgtacatgga ataacatgta attaagtact atgtatcaat gagtaacagg 1021 aaaattttaa aaatacagat agatatatgc tctgcatgtt acataagata aatgtgctga 1081 atggttttca aaataaaaat gaggtactct cctggaaata ttaagaaaga ctatctaaat 1141 gttgaaagat caaaaggtta ataaagtaat tataactaaa aaaa Human CXCL10 Protein Sequence, Genbank SEQ ID NO: 48 #NP_001556.2 MNQTAILICCLIFLTLSGIQGVPLSRTVRCTCISISNQPVNPRSLEKLEIIPASQFCPRVEIIATMKKKGEKRCLNPESKAIK NLLKAVSKERSKRSP Human IFN-alpha cDNA Sequence, Genbank #J00210.1; SEQ ID NO: 49 coding sequence:  221-790    1 aaaacaaaac atttgagaaa cacggctcta aactcatgta aagagtgcat gaaggaaagc   61 aaaaacagaa atggaaagtg gcccagaagc attaagaaag tggaaatcag tatgttccct  121 atttaaggca tttgcaggaa gcaaggcctt cagagaacct agagcccaag gttcagagtc  181 acccatctca gcaagcccag aagtatctgc aatatctacg atggcctcgc cctttgcttt  241 actgatggtc ctggtggtgc tcagctgcaa gtcaagctgc tctctgggct gtgatctccc  301 tgagacccac agcctggata acaggaggac cttgatgctc ctggcacaaa tgagcagaat  361 ctctccttcc tcctgtctga tggacagaca tgactttgga tttccccagg aggagtttga  421 tggcaaccag ttccagaagg ctccagccat ctctgtcctc catgagctga tccagcagat  481 cttcaacctc tttaccacaa aagattcatc tgctgcttgg gatgaggacc tcctagacaa  541 attctgcacc gaactctacc agcagctgaa tgacttggaa gcctgtgtga tgcaggagga  601 gagggtggga gaaactcccc tgatgaatgc ggactccatc ttggctgtga agaaatactt  661 ccgaagaatc actctctatc tgacagagaa gaaatacagc ccttgtgcct gggaggttgt  721 cagagcagaa atcatgagat ccctctcttt atcaacaaac ttgcaagaaa gattaaggag  781 gaaggaataa catctggtcc aacatgaaaa caattcttat tgactcatac accaggtcac  841 gctttcatga attctgtcat ttcaaagact ctcacccctg ctataactat gaccatgctg  901 ataaactgat ttatctattt aaatatttat ttaactattc ataagattta aattattttt  961 gttcatataa cgtcatgtgc acctttacac tgtggttagt gtaataaaac atgttcctta 1021 tatttactca atccattatt ttgtgttgtt cattaaactt ttactatagg aacttcctgt 1081 atgtgttcat tctttaatat gaaattccta gcctgactgt gcaacctgat tagagaataa 1141 agggtatatt ttatttgctt atcattatta tatgtaaga Human IFN-alpha Protein Sequence, Genbank SEQ ID NO: 50 #AAB59403.1 MASPFALLMVLVVLSCKSSCSLGCDLPETHSLDNRRTLMLLAQMSRISPSSCLMDRHDFGFPQEEFDGNQFQKAPAISVLHEL IQQIFNLFTTKDSSAAWDEDLLDKFCTELYQQLNDLEACVMQEERVGETPLMNADSILAVKKYFRRITLYLTEKKYSPCAWEV VRAEIMRSLSLSTNLQERLRRKE Human IFN-gamma IEF SSP 5111 cDNA Sequence, SEQ ID NO: 51 Genbank #L07633.1; coding sequence: 93-842   1 gcggagctgg gtgcgagcgc cctaccgctt tcgctttccc ttcgcggtgc ccactccact  61 ccttgtgcgg cgctaggccc cccgtcccgg tcatggccat gctcagggtc cagcccgagg 121 cccaagccaa ggtggatgtg tttcgtgaag acctctgtac caagacagag aacctgctcg 181 ggagctattt ccccaagaag atttctgagc tggatgcatt tttaaaggag ccagctctca 241 atgaagccaa cttgagcaat ctgaaggccc cattggacat cccagtgcct gatccagtca 301 aggagaaaga gaaagaggag cggaagaaac agcaggagaa ggaagacaag gatgaaaaga 361 agaaggggga ggatgaagac aaaggtcctc cctgtggccc agtgaactgc aatgaaaaga 421 tcgtggtcct tctgcagcgc ttgaagcctg agatcaagga tgtcattgag cagctcaacc 481 tggtcaccac ctggttgcag ctgcagatac ctcggattga ggatggtaac aattttggag 541 tggctgtcca ggagaaggtg tttgagctga tgaccagcct ccacaccaag ctagaaggct 601 tccacactca aatctctaag tatttctctg agcgtggtga tgcagtgact aaagcagcca 661 agcagcccca tgtgggtgat tatcggcagc tggtgcacga gctggatgag gcagagtacc 721 gggacatccg gctgatggtc atggagatcc gcaatgctta tgctgtgtta tatgacatca 781 tcctgaagaa cttcgagaag ctcaagaagc ccaggggaga aacaaaggga atgatctatt 841 gagagccctc tctcccattc tgtgatgagt acagcagaga ccttcctgct ttttactggg 901 gactccagat tttccccaaa cttgcttctg ttgagatttt tccctcacct tgcctctcag 961 gcacaataaa tatagttata ccact Human IFN-gamma IEF SSP 5111 Protein Sequence, SEQ ID NO: 52 Genbank #AAA16521.1 MAMLRVQPEAQAKVDVFREDLCTKTENLLGSYFPKKISELDAFLKEPALNEANLSNLKAPLDIPVPDPVKEKEK EERKKQQEKEDKDEKKKGEDEDKGPPCGPVNCNEKIVVLLQRLKPEIKDVIEQLNLVTTWLQLQIPRIEDGNNF GVAVQEKVFELMTSLHTKLEGFHTQISKYFSERGDAVTKAAKQPHVGDYRQLVHELDEAEYRDIRLMVMEIRNA YAVLYDIILKNFEKLKKPRGETKGMIY Human CCL-19 cDNA Sequence, Genbank #BC027968.1; SEQ ID NO: 53 coding sequence: 125-421   1 catcactcac accttgcatt tcacccctgc atcccagtcg ccctgcagcc tcacacagat  61 cctgcacaca cccagacagc tggcgctcac acattcaccg ttggcctgcc tctgttcacc 121 ctccatggcc ctgctactgg ccctcagcct gctggttctc tggacttccc cagccccaac 181 tctgagtggc accaatgatg ctgaagactg ctgcctgtct gtgacccaga aacccatccc 241 tgggtacatc gtgaggaact tccactacct tctcatcaag gatggctgca gggtgcctgc 301 tgtagtgttc accacactga ggggccgcca gctctgtgca cccccagacc agccctgggt 361 agaacgcatc atccagagac tgcagaggac ctcagccaag atgaagcgcc gcagcagtta 421 acctatgacc gtgcagaggg agcccggagt ccgagtcaag cattgtgaat tattacctaa 481 cctggggaac cgaggaccag aaggaaggac caggcttcca gctcctctgc accagacctg 541 accagccagg acagggcctg gggtgtgtgt gagtgtgagt gtgagcgaga gggtgagtgt 601 ggtcagagta aagctgctcc acccccagat tgcaatgcta ccaataaagc cgcctggtgt 661 ttacaactaa aaaaaaaaaa aaaaaaaaaa aaaa SEQ ID NO: 54 Human CCL-19 Protein Sequence, Genbank #AAH27968.1 ALLLALSLLVLWTSPAPTLSGTNDAEDCCLSVTQKPIPGYIVRNFHYLLIKDGCRVPAVVFTTLRGRQLCAPPDQPWVERIIQ RLQRTSAKMKRRSS Human CCL-21 cDNA Sequence, Genbank #BC027918.1; SEQ ID NO: 55 coding sequence:  8-412   1 cacagacatg gctcagtcac tggctctgag cctccttatc ctggttctgg cctttggcat  61 ccccaggacc caaggcagtg atggaggggc tcaggactgt tgcctcaagt acagccaaag 121 gaagattccc gccaaggttg tccgcagcta ccggaagcag gaaccaagct taggctgctc 181 catcccagct atcctgttct tgccccgcaa gcgctctcag gcagagctat gtgcagaccc 241 aaaggagctc tgggtgcagc agctgatgca gcatctggac aagacaccat ccccacagaa 301 accagcccag ggctgcagga aggacagggg ggcctccaag actggcaaga aaggaaaggg 361 ctccaaaggc tgcaagagga ctgagcggtc acagacccct aaagggccat agcccagtga 421 gcagcctgga gccctggaga ccccaccagc ctcaccagcg cttgaagcct gaacccaaga 481 tgcaagaagg aggctatgct caggggccct ggagcagcca ccccatgctg gccttgccac 541 actctttctc ctgctttaac caccccatct gcattcccag ctctaccctg catggctgag 601 ctgcccacag caggccaggt ccagagagac cgaggaggga gagtctccca gggagcatga 661 gaggaggcag caggactgtc cccttgaagg agaatcatca ggaccctgga cctgatacgg 721 ctccccagta caccccacct cttccttgta aatatgattt atacctaact gaataaaaag 781 ctgttctgtc ttcccaccca aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 841 aaaaaaaaaa aaaaaa SEQ ID NO: 56 Human CCL-21 Protein Sequence, Genbank #AAH27918.1 MAQSLALSLLILVLAFG1PRTQGSDGGAQDCCLKYSQRKIPAKVVRSYRKQEPSLGCSIPAILFLPRKRSQAELCADP KELWVQQLMQHLDKTPSPQKPAQGCRKDRGASKTGKKGKGSKGCKRTERSQTPKGP Human TNF DNA Sequence, Genbank #NM_000594.2; SEQ ID NO: 57 coding sequence: 170-871    1 ctccctcagc aaggacagca gaggaccagc taagagggag agaagcaact acagaccccc   61 cctgaaaaca accctcagac gccacatccc ctgacaagct gccaggcagg ttctcttcct  121 ctcacatact gacccacggc tccaccctct ctcccctgga aaggacacca tgagcactga  181 aagcatgatc cgggacgtgg agctggccga ggaggcgctc cccaagaaga caggggggcc  241 ccagggctcc aggcggtgct tgttcctcag cctcttctcc ttcctgatcg tggcaggcgc  301 caccacgctc ttctgcctgc tgcactttgg agtgatcggc ccccagaggg aagagttccc  361 cagggacctc tctctaatca gccctctggc ccaggcagtc agatcatctt ctcgaacccc  421 gagtgacaag cctgtagccc atgttgtagc aaaccctcaa gctgaggggc agctccagtg  481 gctgaaccgc cgggccaatg ccctcctggc caatggcgtg gagctgagag ataaccagct  541 ggtggtgcca tcagagggcc tgtacctcat ctactcccag gtcctcttca agggccaagg  601 ctgcccctcc acccatgtgc tcctcaccca caccatcagc cgcatcgccg tctcctacca  661 gaccaaggtc aacctcctct ctgccatcaa gagcccctgc cagagggaga ccccagaggg  721 ggctgaggcc aagccctggt atgagcccat ctatctggga ggggtcttcc agctggagaa  781 gggtgaccga ctcagcgctg agatcaatcg gcccgactat ctcgactttg ccgagtctgg  841 gcaggtctac tttgggatca ttgccctgtg aggaggacga acatccaacc ttcccaaacg  901 cctcccctgc cccaatccct ttattacccc ctccttcaga caccctcaac ctcttctggc  961 tcaaaaagag aattgggggc ttagggtcgg aacccaagct tagaacttta agcaacaaga 1021 ccaccacttc gaaacctggg attcaggaat gtgtggcctg cacagtgaag tgctggcaac 1081 cactaagaat tcaaactggg gcctccagaa ctcactgggg cctacagctt tgatccctga 1141 catctggaat ctggagacca gggagccttt ggttctggcc agaatgctgc aggacttgag 1201 aagacctcac ctagaaattg acacaagtgg accttaggcc ttcctctctc cagatgtttc 1261 cagacttcct tgagacacgg agcccagccc tccccatgga gccagctccc tctatttatg 1321 tttgcacttg tgattattta ttatttattt attatttatt tatttacaga tgaatgtatt 1381 tatttgggag accggggtat cctgggggac ccaatgtagg agctgccttg gctcagacat 1441 gttttccgtg aaaacggagc tgaacaatag gctgttccca tgtagccccc tggcctctgt 1501 gccttctttt gattatgttt tttaaaatat ttatctgatt aagttgtcta aacaatgctg 1561 atttggtgac caactgtcac tcattgctga gcctctgctc cccaggggag ttgtgtctgt 1621 aatcgcccta ctattcagtg gcgagaaata aagtttgctt agaaaagaa SEQ ID NO: 58 Human TNF Protein Sequence, Genbank #NP_000585.2 MSTESMIRDVELAEEALPKKTGGPQGSRRCLFLSLFSFLIVAGATTLFCLLHFGVIGPQREEFPRDLSLISPLAQAVRSSSRT PSDKPVAHVVANPQAEGQLQWLNRRANALLANGVELRDNQLVVPSEGLYLIYSQVLFKGQGCPSTHVLLTHTISRIAVSYQTK VNLLSAIKSPCQRETPEGAEAKPWYEPIYLGGVFQLEKGDRLSAEINRPDYLDFAESGQVYFGIIAL Human IL-27 cDNA Sequence, Genbank #BC062422.1; SEQ ID NO: 59 coding sequence: 27-758   1 ggggaccaaa gaggctgggc cccgccatgg gccagacggc aggcgacctt ggctggcggc  61 tcagcctgtt gctgcttccc ttgctcctgg ttcaagctgg tgtctgggga ttcccaaggc 121 ccccagggag gccccagctg agcctgcagg agctgcggag ggagttcaca gtcagcctgc 181 atctcgccag gaagctgctc gccgaggttc ggggccaggc ccaccgcttt gcggaatctc 241 acctgccagg agtgaacctg tacctcctgc ccctgggaga gcagctccct gatgtttccc 301 tgaccttcca ggcctggcgc cgcctctctg acccggagcg tctctgcttc atctccacca 361 cgcttcagcc cttccatgcc ctgctgggag ggctggggac ccagggccgc tggaccaaca 421 tggagaggat gcagctgtgg gccatgaggc tggacctccg cgatctgcag cggcacctcc 481 gcttccaggt gctggctgca ggattcaacc tcccggagga ggaggaggag gaagaggagg 541 aggaggagga ggagaggaag gggctgctcc caggggcact gggcagcgcc ttacagggcc 601 cggcccaggt gtcctggccc cagctcctct ccacctaccg cctgctgcac tccttggagc 661 tcgtcttatc tcgggccgtg cgggagttgc tgctgctgtc caaggctggg cactcagtct 721 ggcccttggg gttcccaaca ttgagccccc agccctgatc ggtggcttct tagccccctg 781 ccccccaccc tttagaactt taggactgga gtcttggcat cagggcagcc ttcgcatcat 841 cagccttgga caagggaggg ctcttccagc cccctgcccc aggccctacc cagtaactga 901 aagcccctct ggtcctcgcc agctatttat ttcttggata tttatttatt gtttagggag 961 atgatggttt atttattgtc ttggggcccg atggtcctcc tcgggccaag cccccatgct 1021 gggtgcccaa taaagcactc tcatccataa aaaaaaaaaa aaaaaaaaaa aaaaaaa SEQ ID NO: 60 Human IL-27 Protein Sequence, Genbank #AAH62422.1 MGQTAGDLGWRLSLLLLPLLLVQAGVWGFPRPPGRPQLSLQELRREFTVSLHLARKLLAEVRGQAHRFAESHLPGVNLYLLPL GEQLPDVSLTFQAWRRLSDPERLCFISTTLQPFHALLGGLGTQGRWTNMERMQLWAMRLDLRDLQRHLRFQVLAAGFNLPEEE EEEEEEEEEERKGLLPGALGSALQGPAQVSWPQLLSTYRLLHSLELVLSRAVRELLLLSKAGHSVWPLGFPTLSPQP SEQ ID NO: 61 mCherry sequence ATGGTGAGCA AGGGCGAGGA GGATAACATG GCCATCATCA AGGAGTTCAT GCGCTTCAAG GTGCACATGG AGGGCTCCGT GAACGGCCAC GAGTTCGAGA TCGAGGGCGA GGGCGAGGGC CGCCCCTACG AGGGCACCCA GACCGCCAAG CTGAAGGTGA CCAAGGGTGG CCCCCTGCCC TTCGCCTGGG ACATCCTGTC CCCTCAGTTC ATGTACGGCT CCAAGGCCTA CGTGAAGCAC CCCGCCGACA TCCCCGACTA CTTGAAGCTG TCCTTCCCCG AGGGCTTCAA GTGGGAGCGC GTGATGAACT TCGAGGACGG CGGCGTGGTG ACCGTGACCC AGGACTCCTC CCTGCAGGAC GGCGAGTTCA TCTACAAGGT GAAGCTGCGC GGCACCAACT TCCCCTCCGA CGGCCCCGTA ATGCAGAAGA AGACCATGGG CTGGGAGGCC TCCTCCGAGC GGATGTACCC CGAGGACGGC GCCCTGAAGG GCGAGATCAA GCAGAGGCTG AAGCTGAAGG ACGGCGGCCA CTACGACGCT GAGGTCAAGA CCACCTACAA GGCCAAGAAG CCCGTGCAGC TGCCCGGCGC CTACAACGTC AACATCAAGT TGGACATCAC CTCCCACAAC GAGGACTACA CCATCGTGGA ACAGTACGAA CGCGCCGAGG GCCGCCACTC CACCGGCGGC ATGGACGAGC TGTACAAGTA A SEQ ID NO: 62 Mouse CCL-21-mCherry-mINT fusion DNA sequence ATGGCTCAGATGATGACTCTGAGCCTCCTTAGCCTGGTCCTGGCTCTCTGCATCCCCTGGACCCAAGGCAGTGATGGAGGGGG TCAGGACTGCTGCCTTAAGTACAGCCAGAAGAAAATTCCCTACAGTATTGTCCGAGGCTATAGGAAGCAAGAACCAAGTTTAG GCTGTCCCATCCCGGCAATCCTGTTCTCACCCCGGAAGCACTCTAAGCCTGAGCTATGTGCAAACCCTGAGGAAGGCTGGGTG CAGAACCTGATGCGCCGCCTGGACCAGCCTCCAGCCCCAGGGAAACAAAGCCCCGGCTGCAGGAAGAACCGGGGAACCTCTAA GTCTGGAAAGAAAGGAAAGGGCTCCAAGGGCTGCAAGAGAACTGAACAGACACAGCCCTCAAGAGGAAGATCC ATGGTGAGCA AGGGCGAGGA GGATAACATG GCCATCATCA AGGAGTTCAT GCGCTTCAAG GTGCACATGG AGGGCTCCGT GAACGGCCAC GAGTTCGAGA TCGAGGGCGA GGGCGAGGGC CGCCCCTACG AGGGCACCCA GACCGCCAAG CTGAAGGTGA CCAAGGGTGG CCCCCTGCCC TTCGCCTGGG ACATCCTGTC CCCTCAGTTC ATGTACGGCT CCAAGGCCTA CGTGAAGCAC CCCGCCGACA TCCCCGACTA CTTGAAGCTG TCCTTCCCCG AGGGCTTCAA GTGGGAGCGC GTGATGAACT TCGAGGACGG CGGCGTGGTG ACCGTGACCC AGGACTCCTC CCTGCAGGAC GGCGAGTTCA TCTACAAGGT GAAGCTGCGC GGCACCAACT TCCCCTCCGA CGGCCCCGTA ATGCAGAAGA AGACCATGGG CTGGGAGGCC TCCTCCGAGC GGATGTACCC CGAGGACGGC GCCCTGAAGG GCGAGATCAA GCAGAGGCTG AAGCTGAAGG ACGGCGGCCA CTACGACGCT GAGGTCAAGA CCACCTACAA GGCCAAGAAG CCCGTGCAGC TGCCCGGCGC CTACAACGTC AACATCAAGT TGGACATCAC CTCCCACAAC GAGGACTACA CCATCGTGGA ACAGTACGAA CGCGCCGAGG GCCGCCACTC CACCGGCGGC ATGGACGAGC TGTACAAGTA Atgcacacaacactg gcaggatgct gtgccttgga cagaactcct cagtctacag acagaggatg gcttctggaa acttacacca gaactgggac ttatattaaa tcttaataca aatggtttgc acagctttct taaacaaaaa ggcattcaat ctctaggtgt aaaaggaaga gaatgtctcc tggacctaat tgccacaatg ctggtactac agtttattcg caccaggttg gaaaaagagg gaatagtgtt caaatcactg atgaaaatgg atgacccttc tatttccagg aatattccct gggcttttga ggcaataaag caagcaagtg aatgggtaag aagaactgaaggacagtacc catctatctg cccacggctt gaactgggga acgactggga ctctgccacc aagcagttgc tgggactcca gcccataagc actgtgtccc ctcttcatag agtcctccat tacagtcaag gctaa SEQ ID NO: 63 Mouse CCL21-forward primer GCGCGGATCCCCATGGCTCAGATGATG SEQ ID NO: 64 Mouse CCL-21-reverse primer GCGCAGATCTTCCTCTTGAGGGCTGTGTCTG SEQ ID NO: 65 Human CCL21 primer CCCCACTAGTCCAGTTCTCAGTCACTGGCTCTG SEQ ID NO: 66 Human CCL21 primer CCCCGCTAGCTGGCCCTTTAGGGGTCTGTG SEQ ID NO: 67 Human CCL21 primer CCCCGCTAGCTGCACACAACACTGGCAGGA SEQ ID NO: 68 Human CCL21 primer GGGGCTCGAGTTAGCCTTGACTGTAATGGA Human mINT protein sequence (residues 1473-1724 of SEQ ID NO: 69 human VPARP protein sequence) Ala Asn Leu Arg Leu Pro Met Ala Ser Ala Leu Pro Glu Ala Leu Cys Ser Gln Ser Arg Thr Thr Pro Val Asp Leu Cys Leu Leu Glu Glu Ser Val Gly Ser Leu Glu Gly Ser Arg Cys Pro Val Phe Ala Phe Gln Ser Ser Asp Thr Glu Ser Asp Glu Leu Ser Glu Val Leu Gln Asp Ser Cys Phe Leu Gln Ile Lys Cys Asp Thr Lys Asp Asp Ser Ile Pro Cys Phe Leu Glu Leu Lys Glu Glu Asp Glu Ile Val Cys Thr Gln His Trp Gln Asp Ala Val Pro Trp Thr Glu Leu Leu Ser Leu Gln Thr Glu Asp Gly Phe Trp Lys Leu Thr Pro Glu Leu Gly Leu Ile Leu Asn Leu Asn Thr Asn Gly Leu His Ser Phe Leu Lys Gln Lys Gly Ile Gln Ser Leu Gly Val Lys Gly Arg Glu Cys Leu Leu Asp Leu Ile Ala Thr Met Leu Val Leu Gln Phe Ile Arg Thr Arg Leu Glu Lys Glu Gly Ile Val Phe Lys Ser Leu Met Lys Met Asp Asp Pro Ser Ile Ser Arg Asn Ile Pro Trp Ala Phe Glu Ala Ile Lys Gln Ala Ser Glu Trp Val Arg Arg Thr Glu Gly Gln Tyr Pro Ser Ile Cys Pro Arg Leu Glu Leu Gly Asn Asp Trp Asp Ser Ala Thr Lys Gln Leu Leu Gly Leu Gln Pro Ile Ser Thr Val Ser Pro Leu His Arg Val Leu His Tyr Ser Gln Gly

REFERENCES CITED

-   1. Kedersha N L, Rome L H: Isolation and characterization of a novel     ribonucleoprotein particle: large structures contain a single     species of small RNA. J Cell Biol 1986, 103(3): 699-709. -   2. Kong L B, Siva A C, Rome L H, Stewart P L: Structure of the     vault, a ubiquitous cellular component. Structure 1999, 7(4):     371-379. -   3. Kedersha N L, Heuser J E, Chugani D C, Rome L H: Vaults. III.     Vault ribonucleoprotein particles open into flower-like structures     with octagonal symmetry. J Cell Biol 1991, 112(2): 225-235. -   4. Suprenant K A: Vault ribonucleoprotein particles: sarcophagi,     gondolas, or safety deposit boxes? Biochemistry 2002,     41(49):14447-14454. -   5. Berger W, Steiner E, Grusch M, Elbling L, Micksche M: Vaults and     the major vault protein: novel roles in signal pathway regulation     and immunity. Cell Mol Life Sci 2009, 66(1): 43-61. -   6. Champion C I, Kickhoefer V A, Liu G, Moniz R J, Freed A S,     Bergmann L L, Vaccari D, Raval-Fernandes S, Chan A M, Rome L H et     al: A vault nanoparticle vaccine induces protective mucosal     immunity. PLoS One 2009, 4(4): e5409. Epub 29 April 5430. -   7. Stephen A G, Raval-Fernandes S, Huynh T, Torres M, Kickhoefer V     A, Rome L H: Assembly of vault-like particles in insect cells     expressing only the major vault protein. J Biol Chem 2001, 276(26):     23217-23220. Epub 22001 May 23210. -   8. Kickhoefer V A, Garcia Y, Mikyas Y, Johansson E, Zhou J C,     Raval-Fernandes S, Minoofar P, Zink J I, Dunn B, Stewart P L et al:     Engineering of vault nanocapsules with enzymatic and fluorescent     properties. Proc Natl Acad Sci USA 2005, 102(12): 4348-4352. Epub 25     March 4347. -   9. Gunn M, Tangemann K, Tam C, Cyster J, Rosen S, Williams L: A     chemokine expressed in lymphoid high endothelial venules promotes     the adhesion and chemotaxis of naive T lymphocytes. Proceedings of     the National Academy of Sciences of the United States of America     1998, 695(1): 259-263. -   10. Warnock R A, Campbell J J, Dorf M E, Matsuzawa A, McEvoy L M,     Butcher E C: The role of chemokines in the microenvironmental     control of T versus B cell arrest in Peyer's patch high endothelial     venules. J Exp Med 2000, 191(1): 77-88. -   11. Willimann K, Legler D F, Loetscher M, Roos R S, Delgado M B,     Clark-Lewis I, Baggiolini M, Moser B: The chemokine SLC is expressed     in T cell areas of lymph nodes and mucosal lymphoid tissues and     attracts activated T cells via CCR7. Eur J Immunol 1998, 28(6):     2025-2034. -   12. Sharma S, Stolina M, Luo J, Strieter R M, Burdick M, Zhu L X,     Batra R K, Dubinett S M: Secondary lymphoid tissue chemokine     mediates T cell-dependent antitumor responses in vivo. J Immunol     2000, 164(9): 4558-4563. -   13. Yang S C, Hillinger S, Riedl K, Zhang L, Zhu L, Huang M,     Atianzar K, Kuo B Y, Gardner B, Batra R K et al: Intratumoral     administration of dendritic cells overexpressing CCL21 generates     systemic antitumor responses and confers tumor immunity. Clin Cancer     Res 2004, 10(8): 2891-2901. -   14. Yang S C, Batra R K, Hillinger S, Reckamp K L, Strieter R M,     Dubinett S M, Sharma S: Intrapulmonary administration of CCL21     gene-modified dendritic cells reduces tumor burden in spontaneous     murine bronchoalveolar cell carcinoma. Cancer Res 2006, 66(6):     3205-3213. -   15. Kirk C J, Hartigan-O'Connor D, Mule J J: The dynamics of the     T-cell antitumor response: chemokine-secreting dendritic cells can     prime tumor-reactive T cells extranodally. Cancer Res 2001, 61(24):     8794-8802. -   16. Novak L, Igoucheva O, Cho S, Alexeev V: Characterization of the     CCL21-mediated melanoma-specific immune responses and in situ     melanoma eradication. Mol Cancer Ther 2007, 6(6): 1755-1764. -   17. Liang C M, Zhong C P, Sun R X, Liu B B, Huang C, Qin J, Zhou S,     Shan J, Liu Y K, Ye S L: Local expression of secondary lymphoid     tissue chemokine delivered by adeno-associated virus within the     tumor bed stimulates strong anti-liver tumor immunity. J Virol 2007,     81(17): 9502-9511. Epub 27 June 9513. -   18. Wu S, Xing W, Peng J, Yuan X, Zhao X, Lei P, Li W, Wang M, Zhu     H, Huang B et al: Tumor transfected with CCL21 enhanced reactivity     and apoptosis resistance of human monocyte-derived dendritic cells.     Immunobiology 2008, 213(5): 417-426. Epub 27 Nov. 2028. -   19. Yousefieh N, Hahto S M, Stephens A L, Ciavarra R P: Regulated     Expression of CCL21 in the Prostate Tumor Microenvironment Inhibits     Tumor Growth and Metastasis in an Orthotopic Model of Prostate     Cancer. Cancer Microenviron 2009, 6: 6. -   20. Baratelli F, Takedatsu H, Hazra S, Peebles K, Luo J, Kurimoto P     S, Zeng G, Batra R K, Sharma S, Dubinett S M et al: Pre-clinical     characterization of GMP grade CCL21-gene modified dendritic cells     for application in a phase I trial in Non-Small Cell Lung Cancer. J     Transl Med 2008, 6(1): 38. -   21. Lai C Y, Wiethoff C M, Kickhoefer V A, Rome L H, Nemerow G R:     Vault nanoparticles containing an adenovirus-derived membrane lytic     protein facilitate toxin and gene transfer. ACS Nano 2009, 3(3):     691-699. -   22. Siva A C, Raval-Fernandes S, Stephen A G, LaFemina M J, Scheper     R J, Kickhoefer V A, Rome L H: Up-regulation of vaults may be     necessary but not sufficient for multidrug resistance. Int J Cancer     2001, 92(2): 195-202. -   23. Kickhoefer V A, Siva A C, Kedersha N L, Inman E M, Ruland C,     Streuli M, Rome L H: The 193-kD vault protein, VPARP, is a novel     poly(ADP-ribose) polymerase. J Cell Biol 1999, 146(5): 917-928. -   24. Andersson A, Yang S C, Huang M, Zhu L, Kar U K, Batra R K,     Elashoff D, Strieter R M, Dubinett S M, Sharma S: IL-7 promotes     CXCR3 ligand-dependent T cell antitumor reactivity in lung cancer. J     Immunol 2009, 182(11): 6951-6958. -   25. Chen H, Liakou C I, Kamat A, Pettaway C, Ward J F, Tang D N, Sun     J, Jungbluth A A, Troncoso P, Logothetis C et al: Anti-CTLA-4     therapy results in higher CD4+ICOShi T cell frequency and IFN-gamma     levels in both nonmalignant and malignant prostate tissues. Proc     Natl Acad Sci USA 2009, 106(8): 2729-2734. Epub 29 Feb. 2726. -   26. Mikyas Y, Makabi M, Raval-Fernandes S, Harrington L, Kickhoefer     V A, Rome L H, Stewart P L: Cryoelectron microscopy imaging of     recombinant and tissue derived vaults: localization of the MVP N     termini and VPARP. J Mol Biol 2004, 344(1): 91-105. -   27. Sharma S, Stolina M, Zhu L, Lin Y, Batra R, Huang M, Strieter R,     Dubinett S M: Secondary lymphoid organ chemokine reduces pulmonary     tumor burden in spontaneous murine bronchoalveolar cell carcinoma.     Cancer research 2001, 61(17): 6406-6412. -   28. Sharma S, Yang S C, Hillinger S, Zhu L X, Huang M, Batra R K,     Lin J F, Burdick M D, Strieter R M, Dubinett S M: SLC/CCL21-mediated     anti-tumor responses require IFNgamma, MIG/CXCL9 and IP-10/CXCL10.     Molecular cancer 2003, 2(1): 22. -   29. Kickhoefer V A, Han M, Raval-Fernandes S, Poderycki M J, Moniz R     J, Vaccari D, Silvestry M, Stewart P L, Kelly K A, Rome L H:     Targeting vault nanoparticles to specific cell surface receptors.     ACS Nano 2009, 3(1): 27-36. -   30. Johnson S K, Kerr K M, Chapman A D, Kennedy M M, King G,     Cockburn J S, Jeffrey R R: Immune cell infiltrates and prognosis in     primary carcinoma of the lung. Lung Cancer 2000, 27(1): 27-35. -   31. Hiraoka K, Miyamoto M, Cho Y, Suzuoki M, Oshikiri T, Nakakubo Y,     Itoh T, Ohbuchi T, Kondo S, Katoh H: Concurrent infiltration by CD8+     T cells and CD4+ T cells is a favourable prognostic factor in     non-small-cell lung carcinoma. Br J Cancer 2006, 94(2): 275-280. -   32. Dieu-Nosjean M C, Antoine M, Danel C, Heudes D, Wislez M, Poulot     V, Rabbe N, Laurans L, Tartour E, de Chaisemartin L et al: Long-term     survival for patients with non-small-cell lung cancer with     intratumoral lymphoid structures. J Clin Oncol 2008, 26(27):     4410-4417. -   33. Woo E Y, Yeh H, Chu C S, Schlienger K, Carroll R G, Riley J L,     Kaiser L R, June C H: Cutting edge: Regulatory T cells from lung     cancer patients directly inhibit autologous T cell proliferation. J     Immunol 2002, 168(9): 4272-4276. -   34. Yannelli J R, Tucker J A, Hidalgo G, Perkins S, Kryscio R,     Hirschowitz E A: Characteristics of PBMC obtained from leukapheresis     products and tumor biopsies of patients with non-small cell lung     cancer. Oncol Rep 2009, 22(6): 1459-1471. -   35. Li L, Chao Q G, Ping L Z, Xue C, Xia Z Y, Qian D, Shi-ang H: The     prevalence of FOXP3+ regulatory T-cells in peripheral blood of     patients with NSCLC. Cancer Biother Radiopharm 2009, 24(3): 357-367. -   36. Ju S, Qiu H, Zhou X, Zhu B, Lv X, Huang X, Li J, Zhang Y, Liu L,     Ge Y et al: CD13+CD4+CD25hi regulatory T cells exhibit higher     suppressive function and increase with tumor stage in non-small cell     lung cancer patients. Cell cycle (Georgetown, Ill. 2009, 8(16):     2578-2585. -   37. Sakaguchi S: Regulatory T cells: key controllers of immunologic     self-tolerance. Cell 2000, 101(5): 455-458. -   38. Boon T, Cerottini J-C, Van den Eynde B, van der Bruggen P, Van     Pel A: Tumor antigens recognized by T lymphocytes. Annu Rev Immunol     1994, 12: 337-365. -   39. Li C, Heidt D G, Dalerba P, Burant C F, Zhang L, Adsay V, Wicha     M, Clarke M F, Simeone D M: Identification of pancreatic cancer stem     cells. Cancer research 2007, 67(3): 1030-1037. -   40. Smyth M J, Teng M W, Swann J, Kyparissoudis K, Godfrey D I,     Hayakawa Y: CD4+CD25+T regulatory cells suppress N K cell-mediated     immunotherapy of cancer. J Immunol 2006, 176(3): 1582-1587. -   41. Young M R, Wright M A, Pandit R: Myeloid differentiation     treatment to diminish the presence of immune-suppressive CD34+ cells     within human head and neck squamous cell carcinomas. J Immunol 1997,     159(2): 990-996. -   42. Kusmartsev S A, Kusmartseva I N, Afanasyev S G, Cherdyntseva N     V: Immunosuppressive cells in bone marrow of patients with stomach     cancer. Adv Exp Med Biol 1998, 451: 189-194. -   43. Almand B, Clark J I, Nikitina E, van Beynen J, English N R,     Knight S C, Carbone D P, Gabrilovich D I: Increased production of     immature myeloid cells in cancer patients: a mechanism of     immunosuppression in cancer. J Immunol 2001, 166(1): 678-689. -   44. Diaz-Montero C M, Salem M L, Nishimura M I, Garrett-Mayer E,     Cole D J, Montero A J: Increased circulating myeloid-derived     suppressor cells correlate with clinical cancer stage, metastatic     tumor burden, and doxorubicin-cyclophosphamide chemotherapy. Cancer     Immunol Immunother 2009, 58(1): 49-59. -   45. Liu C Y, Wang Y M, Wang C L, Feng P H, Ko H W, Liu Y H, Wu Y C,     Chu Y, Chung F T, Kuo C H et al: Population alterations of L:     -arginase-and inducible nitric oxide synthase-expressed     CD11b(+)/CD14 (−)/CD15 (+)/CD33 (+) myeloid-derived suppressor cells     and CD8 (+) T lymphocytes in patients with advanced-stage non-small     cell lung cancer. J Cancer Res Clin Oncol 2009. -   46. Srivastava M K, Bosch J J, Thompson J A, Ksander B R, Edelman M     J, Ostrand-Rosenberg S: Lung cancer patients' CD4(+) T cells are     activated in vitro by MHC II cell-based vaccines despite the     presence of myeloid-derived suppressor cells. Cancer Immunol     Immunother 2008, 57(10): 1493-1504. -   47. Young M R, Newby M, Wepsic H T: Hematopoiesis and suppressor     bone marrow cells in mice bearing large metastatic Lewis lung     carcinoma tumors. Cancer Res 1987, 47(1): 100-105. -   48. Subiza J L, Vinuela J E, Rodriguez R, Gil J, Figueredo M A, De     La Concha E G: Development of splenic natural suppressor (NS) cells     in Ehrlich tumor-bearing mice. Int J Cancer 1989, 44(2): 307-314. -   49. Kusmartsev S A, Ogreba V I: [Suppressor activity of bone marrow     and spleen cells in C57Bl/6 mice during carcinogenesis induced by     7,12-dimethylbenz(a)anthracene]. Eksp Onkol 1989, 11(5): 23-26. -   50. Kusmartsev S A, Li Y, Chen S H: Gr-1+ myeloid cells derived from     tumor-bearing mice inhibit primary T cell activation induced through     CD3/CD28 costimulation. J Immunol 2000, 165(2): 779-785. -   51. Sinha P, Clements V K, Ostrand-Rosenberg S: Reduction of     myeloid-derived suppressor cells and induction of M1 macrophages     facilitate the rejection of established metastatic disease. J     Immunol 2005, 174(2): 636-645. -   52. Liu C, Yu S, Kappes J, Wang J, Grizzle W E, Zinn K R, Zhang H G:     Expansion of spleen myeloid suppressor cells represses NK cell     cytotoxicity in tumor-bearing host. Blood 2007, 109(10): 4336-4342. -   53. Maeda et al., Tumor vascular permeability and the EPR effect in     macromolecular therapeutics: a review. J. of Controlled Release     2000, 65: 271-284. -   54. Griesh, K., Enhanced permeability and retention of     macromolecular drugs in solid tumors: A royal gate for targeted     anticancer nanomedicines. J. of Drug Targeting 2007, 15(7-8):     457-464 -   55. Allen et al., Drug Delivery Systems: Entering the Mainstream.     Science 2004, 303: 1818-1822. 

1. A composition comprising a vault complex comprising a chemokine fusion protein comprising a chemokine (C—C motif) ligand 21 (CCL-21) consisting of the amino acid sequence of SEQ ID NO:2 (human) and a major vault protein interaction domain (mINT) consisting of the amino acid sequence of SEQ ID NO:8 (human).
 2. A composition comprising a vault complex comprising a fusion protein comprising a cytokine and a vault targeting domain.
 3. The composition of claim 2, wherein the cytokine is a chemokine.
 4. The composition of claim 2, wherein the cytokine is a cysteine-cysteine (CC) chemokine.
 5. The composition of claim 2, wherein the cytokine is a CCL-21 chemokine.
 6. The composition of claim 2, wherein the cytokine comprises the amino acid sequence of SEQ ID NO:2 (human).
 7. The composition of claim 2, wherein the cytokine consists of the amino acid sequence of SEQ ID NO:2 (human).
 8. The composition of claim 2, wherein the cytokine comprises the amino acid sequence of SEQ ID NO:1 (mouse).
 9. The composition of claims 2-8, wherein the vault targeting domain is a vault interaction domain from a vault poly ADP-ribose polymerase (VPARP).
 10. The composition of claims 2-8, wherein the vault targeting domain is a major vault protein interaction (mINT) domain.
 11. The composition of claims 2-8, wherein the vault targeting domain comprises the amino acid sequence of SEQ ID NO:8 (human).
 12. The composition of claims 2-8, wherein the vault targeting domain consists of the amino acid sequence of SEQ ID NO:8 (human).
 13. The composition of claims 2-8, wherein the vault targeting domain comprises the amino acid sequence of SEQ ID NO:9 (mouse).
 14. The composition of claims 2-13, wherein the vault complex comprises MVP.
 15. The composition of claims 2-14, wherein the fusion protein comprises the amino acid sequence of SEQ ID NO:13 (human).
 16. The composition of claims 2-14, wherein the fusion protein consists of the amino acid sequence of SEQ ID NO:13 (human).
 17. The composition of claims 2-14, wherein the fusion protein comprises the amino acid sequence of SEQ ID NO:12 (mouse).
 18. The composition of claims 2-17, further comprising a vault poly ADP-ribose polymerase (VPARP), a telomerase vault associated protein 1 (TEP1), or an untranslated RNA molecule (vRNA).
 19. The composition of claims 2-18, wherein the fusion protein further comprises a fluorescent protein.
 20. The composition of claims 2-18, wherein the fluorescent protein is a mCherry fluorescent protein.
 21. An isolated nucleic acid encoding a chemokine fusion protein comprising a cytokine encoding sequence and a mINT encoding sequence.
 22. The isolated nucleic acid of claim 21, wherein the mINT encoding sequence comprises the nucleic acid sequence of SEQ ID NO:7 (human).
 23. The isolated nucleic acid of claim 21, wherein the mINT encoding sequence consists of the nucleic acid sequence of SEQ ID NO:7 (human).
 24. The isolated nucleic acid of claim 21, wherein the mINT encoding sequence comprises the nucleic acid sequence of SEQ ID NO:6 (mouse).
 25. The isolated nucleic acid of claim 21, wherein the cytokine encoding sequence consists of the nucleic acid sequence of SEQ ID NO:5 (human) and the mINT encoding sequence consists of the nucleic acid sequence of SEQ ID NO:7 (human).
 26. The isolated nucleic acid of claim 21, wherein the cytokine encoding sequence consists of the nucleic acid sequence of SEQ ID NO:3 (mouse) and the mINT encoding sequence consists of the nucleic acid sequence of SEQ ID NO:6 (mouse).
 27. The isolated nucleic acid of claim 21, wherein the cytokine fusion protein comprises the nucleic acid sequence of SEQ ID NO:11 (human).
 28. The isolated nucleic acid of claim 21, wherein the cytokine fusion protein consists of the nucleic acid sequence of SEQ ID NO:11 (human).
 29. The isolated nucleic acid of claim 21, wherein the cytokine fusion protein comprises the nucleic acid sequence of SEQ ID NO:10 (mouse).
 30. The isolated nucleic acid of claim 21, wherein the cytokine fusion protein comprises the nucleic acid sequence of SEQ ID NO:62 (mouse).
 31. A vector comprising the isolated nucleic acid of claims 21-30.
 32. The vector of claim 30, wherein the vector is a baculovirus expression vector.
 33. A cell comprising the nucleic acid of claims 21-30 or the vector of claims 31-32.
 34. A method of delivering a cytokine to a cell, comprising introducing the composition of claims 2-20 to the cell.
 35. The method of claim 34, wherein the composition is introduced into the extracellular environment surrounding the cell.
 36. A method for stimulating an immune response in a cell, the method comprising contacting the cell with the composition of claims 2-20.
 37. The method of claim 36, wherein the cell is a human cell.
 38. The method of claim 36 or 37, wherein the immune response induces migration of T cells and dendritic cells.
 39. The method of claims 36-38, wherein contacting the cell with the composition of claim 2 increases T cell migration to the cell by at least 5% compared to administration of CCL-21 cytokine alone.
 40. A method for stimulating an immune response in a subject, the method comprising administering the composition of claims 2-20 to the subject.
 41. The method of claim 40, wherein the subject is a human.
 42. A method of treating or managing cancer in a subject in need of treatment or management of cancer, comprising administering to a subject a therapeutically effective amount of the composition of claims 2-20.
 43. The method of claim 42, wherein administering comprises intra-tumoral injection of the composition to a tumor in the subject.
 44. The method of claims 42-43, wherein the cancer is lung cancer.
 45. The method of claims 42-44, wherein administering reduces tumor volume.
 46. The method of claims 42-45, wherein administering reduces tumor growth.
 47. The method of claims 42-46, wherein administering increases interleukin-2 (IL-2) expression.
 48. The method of claim 42-47, wherein the subject is a mammal.
 49. The method of claims 42-47, wherein the subject is a human.
 50. A method of preparing the composition of claims 2-20 comprising a) mixing a fusion protein comprising a cytokine fused to a mINT generated in Sf9 cells with a rat MVP generated in Sf9 cells to generate a mixture; b) incubating the mixture for a sufficient period of time to allow packaging of the fusion protein inside of vault complexes, thereby generating the composition of claims 2-20.
 51. A method of preparing the composition of claims 2-20 comprising a) mixing a fusion protein comprising a cytokine fused to a mINT generated in insect larvae cells with a rat MVP generated in insect larvae cells to generate a mixture; b) incubating the mixture for a sufficient period of time to allow packaging of the fusion protein inside of vault complexes, thereby generating the composition of claims 2-20.
 52. A method of preparing the composition of claims 2-20 comprising a) mixing a fusion protein comprising a cytokine fused to a mINT generated in Sf9 cells or insect larvae cells with a human MVP generated in Sf9 cells or insect larvae cells to generate a mixture; b) incubating the mixture for a sufficient period of time to allow packaging of the fusion protein inside of vault complexes, thereby generating the composition of claims 2-20. 